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ABSTRACT
This thesis reports on controversial aspects of 
polymyalgia rheumatica/giant cell arteritis (PMR/GCA). 
Controversies exist partly because previous studies tended to 
be small and retrospective, patients were seen by different 
doctors and inadequate diagnostic criteria were sometimes 
used. Studies were also biased towards the interests of 
particular specialties. In an attempt to overcome these 
limitations, I have studied prospectively 78 patients with 
active untreated PMR/GCA, referred to me largely by general 
practitioners. Patients were included only if specific 
diagnostic criteria were met.
In an original case finding study in a general practice 
population, all patients over 65 were interviewed using a 
questionnaire previously shown to have high sensitivity and 
specificity for PMR/GCA. Patients with a positive 
questionnaire and ESR > 30 mm were seen again. Two new cases 
of PMR/GCA were detected and 17 existing cases confirmed, 
giving incidence and prevalence figures of 4/1000 and 33/1000 
respectively. These figures are almost ten-fold higher than 
in previous studies, which were usually hospital-based.
Clinical features and laboratory testing in all the 
patients were used to look for an association with stress, 
infection or autoimmune disease? a seasonal bias and 
prodromal illness were suggestive of an infective trigger.
Histological classification of active arteritis,•healed 
arteritis or normal age changes was made from 52 temporal
18
arteries from patients in this study, 26 "positive" biopsies 
from other GCA cases and 10 controls. Sixty per cent of the 
biopsies from my patients were positive; arteritis was 
significantly more common in GCA (82%) but the presence of 
arteritis in 20% of PMR biopsies confirmed the overlap 
between them. The existence of "healed" arteritis was 
established, especially in PMR patients where positive 
biopsies were healed, not active. Patients with positive 
biopsies were significantly older than those with negative 
biopsies, and patients with healed biopsies had a longer 
history.
Immunoperoxidase studies of 22 patients with PMR/GCA 
and 10 controls showed for the first time deposits of IgG, 
IgA, IgM and C3 in 4 active biopsies, particularly near the 
internal elastic lamina (IEL); IgG and IgA deposits were 
seen in 3 healed biopsies. No deposits were seen in negative 
biopsies. Electron microscopy was performed in 3 patients 
and 3 controls. Biopsies with active GCA showed fraying of 
the IEL on the intimal aspect with degeneration of the IEL. 
Smooth muscle cells were also abnormal but these findings in 
combination support the antigenic role of the IEL in the 
pathogenesis of PMR/GCA, rather than the importance of smooth 
muscle cells. Neither of these methods was more sensitive 
than standard light microscopy in detecting arteritis.
Liver alkaline phosphatase levels were elevated equally 
commonly in both PMR and GCA patients, in approximately 40%. 
Isotope scans were carried out in 29 patients with active
19
disease and follow-up scans were done in 15. Twenty-four per 
cent had abnormal isotope scans which surprisingly remained 
abnormal on follow-up, despite clinical recovery. An 
original method of assessing liver involvement by measuring 
the arteria1:tota1 blood flow ratio showed this was 
significantly lower in GCA, possibly due to hepatic 
arteritis. Patients with abnormal scans and flow ratios were 
more likely to have elevated alkaline phosphatase levels. 
Thus clear involvement of the liver in PMR/GCA was 
demonstrated and the mechanism suggested is arteritis.
Joint disease was assessed clinically in all the 
patients, and radiographically and with isotope scans in some 
of them. Age-matched post-mortem control sternoclavicular 
joints were also X-rayed and a control group used in the scan 
study. Only 3/74 patients had joint disease related to 
active PMR/GCA. Coincidental osteoarthritis was common. 
Tomograms of the sternoclavicular joints were carried out in 
22 patients with PMR/GCA for 1-7 years. Two had erosions, 
and 2 "irregular" joints but erosions were also seen in 1 
control. There was no other radiographic or isotope scan 
evidence for significant axial or peripheral joint disease. 
These results are in complete contrast to other studies, 
where the validity is questioned of the limited radiographic 
and isotope studies carried out.
Immune complexes (IC) were elevated in about 40% of all 
the patients using the PEG-CC and Clq binding assays; almost 
all patients had elevated levels as measured by the'PEG C4 
assay, presumably detecting other components. Raised levels
20
were not related to histological arteritis; deposited IC may 
be of more importance than circulating IC.' A new method of 
characterising IC in 15 patients (using PEG precipitation, 
purification with IgG anti Clq or C3c sepharose, gel 
electrophoresis then Western blotting) detected a range of 
components which differed from those found in rheumatoid 
arthritis.
The clinical and laboratory features in the 3 subgroups 
on presentation showed that GCA patients were older. The 
classical features of proximal muscle pain and stiffness, 
headache, visual blurring and malaise were common but visual 
loss at presentation was rare (2 cases). There was an 
extremely rare presentation with myometrial and axillary GCA, 
with PMR. Anaemia was more common in male patients who 
usually had PMR only. Raised acute phase proteins occurred 
in all groups but were not more useful than the ESR in 
assessing disease activity. CRP levels were higher in the 
GCA group. Autoantibodies were negative. The course of the 
disease was also benign in comparison with earlier studies, 
although minor symptoms were common. PMR/GCA patients had 
most relapses but otherwise the overlap group was 
indistinguishable from those with PMR only or GCA only. ESR 
was better than CRP in assessing disease activity during 
follow-up? this is the only large study to compare the two 
parameters. The ESR was elevated in 60% of relapses? false 
positives were rare. No other laboratory parameter was more 
helpful in assessing activity. The results suggested that
21
about 20-25% patients would be able to discontinue steroids 
after 2 years.
An original trial of steroid regimes over the first 2 
months suggested that an initial dose of 10 mg 
prednisolone/day in PMR led to frequent relapses and 20 mg 
gave better control? no more than 40 mg initially was needed 
for GCA in most cases. Side-effects related to steroids were 
more common in the GCA group who had received a higher dose? 
weight gain, fracture and peptic ulcer/dyspepsia were the 
most common problems. Persistent weight gain occurred in one 
group who gained more weight and received more prednisolone 
than those who regained baseline weight. This was only 
partly due to longer follow-up and hence a lower mean daily 
dose in the latter group. A retrospective study of a 
different group of 35 PMR/GCA patients, followed for longer 
and treated with a wider dosage range of prednisolone, showed 
patients with major side-effects had had significantly higher 
maximal and cumulative prednisolone doses than those with no 
side-effects. Steroid-associated side-effects in relation to 
dose have not been previously studied in PMR/GCA, and the 
above results in conjunction with the trial of steroid 
regimes emphasise the importance of using lower doses of 
steroids, particularly in GCA.
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C H A P T E R  O N E
INTRODUCTION
1.1 HISTORICAL BACKGROUND
Polymyalgia rheumatica (PMR) and giant cell arteritis 
(GCA) occur in the elderly. The main features of PMR are 
proximal muscle pain and stiffness. Giant cell arteritis is 
characterised by temporal headache, visual disturbance and 
scalp tenderness; systemic upset may be present in both. 
They form a spectrum of disease and may occur separately or 
together.
The earliest description of GCA may have been in the
10th Century in the Tadkivat of Ali Iba Isn (Hamilton, Shelly
and Tumulty 1971) where removal of the temporal artery was 
recommended as treatment 'not only for migraine and headache 
in those patients that are subject to chronic eye disease, 
but also acute, sharp, catarrhal affections including those 
showing heat and inflammation of the temporal muscles. These 
diseased conditions may terminate in loss of sight'. Canon 
Van der Paele, a distinguished papal nuncio who retired as 
Canon to his native city of Bruges in 1420 may have been a
sufferer of both polymyalgia rheumatica and giant cell
arteritis. Jan Van Eyck's painting in 1436 of 'The Virgin 
with the Canon' shows his thick and prominent left temporal 
artery and contemporary accounts document rheumatic pains, 
difficulty attending morning service with possible stiffness 
and general ill-health. (Dequeker 1981).
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No further evidence for the existence of either PMR or 
GCA exists until the late nineteenth century, when 
recognisable descriptions of each were documented in opposite 
ends of the British Isles. In 1888, Bruce, a Scottish 
physician based in Strathpeffer Spa, described 5 cases of 
'senile rheumatic gout' and commented on 'its severity and 
complete curability even at a very advanced time of life'. It 
fell to a surgeon at the London Hospital (Hutchinson 1890) to 
make the diagnosis of 'arteritis of the aged', readily 
recognisable as GCA, in Mr. Rumbold, the 80 year old father 
of one of the beadles. This elderly gentleman had r-ed 
'streaks on his head' which were painful and prevented his 
wearing a hat. The 'red streaks' proved on examination to be 
his temporal arteries which were swollen and inflamed. 
Pulsation was 'initially feeble, then subsided', according to 
Hutchinson, who noted that the inflammation later settled and 
'the old gentleman lived several years after this without 
any other manifestation of arterial disease'. He attributed 
the arteritis to the pressure of Mr. Rumbold's hat on his 
temples.
For 40 years, there were no published reports of PMR or 
GCA. Several reports of GCA then appeared in the 1930s and 
1940s (Horton, McGrath and Brown 1932, Cooke et al. 1946, 
Kilbourne and Wolff 1946). PMR was described by Kersley 
(1951), Meulengracht and Schwartz (1952) and Bagratuni 
(1953). '
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In the 1950s the connection between the two conditions 
was recognised by Porsman (1951) and by Paulley (1956) who 
later presented a larger series of 67 patients with PMR/GCA 
(Paulley and Hughes, 1960). Histological confirmation of a 
relationship between PMR and GCA was provided by Alestig and 
Barr (1963) and confirmed in a large series from Hamrin, 
Jonsson and Lanberg (1965). Many reports since then have 
documented the frequent occurrence of PMR with GCA, and it is 
now generally accepted that the two conditions are linked.
1.2 CONTROVERSIAL ASPECTS OF PMR/GCA
PMR/GCA is therefore a relatively 'new' disease and many 
features of the condition are controversial or not 
understood. The incidence and prevalence of the condition 
appear to be increasing and show wide variation in different 
reports. The cause of PMR/GCA is unknown. It has been 
proposed that infection or stress may trigger the condition 
in a susceptible elderly population, possibly defined by HLA 
status, but there is no definite evidence for this. The 
nature of the overlap between PMR and GCA is obscure. The 
reported frequency of clinical features varies, and there 
are also conflicting reports on the relapse and complication 
rate. There is disagreement on whether joint involvement 
occurs and whether it causes the profound muscle pain and 
stiffness in PMR. There is no single satisfactory 
diagnostic test or method of measuring disease activity. 
Tests of liver function or immunological activity may be 
abnormal,v but the reasons for these abnormalities are 
unknown. The histological changes in arteries are unique but
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the mechanism remains a mystery. Treatment with 
corticosteroids is regarded by most as Obligatory but the 
optimal dose and duration of therapy remain unclear. The 
incidence of steroid side-effects varies considerably in 
different studies.
Several factors have contributed to the varying data. 
PMR/GCA presents to a wide range of doctors, such as general 
practitioners, rheumatologists, general physicians, 
neurologists and ophthalmologists. Thus considerable bias 
towards particular specialties exists in different series. 
In addition, some include PMR only, some GCA only and some 
both, resulting in further variation in observations made. 
Diagnostic criteria differ, so each series includes - and 
excludes - certain patients. This is to some extent 
inevitable given the lack of a sensitive and specific 
diagnostic test.
However, many series of PMR/GCA patients have now been 
reported, and despite the varying groups included one might 
expect consistent and reproducible data to have emerged. 
This is not the case, and is in part due to the type of 
studies carried out. Most have been retrospective, with 
patients collected over many years, by different doctors 
using varying and rather loose diagnostic criteria. These 
studies were not set out to answer specific questions and 
tend to simply report on what was found and what was done. 
This is clearly seen over treatment recommendations - steroid 
dose ranges have been anecdotally established with no
26
attempt made to compare prospectively different regimes. In 
many studies it is quite unclear whether patients continued 
treatment because of disease activity, or because no-one 
tried to withdraw steroids.
Although there is clearly much valuable information in 
retrospective reviews, and the classical features of PMR/GCA 
are now well established, there is a need for large 
prospective studies carefully observing PMR, GCA and overlap 
patients, and examining specific problems in these groups.
1.3 THESIS AIMS
This thesis is an attempt to perform such a study. 
Between 1982 and 1985, I have collected a series of 78 
patients with active untreated PMR/GCA and followed-up 74 for 
up to three and a half years. Patients were referred to the 
Rheumatology Department between January 1982 and March 1985. 
Sixty-nine were referred from general practitioners, 5 from 
ophthalmologists, 3 from general physicians and 1 from a 
gynaecologist. This prospective study examines the 
presenting clinical and laboratory features, and the course 
of the disease. Specific experiments have been carried out 
to study the aetiology, the histological changes in temporal 
arteries, the hepatic abnormalities, the presence of joint 
disease and types of immune complexes. Different steroid 
regimes are compared, and the incidence of steroid side- 
effects studied. The incidence and prevalence of PMR/GCA is 
examined in a different population in general practice.
These studies are discussed in subsequent chapters.
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C H A P T E R  2 
INCIDENCE AND PREVALENCE OF POLYMYALGIA RHEPMATICA/GIANT CELL
ARTERITIS
2.1 INTRODUCTION
Epidemiological studies have reported a wide range of 
incidence and prevalence rates for PMR/GCA, with an apparent 
increase in rates over the last 20 years. My hypothesis is 
that PMR/GCA occurs much more commonly than present results 
suggest.
Kilbourne and Wolff (1946) found 20 case reports of 
temporal arteritis in the literature in 1946 and this had 
risen to only 248 by 1954 (Cameron 1959). Larger series were 
reported in the 1960's especially from Scandinavia - Kogstad 
(1965) saw 70 cases of PMR between 1962 - 1964 and Hamrin 
(1972) reported 93 cases of 'polymyalgia arteritica' between 
1961 - 1968, 48 of which were biopsy positive. The incidence 
of PMR was felt to be about the same as gout, greater than 
that of ankylosing spondylitis and about one tenth that of 
rheumatoid arthritis, except in patients over 70 where it 
rose to half that of rheumatoid (Dixon et al. 1966).
More precise incidence and prevalence figures have since 
been produced. A survey from the Lothian region in Scotland 
(Jonasson, Cullen and Elton 1979) between 1964 - 1971 found 
136 biopsy positive cases of GCA, which gave an annual 
incidence, of 4.23/100,000 in those over 50 years. In a 25 
year retrospective study of the Mayo Clinic and Olmsted
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County records, Huston et al. (1978) found that the annual 
incidence of temporal arteritis in those over 50 years rose 
from 5.1/100,000 between 1950 - 1959 to 17.4/100,000 from 
1970 - 1974. The prevalence in 1975 in those over 50 years 
was 133/100,000. About half the patients also had PMR. A 
further study from the same area (Chuang et al. 1982) 
identified 96 patients with PMR, 15 of whom also had GCA, 
between 1970 - 1979. The average annual incidence rose from 
19.8/100,000 in 50 - 59 year olds to 112.2/100,000 in those 
aged 70 - 79 years with an average annual incidence rate of 
53.7 for those over 50 years. The incidence was higher in 
women (1.5:1) as has been reported in most series. The 
prevalence of PMR in 1980 of those over 50 years was 
estimated at 442/100,000. This included active cases plus 
cases in remission. The diagnostic criteria used, however, 
were less stringent than those of Jones and Hazleman (1981).
The Swedish workers, Bengtsson and Malmvall (1981a), 
looked at the incidence and prevalence of giant cell 
arteritis/polymyalgia rheumatica in Goteburg between 1973 and 
1975 by examining medical and pathology records, and found 
126 cases, 71% of whom had features of PMR. PMR was 
significantly more common in women. 39% had symptoms or 
signs of GCA. The prevalence was 28.6/100,000 in those over 
50 years, with 16.8/100,000 biopsy positive cases. The 
highest incidence was found in those over 80 years, where the 
condition was 10 times commoner than in those under 60 years.
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Thus in the last 10 years the reported incidence of 
PMR/GCA in those over 50 years ranges from 4.23/100,000 to 
53.7/100,000.
Most of these studies were derived from hospital based 
populations and are likely to have underestimated the true 
incidence. Some of the variation can be explained by the 
different diagnostic criteria used. The Minnesota study 
(Chuang et al. 1982) allowed the inclusion of patients with 
muscle symptoms for one month or less and some were treated 
successfully with non-steroidal anti-inflammatory drugs 
alone. Some studies included only histologically proven 
cases of giant cell arteritis, others PMR alone and not GCA.
There are two important studies which support the 
hypothesis that PMR/GCA occurs more commonly than suggested 
by hospital based studies. Firstly, in a study of 889 
routine post-mortem cases Ostberg (1973) found evidence of 
arteritis in the temporal arteries or aorta in 16 (1.7%)
suggesting a prevalence of 1700/100,000. Secondly, in 1981 
Silman and Currey reported a case seeking study for PMR/GCA 
using a questionnaire. They looked at 247 elderly people 
receiving social services care in day centres and old 
people*s homes and detected 3 cases, 2 of whom were 
previously undiagnosed, giving a prevalence of 1200/100,000. 
However, as over 80% of those assessed were female, it 
appeared that about 1500/100,000 of the elderly females in 
this study had PMR.
There have been no major general practice studies of 
the incidence, but a few reports support the view that the
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prevalence of PMR/GCA is higher than previously thought. 
Cameron (1959) reported 9 cases of temporal arteritis in his 
Tunbridge Wells practice of 3,700 between 1953 and 1959. 
This practice, however, contained twice as many elderly as 
the national average at that time (21.6% compared to 10.6%). 
Rhodes (1976) reported 7 cases of PMR and 4 of GCA in a 
Milton Keynes practice of 3,000 between 1969 - 1975. A 
letter from two general practitioners (GPs) in Northumberland 
(Harle and Cunningham 1981) reported 9 cases of PMR/GCA in a 
practice of 5,000 between 1974 - 1979. Only three were 
referred to hospital. Turner (1983) in a urban practice 
which increased from 8,000 - 11,000 between 1974 and 1982 
found 10 cases of PMR and 2 of GCA. Five were diagnosed 
without hospital referral. Only 8% of the practice were over 
65 years (just over half the national average).
The fact that around half of the GP cases reported were 
not referred to hospital supports the view that hospital 
studies have underestimated incidence rates. However, some 
of these reports are again limited by their variation in 
diagnostic criteria, the inclusion of PMR or GCA rather than 
both and the reliance on retrospective examination of 
records.
In this chapter I report the results of a case-finding 
prospective study of PMR/GCA in the general population in an 
attempt to define the true incidence and prevalence.
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2.2 METHOD
A surburban health centre-based general practice on the 
outskirts of Cambridge was studied. 5,500 people were 
registered with the practice. There were no old people's 
homes in the practice area, and there was a normal 
distribution of social class. All the patients aged 65 years 
and over (650 in total) were identified from the practice 
age/sex register and were sent a standard letter from their 
general practitioner explaining the purpose of the study. 
They were invited to be interviewed either at home or in the 
Health Centre, depending on which their GP felt to be 
appropriate. Those known to be demented or terminally ill 
were excluded. Patients who failed to attend, or who were 
out when visited, were sent further appointments. Patients 
with known PMR/GCA were included in the study, and in most 
cases I was unaware of their diagnostic status at the time of 
interview.
I then interviewed the patients with a questionnaire 
(Figure 1) which had been shown previously to have a 
specificity of 97% (Silman and Currey 1982) in the detection 
of PMR/GCA. The presence of bilateral pain and stiffness in 
the shoulder girdle, or headache with visual loss or scalp 
tenderness suggested possible PMR/GCA - ie the questionnaire 
was considered positive for possible PMR if there was a 
positive response to questions 2 and 3, with a negative 
response to questions 1, 4 and 5? a positive response to 
question 6 in the absence of an obvious cause for- these 
symptoms suggested possible GCA. An erythrocyte sedimentation
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NAME
AGE ................................. ....................
HOME/HEALTH CENTRE DATE ...................
1. Have you ever at any time had YES/NO
arthritis or rheumatism?
2. Do you have stiffness around the neck 
and both shoulders? YES/NO
3. Do you wake up with stiffness or aching in 
your shoulder? YES/NO
4. Do you wake up with stiffness or aching in 
your joints?
5. Have you ever had swelling in any joints?
YES/NO 
YES/NO
6. Symptoms of temporal arteritis:
Scalp tenderness 
Severe headaches 
Visual loss
YES/NO 
YES/NO 
YES/NO
FIGURE 1.
Questionnaire used to detect PMR/GCA in general practice
rate (ESR) was measured in all patients with a positive 
questionnaire, and if this was greater than 30 mm in the 
first hour (Westergren), a full assessment was carried out. 
Patients noted to have a diagnosis of PMR/GCA from the 
practice diagnostic index were assessed in the same way, 
irrespective of their questionnaire answers. A definite 
diagnosis of PMR/GCA was made if the criteria of Jones and 
Hazleman (1981) were fulfilled (Appendix 1).
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2.3 RESULTS
579 people completed the questionnaire, a response rate 
of 89%. Twenty of the non-responders were considered 
unsuitable by their general practitioner, usually because of 
mental illness or terminal disease: the remaining 51 could
not be contacted or were unwilling to participate. The age 
and sex of these non-responders did not differ from the 
responders (Table 1).
Thirty-two (5.5%) had a positive questionnaire and 
therefore had an ESR checked. Eighteen of these were 
included on the practice diagnostic index of known cases of 
PMR/GCA. Of the remaining 14 of the 32 with positive 
questionnaires, 6 were suggestive of PMR and 8 of GCA. 4 of 
these patients had an ESR greater than 30 (2 PMR, 2 GCA). 
All were female. On full assessment, one had PMR and one 
GCA. Of the other two, one had myeloma and the other 
rheumatoid arthritis (Table 2).
The practice diagnostic index listed 19 cases of 
PMR/GCA diagnosed within the past 8 years. Seventeen of 
these 19 patients on further assessment fulfilled the 
diagnostic criteria for PMR/GCA and 2 did not: in one, all
symptoms had resolved and the ESR became normal within 3 
months without treatment? the other case had atypical facial 
pain and pelvic stiffness, the ESR was normal and a trial of 
steroids resulted in only moderate improvement. Of the 17 
definite cases, 10 had PMR alone, and 7 GCA. Details are 
shown in Table 3. Four cases were no longer taking steroids 
but one of these had recently had a recurrence of symptoms.
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TABLE 2
PATIENTS WITH POSITIVE QUESTIONNAIRE AND ESR >50
Age Sex Questionnaire Diagnosis ESR Final Diagnosis
74 F PMR 5** PMR
65 F GCA 48 GCA
66 F PMR 34 RA
72 F GCA 113
.
Mye1oma
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TABLE 3
PATIENTS WITH KNOWN PMR/GCA IN THE PRACTICE
Age at Onset Sex Presenting
features
Number still 
requiring steroids
1 65 M PMR +
2 73 M PMR +
3 60 M PMR -
k 78 M GCA _*
5 69 M PMR +
6 78 F GCA +
7 60 F PMR -
8 69 F PMR +
9 72 F GCA +
10 63 F GCA +
11 54 F PMR +
12 70 F PMR +
13 65 F PMR +
14 63 F GCA -
15 63 F GCA +
16 80 F PMR +
17 72 F GCA +
*= Recent relapse off steroids
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The disease duration in those 13 still requiring steroids 
ranged from 6 months to 5 years. It was of interest that 
only 8 of the 17 had been referred to a rheumatologist for 
confirmation of the diagnosis.
Thus there were 1-9 patients with PMR/GCA in the 
practice, 2 detected as a result of the study and 17 
diagnosed in the preceding 8 years. The prevalence of PMR/GCA 
was calculated to be 3300/100,000 (95% confidence interval 
18.5 - 47.4) in those over 65 years. Table 4 gives these 
results with reference to age and sex; as expected PMR/GCA 
occurs more commonly in women. In the absence of data about 
changes in practice population during the preceding 8 years 
it is possible to make only an estimate of the incidence 
during this period. Population mobility is, however, low in 
this age group and thus the minimum average annual incidence 
was approximately 410 new cases/100,000. As 2 patients 
previously undiagnosed were detected in this study, the 
screening detection rate was 3500/100,000 screened.
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TABLE k 
PREVALENCE BY AGE AND SEX
Age (Yeais) Sex Number of Responders
Cases
PMR/GCA
Prevalence/
1,000
<75 M 177 3 16
<75 F 213 13 61
>75 M 95 2 21
>/75 F 94 2 21
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2.4 DISCUSSION
This is the first study based on an active detection 
programme of the occurrence of PMR/GCA in general practice. 
The incidence of 410/100,000 in this study and prevalence of 
3300/100,000 is substantially higher than that previously 
reported by others.
The evidence is, therefore, that when the occurrence is 
studied outside hospital, whether in general practice, old 
people's homes or at post-mortem, PMR/GCA is found to be much 
more common than previously thought. Without further 
comparable data it is difficult to assess wider applicability 
of the results in this study but there are no a priori 
reasons to suggest large geographical or social class 
variations in occurrence within the U.K. It would obviously 
be of interest to repeat this study in other practices.
Why have previous studies underestimated the occurrence? 
The first reason is that most GPs do not refer straight­
forward cases of PMR/GCA to hospital for specialist opinion. 
On the evidence available only half the cases presenting to 
GPs will be referred.
Secondly, some of the previous studies have examined 
only PMR and in some cases only histologically positive GCA. 
As PMR/GCA is a spectrum this will underestimate the real 
incidence.
Thirdly there may be patients suffering from PMR/GCA who 
attribute their symptoms to old age or 'rheumatics' and do 
not consult their GP. Both this study and Silman and 
Currey's (1982) suggest that this is the case. The
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questionnaire appears to be a sensitive method of detecting 
cases (18 of 19 known cases in this study)-., Although only 2 
new cases were detected in this study, this practice was 
well aware of PMR/GCA and had not missed any cases. This may 
not be applicable to all practices, and the screening benefit 
might well be higher elsewhere.
Finally, the incidence may be rising, but it seems more 
likely that doctors are simply becoming increasingly aware of 
a syndrome which has been recognised for the comparatively 
short period of 30 years.
Some of the variation in incidence and prevalence 
figures may be due to differing diagnostic criteria, but the 
rather rigid criteria used in this study would, if anything, 
underestimate the number of cases of PMR/GCA.
It is important that GPs and hospital doctors become 
aware that PMR/GCA is common in the elderly, as steroid 
therapy both prevents disastrous complications such as 
blindness and results in dramatic relief of symptoms.
Future work to assess the occurrence in other practices 
is clearly needed, and with growing awareness of the 
condition, it is likely that incidence figures will continue 
to rise.
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C H A P T E R  3 
CONTROVERSIAL ASPECTS OF THE AETIOPATHOGENESIS OF PMR/GCA
In this chapter I will examine five areas in relation 
to the aetiopathogenesis of the condition.
(1) Abnormalities associated with disease development
(2) Abnormalities in temporal artery biopsies
(3) Hepatic abnormalities
(4) Abnormalities in joints
(5) The occurrence and characterisation of immune complexes.
3.1 ABNORMALITIES ASSOCIATED WITH DISEASE DEVELOPMENT
3.1.1 INTRODUCTION
PMR/GCA occurs in people over 50 years old, with the 
relative incidence rising in each decade (Bengtsson and 
Malmvall 1981a). A triggering infection in a susceptible 
elderly population has been sought but no direct evidence 
found.
Fessel (1969) proposed that contact with pet birds, in 
particular parakeets, might lead to an immunological reaction 
but others have not confirmed this (Ornilla, Swannell and 
Dixon 1970, White and Innes 1972). Viral studies have 
produced negative results (Mowat and Hazleman 1974). Bacon, 
Doherty and Zuckerman (1975) reported an increase in HBsAb in 
PMR but this has not been confirmed.
Circumstantial evidence for an infective cause rests 
firstly on the reports of a flu-like prodromal illness in 
some patients (Kogstad 1965, Bell and Klinefelter 1967,
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Bengtsson and Malmvall 1978). However, . in other studies 
there has been an acute onset with no prodrome (Calamia and 
Hunder 1980f Knudsen, Christensen and Krohn 1982). 
Secondly, a seasonal bias of onset has been noted (Kinmont 
and McCallum 1965, Coomes, Ellis and Kay 1976, Jonasson et 
al. 1979), although other studies have not confirmed this 
(Kogstad 1965, Bengtsson and Malmvall 1978, Chuang et al. 
1982, Knudsen et al. 1982). Finally, the development of 
PMR/GCA in spouses or close relatives of patients with the 
condition suggests an infective origin (Kvernebo and Brath 
1980, Nielson 1980, Hickstein, Gravelyn and Wharton 1981, 
Kyle, Hazleman and King 1984, Garfinkel et al. 1984). 
Worldwide studies have shown that PMR/GCA appears to be more 
common in Scandinavia, the United Kingdom and Northern United 
States. Although this might suggest that environmental 
factors are important, the condition appears to be much 
commoner in the Caucasian population and very few cases have 
been reported in American blacks (Sanford and Berney 1977, 
Smith, Fidler and Pinals 1983) or American Chinese (Wilske 
and Healey 1984).
The variation in incidence may therefore be at least 
partly genetic in origin. Recent HLA studies reported a 
significantly increased frequency of DR3 and DR4 alone and in 
combination (Lowenstein et al. 1983) and an increased 
frequency of D4 only (Armstrong et al. 1983, Bignon et al. 
1984). However, earlier studies reported no significant 
differences from controls (Terasaki, Healey and Wilske 1976, 
Hunder et al. 1979, Kemp et al. 1980) or isolated differences
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not confirmed (Table 5).
As an increase in DR3 and DR4 occurs in other 
autoimmune conditions, this lends support to the hypothesis 
that PMR/GCA is an immune disorder. Further indirect 
evidence for an immunological basis to the disease are the 
reports of an increase in other autoimmune disorders in 
PMR/GCA, in particular thyroid disease (How et al. 1977, Dent 
and Edwards 1978, Nicholson et al. 1984) and primary biliary 
cirrhosis (Robertson, Batstone and Loebl 1978, Hamblin 1981, 
Sattar, Cawley and Robertson 1982).
Psychological factors have also been implicated. 
Paulley and Hughes (1960) stated that 'a depressive state, 
often concealed, invariably precedes the somatic 
manifestations of the disease by a few weeks or months', and 
felt that stress, particularly bereavement, played an 
important role. Paulley believes that 'pathological' 
mourning rather than other emotional precipitants is 
invariably present in the pathogenesis.
The only fact that clearly emerges from these 
contradictory studies is that the cause of PMR/GCA is unknown 
and is probably multifactorial.
I have therefore looked for supporting evidence for the 
possible roles of infection, stress and autoimmunity in 
patients with active untreated PMR/GCA. If infection were 
important, one might expect to find a high frequency of 
prodromal illness in patients, evidence of infection in those 
they lived with and a seasonal peak of onset. An increased
TABLE 5
REPORTED INCREASE IN FREQUENCY OF HLA ANTIGENS
HLA Antigen Increased Diagnosis
A8, AlO PMR Rosenthal et al. 1975
B14 GCA Seignalet et al. 1977
Bw 38, B5 PMR Seignalet et al. 1977
Bwl6, Aw 30 PMR Sanford and Berney 1977
B8, AlO PMR/GCA Hazleman et al. 1977
No increase GCA Kemp et al. 1980
Cw6, Cw3, DR4 PMR/GCA Armstrong et al. 1983
Al PMR Armstrong et al. 1983
DR3, DR4 PMR/GCA Lowenstein et al. 1983
DR4 GCA Bignon et al. 1984
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frequency of other autoimmune disorders in patients or 
relatives would support an autoimmune basis to PMR/GCA, and 
if psychological factors were the trigger for the disease, an 
increase in recent stressful events should be detectable.
3.1.2 METHODS
The patients studied were the 74 new cases of PMR/GCA 
described earlier in this thesis. Evidence for aetiological 
factors was sought as follows:
Infection
Patients were asked on first interview whether they had 
experienced a prodromal illness before clear symptoms of PMR 
or GCA developed; the nature of any such prodrome was noted.
Close relatives, spouses or other occupants of the 
patient's home were asked to give blood to measure C-reactive 
protein levels (CRP) , as indirect evidence of recent 
infection. CRP levels were measured by Beckman rate 
nephelometer.
The season of onset of the illness was recorded for 
each quarter of the year. Where PMR preceded GCA, or vice 
versa, the onset of the first condition was taken, even if 
subsequent symptoms were more severe.
Autoimmunity
Details of other auto-immune disorders in patients or 
close relatives were recorded.
Psychological Factors
Patients were asked if they had experienced any 
potentially stressful events in the year preceding the onset 
of illness, and these were classified as follows:
Bereavement
Job change/loss
Illness in relatives/friends
Housing problems/moves
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Separation/divorce
Patients scored the stress as none, mild or severe, and 
any change they had noted in mental state was also recorded.
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3.1.3 RESULTS 
Season of Onset
No definite seasonal bias occurred, although the onset 
was between October-December in one-third of patients, and it 
was less common for symptoms to develop between July and 
September. Results are shown in Figure 2. Three patients 
were unsure of when symptoms had first occurred. There was 
no significant difference between PMR and GCA.
Prodromal Illness
Seventeen patients (22%) reported a prodromal illness 
preceding specific symptoms of PMR/GCA. Six had upper 
respiratory tract infections, 2 had a flu-like illness and 9 
reported malaise.
CRP
This was measured in only 4 cases, because it proved 
too difficult to arrange for spouses or relatives to attend 
the clinic. CRP was elevated (1.43 mg/dl and >12 mg/dl) in 
the spouses of 2 patients with PMR.
Stress
Eighteen patients (23%) reported possible sources of 
stress (Table 6). Only 4 of these were bereavements. Most 
patients had not perceived these experiences as particularly 
stressful (except for the bereavements, and illness in a 
relative in one case). Events occurred equally commonly in 
those who developed PMR only compared with those who 
developed GCA, with or without PMR.
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Figure 2
Blocks show the number of patients 
whose symptoms of PMR/GCA started in 
each three month period.
TABLE 6
STRESSFUL EVENTS PRECEDING THE ONSET OF PMR/GCA
PMR GCA BOTH
Bereavement - 2 2
Joh change 2 - -
Illness in relatives 1 1 -
Housing problems/moves 2 2 -
Separation/divorce 1 - -
Other 2
V ■ ■
3
PMR = patients with PMR only
GCA = patients with GCA only
Both = patients with PMR and GCA
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Autoimmune Disease in Relatives
One patient had a daughter with auto-immune thyroid 
disease and 2 had relatives with pernicious anaemia. Ten had 
relatives with diabetes mellitus? this appeared to be Type 
II (non-insulin dependent) in all cases; 2 patients were 
unsure about type.
The husband of one patient with GCA had had PMR 
diagnosed 5 years previously.
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3.1.4 DISCUSSION
No definite seasonal bias was observed although this 
may have been concealed by looking at year quarters, rather 
than individual months. The increased incidence between 
October and December might be related to a higher rate of 
infection in the community at that time. It is also not 
clear how accurately some patients dated their initial 
symptoms, given that the presentation delay was a year or 
more in some cases. However, almost a quarter reported a 
prodromal illness experienced separately from any malaise 
associated with the condition, and this also suggests a 
possible infective trigger. It is of anecdotal interest that 
one woman had attended a party about a week before she 
developed PMR, and subsequently discovered that 2 other women 
at the party also developed PMR around the same time. The 
CRP results cannot be interpreted because numbers were so 
small, but the hypothesis of a triggering infection in a 
susceptible population, possibly genetically defined by HLA 
status, remains an attractive one. A weak association with 
autoimmune conditions was noted.
Stress, and in particular pathological mourning, did 
not appear to be relevant in these patients.
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3.2 ABNORMALITIES IN TEMPORAL ARTERY BIOPSIES 
3.2.1. INTRODUCTION
Histological demonstration of giant tell arteritis 
remains the only definitive diagnostic test for PMR/GCA. In 
classical acute GCA, there is marked intimal thickening, 
usually with reduction of the vascular lumen. The internal 
elastic lamina is fragmented and in places destroyed. There 
is a marked inflammatory infiltrate of histiocytes, 
lymphocytes, epithelioid and giant cells in the artery wall, 
particularly in the media and intima adjacent to the internal 
elastic lamina but also in the adventitia. Smooth muscle is 
seen in the inner intima. Fibrinoid necrosis may be present. 
The first description of GCA by Hutchinson in 1890 recognised 
on external examination that the temporal arteries were 
inflamed and the vascular lumen reduced then obliterated. 
Horton et al. (1932) provided the first histological 
description of GCA, reporting 'an undescribed form of 
arteritis of the temporal vessels'. Gilmour (1941) confirmed 
these features and demonstrated that other arteries, 
especially the aorta, arch and branches, could be affected. 
Alestig and Barr (1963) and Hamrin et al. (1964) established 
that the histological changes of GCA also occurred in 
patients with PMR.
Ageing Changes and Classification of Arteritic Changes
Other studies have examined the changes in temporal 
arteritis and compared them to normal ageing changes. 
Ainsworth, Gresham and Balmforth (1961) looked at random 
cadaver studies of temporal arteries in different age groups.
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Intimal thickening increased with age and could be marked in 
those over 60 years, and degenerative change in the internal 
elastic lamina also occurred in this age group, with 
fragmentation and altered staining. However, these ageing 
changes could be distinguished from GCA because intimal 
thickening and elastin destruction and duplication were less 
marked, there was no inflammatory infiltrate, no increase in 
smooth muscle layer by the lumen and no vascularisation of 
the arterial walls as seen in GCA. Ageing changes could also 
be distinguished from healed arteritis, where intimal 
thickening and medial fibrosis were still present but the 
inflammatory infiltrate was minimal. These authors felt that 
it would be difficult to distinguish ageing changes from 
cases where steroids had been taken before gross intimal 
thickening and vascularisation of the wall had taken place. 
Lie, Brown and Carter (1970) studied the distinctions between 
ageing arteries, healed and active arteritis. They felt that 
ageing changes could be distinguished from healed arteritis 
especially by different zonal arrangements of intimal 
proliferation. Ageing arteries had a collagenous intima with 
few cells present? elastin fibres were irregularly stained 
and fragmented. In healed GCA, a narrow compact zone of 
circular muscle and new elastin fibre surrounded by a broader 
looser zone of longitudinal muscle collagen and disorganised 
granular elastic fibres was seen. The vessel walls were 
often vascularised. Hamrin's (1972) classification was 
derived from examinations of temporal artery biopsies from
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93 PMR patients. Some showed mild intimal thickening with 
some vascular sclerosis but no inflammation, and these 
.sclerotic changes were also seen in some normal controls. A 
further group showed 'nonspecific' arteritis with 
inflammatory infiltrate but no fibrinoid necrosis, and the 
third group had classical GCA changes with an intense 
inflammatory reaction including giant cells, sometimes with 
fibrinoid necrosis and sclerosis of the vessel walls.
Parker et al. (1975) also commented on the normal age 
changes in temporal arteries, with intimal thickening but 
preservation of the lumen and only occasional missing 
segments of internal elastic lamina. They noted that these 
changes were quite different from those in active GCA and 
that the internal elastic lamina abnormalities on electron 
microscopy (vide infra) in GCA did not occur in ageing 
arteries.
In Mambo's (1979) classification of the histological 
changes in GCA, he recognised three main groups, all of whom 
had varying damage to the internal elastic lamina. The 
first group showed intimal proliferation predominantly, with 
some cellular infiltrate there, but generalised granulomatous 
infiltration was not marked. He felt this subgroup 
represented a variant of GCA rather than healed arteritis. 
The second group had marked intimal thickening, fibrinoid 
necrosis, a granulomatous inflammatory infiltrate especially 
near the internal elastic lamina but no giant cells. The 
third group showed similar changes but giant cells were 
present. He postulated that one type might progress to
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another, and that the variations might be a function of the 
.patient's immune status. There was no correlation between 
histological type and prognosis. Allsop and Gallagher (1981) 
provided yet another classification: (a) Classical GCA,
with marked intimal thickening, dense sometimes granulomatous 
chronic inflammation including lymphocytes, histiocytes and 
giant cells often closely related to the fragmented elastica. 
(b) Atypical GCA with less dense chronic inflammation, 
occasional giant cells, moderate to marked intimal 
thickening, sometimes with dense medial fibrosis, (c) Healed 
arteritis, with irregular intimal thickening, intimal and 
medial fibrosis and focal areas of persistent chronic 
inflammation. (d) Arteriosclerosis - concentric intimal 
thickening, fragmentation and reduplication of the internal 
elastic lamina and occasional focal calcification were seen 
but no inflammation and very little medial fibrosis. (e) 
Atherosclerosis, with irregular but sometimes marked intimal 
thickening, focal areas of intimal necrosis and medial 
fibrosis. There was a patchy adventitial lymphocyte 
infiltrate but no giant cells, (f) Normal arteries showed 
progressive age-related intimal thickening.
The Incidence of Arteritis on Temporal Artery Biopsy (TAB)
The reported incidence of positive TAB varies from 6- 
92% (Healey and Wilske 1978, Roth et al. 1982). There are 
several probable reasons for this:^
(1) Patient selection - some studies include patients with 
GCA only, others those with both GCA and PMR.
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(2) Variation in histological definition, as discussed 
above.
(3) The prevalence of 'skip lesions'. Two groups, Klein, 
Campbell and Hunder (1976) and Albert, Ruchman and Keltner 
(1976), have reported normal segments adjacent to sections 
showing arteritis in about 30% of TAB from GCA patients. 
However, Wilkinson and Russell (1972) reported 100% 
involvement of the arteries they examined, and Cohen and 
Smith (1974) also disputed the existence of skip lesions.
Most Scandinavian studies report positive TAB in 60-70% 
of patients (Alestig and Barr 1963, Hamrin 1972). Bengtsson 
and Malmvall (1981a) found arteritis in 31% of PMR patients; 
this figure rose to 59% when patients with GCA were also 
included. British and U.S. studies report a broader range. 
Coomes, Ellis amd Kay (1976) reported positive TAB in 42 
(28%) PMR/GCA patients. Allsop and Gallacher (1981) found 
positive TAB in less than 60% of those with clinical GCA, 
using their classification of active, atypical or healed 
arteritis. Chuang et al. (1982) reported positive biopsies 
in 14 (35%) patients presenting with PMR; however, 13 of 
those patients also had clinical features of arteritis. 
Hedges, Greer and Albert (1983) found no clinical features 
had as high specificity as positive TAB in making a diagnosis 
of PMR/GCA; they found only 3 false negative biopsies in a 
group of 91 TAB, 28 of which were positive. Hall et al. 
(1983) suggested that TAB predicted the need for steroids - 
of 88 TAB negative patients from a series of 134 TAB, only 8 
required longterm steroids. However, 57 of these with
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negative TAB did not have PMR/GCA, and presumably this became 
apparent clinically with time. In contrast, a later paper by 
Allison and Gallagher (1984) found a 'significant' percentage 
(18%) of classical GCA patients with negative biopsies and 
only 2 cases from 132 showed 'healed' arteritis.
The Effect of Steroids
The effect of steroid therapy on the histological 
changes of GCA is controversial and may cause problems in 
histological confirmation of a diagnosis after treatment has 
been started. Hamrin (1972) examined TAB before, during and 
after treatment and found the incidence of positive biopsies 
to be the same in each group. Fauchald, Rygvold and Oystese 
(1972) reported that TAB were still abnormal after several 
months of treatment in some cases. Two biopsies showed 
active GCA, 2 and 10 years after treatment, 4 showed residual 
infiltration and 14 healed arteritis. Three patients with 
residual or healed arteritis still had signs of clinical 
activity. Allison and Gallacher (1984) reported a significant 
fall-off in positive biopsies after treatment with steroids 
was started: active GCA was seen in 82% of biopsies before
treatment, 61% of biopsies taken within 1 week of treatment 
but only 10% taken thereafter. This led them to suggest 
that TAB was not worth doing after a trial of steroids had 
been given, in cases where the clinical diagnosis was 
PMR/GCA.
There is thus still argument over the definition of 
active, atypical and healed GCA, and where this merges into
58
normal ageing changes. The reported incidence of positive 
TAB has a wide range and the predictive value of the test 
has been questioned. The effect of steroids seems to be
variable.
Pathogenesis
The extensive fragmentation and duplication of the 
internal elastic lamina (IEL) is not seen in other vascular 
disorders, and the apparent concentration of inflammatory 
cells around the IEL has led to the hypothesis that the 
arteritis is due to an immunological reaction to a component 
of the artery wall, such as elastin. Shionoya, Tsunekawa and 
Kaniya ( 1 9 65) demonstrated in rabbits a giant cell 
granulomatous reaction to specific elastin destruction 
enhanced by the use of vaccines to stimulate the 
reticuloendothelial system. Papajiannis, Spina and Gotte 
(1970) have demonstrated a cellular reaction to degraded 
elastin. Animal work, looking at the effects of elastin 
injection or implants, has shown elastic lamina destruction 
with fibrosis and necrosis (Robert et al. 1971, Tsonev et al. 
1972). Although elastin was initially thought to be non- 
antigenic, antibodies have been raised to it (Darnule et al. 
1980). It has been noted that arteritis is largely confined 
to vessels containing elastin (Wilkinson and Russell 1972) 
and that both humoral (Espinoza et al. 1982) and cellular 
(Benlahrache et al. 1983) immunological abnormalities occur 
in the sera of PMR/GCA patients. Further evidence for an 
immune basis has been sought by examining affected arteries 
for immune complex deposition, using immunofluorescence and
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immunocytochemistry.
Immunofluorescence Studies
Liang, Simpkin and Mannik (1974) reported 4 main staining 
patterns: intracellular cytoplasmic staining near the IEL,
homogenous intracellular nuclear staining in the adventitia, 
linear extracellular deposits, usually in the adventitia, and 
extracellular immunoglobulin deposits by the elastic lamina. 
This last pattern was never seen in controls. Waaler, Tonder 
and Milde (1976) demonstrated anti IgG activity with 
immunofluorescence; this was usually IgA and they related it 
to disease activity in that it occurred in arteries with 
active granulomatous arteritis, not in those showing healed 
scar changes and only occasionally and weakly in arteries 
with minimal inflammatory activity. They suggested that this 
might be a more sensitive method of confirming arteritis. 
Park and Hazleman (1978) also carried out fluorescence 
studies and found 3 patterns - staining in the media of more 
than one immunoglobulin class and the third component of 
complement (C3) in all patients with histologically active 
disease and one with inactive disease; fluorescence along the 
internal elastic lamina (but this occurred equally commonly 
in negative biopsies and controls) and non-specific 
background staining again occurring in both patients and 
controls. No cytoplasmic staining was seen, and the IEL 
stains were not felt to be significant. Where minimal 
changes were seen on routine histology Bonnetblanc et al. 
(1978) found IgM deposits in 6 of 9 patients with
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histologically active GCA but only 2 with negative temporal 
artery biopsies, one of whom had PMR. Roth et al. (1982) 
examined 36 TAB from PMR patients; 21 showed arteritis. 
Twenty-four showed deposits of fibrin, immunoglobulin and 
complement in the artery wall and/or vasavasorum using 
immunofluorescence. Fourteen controls showed neither 
arteritis nor immunoglobulins. Positive biopsies were thus 
found in 91.6% PMR patients when simultaneous light 
microscopy and immunofluorescence studies were carried out. 
Immunochemical Studies
Immunocytochemistry has been used in one study to 
detect immunoglobulins and complement. Gallacher and Jones 
(1982) used immunoperoxidase to stain 15 TAB from patients 
with active arteritis; renal biopsies positive for IgG and 
C3 on immunofluorescence were also examined. Although 
intracellular IgG was seen in plasma cells, macrophages and 
giant cells, only one patient had extracellular IgG in the 
outer intima and inner media. In some cases a thin rim of 
IgG or IgM was seen on the vascular lumen or endothelial 
surfaces; this was felt to be due to reaction with plasma 
Ig. No complement was seen and there was no significant 
staining in atherosclerotic or normal temporal arteries.
Banks et al. (1983) reported nonspecific Ig staining in 
14 patients using monoclonal antibodies to kappa light 
chains; this was present as scattered foci and strands 
within inflammatory lesions. Faint and dispersed 
immunoglobulin staining intracellularly was interpreted as
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plasma globulin incorporated by cells of the mononuclear- 
phagocytic system. Staining of moderate intensity along the 
IEL was seen in 6 cases. A few cells showing strongly 
positive cytoplasmic staining were felt to be plasma cells. 
They also demonstrated predominantly helper T cells in the 
inflammatory infiltrate, and felt that cell mediated immunity 
was of importance.
Thus no unanimous conclusions were reached from these 
studies, with disagreement over the type and site of deposits 
and particularly over whether significant immunoglobulin or 
complement deposits occurred near the internal elastic 
lamina.
Electron Microscopy Studies
Four electron microscopy studies of temporal arteries 
have been carried out (Smith 1969, Kuwabara and Reinecke 
1970, Parker et al. 1975, Albert, Searl and Craft 1982).
In general the ultrastructural appearances corresponded 
to those in standard light microscopy with an inflammatory 
infiltrate and IEL fragmentation and destruction. However, 
each study reported features felt to be unique to GCA, but 
without complete agreement on what these were.
Smith (1969) reported one case of GCA and one control, 
and documented giant cells with many organelles, mononuclear 
cells and masses of fibrillar material in the extracellular 
space, near giant cells. He felt this represented fragmented 
elastica or mucinous degeneration which might be undergoing 
phagocytosis, although it was not seen intracellularly.
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Kuwabara and Reinecke's study (1970) looked at 
consecutive TAB in untreated then treated disease in 3 
patients. In the untreated phase of GCA, there were spaces 
between smooth mucle cells with inceased extracellular space 
(unlike normal arteries) and the cells were swollen and 
irregular with increased mitochondria and endoplasmic 
reticulum. The IEL was moth-eaten and fragmented. After 
steroid treatment for 2 months, biopsies showed the 
intercellular space was occupied by basal lamina substance 
and increased collagen fibres, with a marble-like appearance 
to the IEL. The basal lamina of the smooth muscle cells was 
thought to be forming new elastica and collagen, explaining 
the splitting of the elastica.
Parker et al. (1975) described changes in 8 TABs with 
active GCA clinically and histologically, and 18 controls. 
They noted dense granular and fragmented IEL in the GCA 
cases but did not see phagocytosis of the elastic lamina. 
Smooth muscle cells contained increased rough and smooth 
endoplasmic reticulum and the cells of an inflammatory 
granulomatous reaction were seen. They felt that elastic 
lamina degeneration was the primary event and that the 
smooth muscle cell abnormalities were not specific for GCA.
A more recent study by Albert et al. (1982) of 19 TAB 
positive for GCA showed degenerating smooth muscle cells 
contributing to sub intimal cellular proliferation; 
fragmented IEL was seen beside but not within giant cells. 
Material resembling smooth muscle basement membrane was seen 
in the med^.a in vacuoles in macrophage cytoplasm. They felt
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altered or damaged smooth muscle cells were important in the 
pathogenesis, as had Reinecke and Kuwabara (1969) in a 
preliminary study and in the above-mentioned paper the 
following year.
These studies were unable to agree on whether smooth 
muscle cell changes or IEL destruction and phagocytosis 
were of primary importance.
A confused picture thus emerges, with disagreement over 
the classification and staging of histological changes in 
GCA, the presence and significance of immune deposits and the 
meaning of ultrastructural changes.
I have therefore examined temporal artery biopsies with 
the help of colleagues, using standard histology to classify 
the changes seen in GCA, immunoperoxidase stains to look for 
immunoglobulin and complement deposition, and electron 
microscopy to examine the ultrastructure.
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3.2.2 METHODS
Temporal artery biopsy was attempted in 61 of the 78 
.patients with active untreated GCA described in Chapter 2. 
Details of age, sex, initial ESR, and relapses were also 
noted. Twenty-six positive TAB were examined from a further 
26 patients with active untreated GCA. Specimens were also 
examined from 2 patients with a severe flare of GCA despite 
several months therapy, 2 post-mortem specimens from treated 
GCA patients and 10 patients where PMR/GCA had been suspected 
but alternative diagnoses were later made. Thus 101 TAB in 
total were studied. Biopsies 0.5 - 1 cm in length were taken 
from a tender thickened section of artery where possible. 
Standard Histology
Biopsies were stained with haematoxylin-eosin and 
Weigert's Resorcin Fuchsia and Ponceau-S stains. Sections 
were defined as active or healed GCA, or normal as follows:
Active - Marked intimal thickening, mostly smooth muscle and 
elastin. Disruption and fragmentation of the internal elastic 
lamina with poor elastin staining. Mononuclear and giant 
cell inflammatory infiltrate in the media and adventitia. 
Healed - Marked intimal thickening, and fragmentation of the 
internal elastic lamina with poor staining. Inflammatory 
change much less marked but small scattered foci of 
mononuclear cells in the adventitia, and marked fibrosis in 
the intima and media.
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Normal Age Change
Intimal thickening, non uniform. Internal elastic 
lamina stretched and sometimes duplicated but only 
occasionally broken, with good elastin staining. No 
significant medial fibrosis but patchy new collagen formation 
and calcification underneath the elastic lamina.
Immunohistochemistry
Immunoperoxidase studies were carried out on TAB from 
22 patients with a clinical diagnosis of PMR/GCA and 10 
patients where an alternative diagnosis was later reached. 
These were stained with antisera to immunoglobulins G, A ands
M and the third component of complement C3.
Electron Microscopy
Seventeen TABs were fixed for electron microscopy. Six 
were from patients with active GCA, 3 from patients with PMR 
and one was from a patient where PMR/GCA was suspected but 
later disproved. Seven post-mortem control TABs were also 
examined. Survey light micrographs of 1 urn sections were 
made on all the arteries, and electron micrographs of ultra 
thin sections of 3 with active GCA, 1 control where GCA had 
been wrongly suspected and 2 post-mortem controls. One of 
these was a 'cot death1 case of a baby of 3 months and the 
other a 72 year old man who died from myocardial infarction 
but had no evidence of PMR/GCA.
I fixed the biopsies immediately after they were 
taken in 2.5% glutaraldehyde in 0.09 M cacodylate buffer, (pH 
7.2), containing 3 mM calcium chloride for 2 hours at room 
temperature. They were then stored in the same buffer at 4°C
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before further processing. Subsequently the biopsies were 
fixed in 1% (w/v) osmium tetroxide in 0.1 M-cacodylate
buffer, (pH 7.2) containing 3 mM-calcium chloride, for 1 h at 
room temperature, rinsed briefly with distilled water,stained 
with 0.5% (w/v) aqueous uranyl acetate for 1 h at room
temperature, dehydrated in ethanol and flat-embedded in 
Araldite in silicone rubber moulds.
For light microscopy, sections 1 urn thick were cut from 
the Araldite blocks and stained with Toluidine Blue. Adjacent 
thin sections (50-80 nm) for electron microscopy were stained 
with lead citrate and examined in a Philips 201C electron 
microscope operating at 60 kV.
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3.2.3. RESULTS 
Histology
Temporal artery biopsy was attempted in 61 patients 
from my prospective study. Eight biopsies were unsuccessful 
and one patient refused to go through with the procedure. 
Of the 52 successful TAB, 31 (60%) were positive for GCA, 15 
showing active arteritis and 16 healed arteritis.
Figures 3, 4 and 5 show typical examples of active, 
healed and normal biopsies. Figure 6 and 7 show examples of 
normal age changes. Classification of the biopsies was 
generally made without difficulty? later blind review by one 
pathologist yielded the same results. There was one case 
where it was difficult to decide whether healed arteritis or 
ageing changes were present? an eventual diagnosis of healed 
arteritis was made. The distribution of active, healed and 
negative biopsies in relation to the presenting diagnosis is 
shown in Table 7. Table 8, 9 and 10 show the age, sex, 
presenting diagnosis, length of history, initial ESR and 
number of relapses over the period of follow-up, separating 
the patients by the TAB result. Three patients were included 
in the study of data on presentation but not followed-up. 
Diagnosis
Patients with PMR were significantly more likely to 
have a negative biopsy than those with GCA, (p < 0.001). 
The incidence of active, healed or negative biopsies was 
significantly different (p < 0.001) for PMR patients compared 
to GCA (Table 7).
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ACTIVE ARTERITIS ON TEMPORAL ARTERY BIOPSY
Figure 3
There is marked intimal proliferation with virtual 
obliteration of the lumen (l) and an inflammatory 
infiltrate including giant cells (gc). (H & E x 80)
HEALED ARTERITIS ON TEMPORAL ARTERY BIOPSY
Figure k
Intimal thickening with fragmentation of the internal 
elastic lamina ^IEL) and fibrosis in the intima and 
media.(Weigert1s Resorcin Fuschin and Ponceau S x 80)
NORMAL TEMPORAL ARTERY BIOPSY
Figure 3
Artery taken from a child, showing intact elastic lamina 
(IEL) bordering on the lumen with no inflammatory infiltrate. 
(Weigert!s Resorcin Fuschin and Ponceau S x 80)
NORMAL AGE CHANGES IN TEMPORAL ARTERY BIOPSY
Intima
Figure 6
Moderate intimal thickening, with some stretching and 
duplication of the internal elastic lamina 1-^1,no 
fragmentation.! Weigert’s Resorcin Fuschin and Ponceau 
S x 80)
NORMAL AGE CHANGES IN TEMPORAL ARTERY BIOPSY
Intiroa...
Figure 7
Intimal thickening with duplication of the internal 
elastic lamina (IEL); no inflammatory infiltrate.
(Weigert’s Resorcin Fuschin and Ponceau S x 200)
TABLE 7
TEMPORAL ARTERY BIOPSY RESULTS AND DIAGNOSIS
Active Healed Negative
GCA 15 11 h
PMR 0 5 17
69
TABLE 8
CLINICAL CHARACTERISTICS AND ESR OF PATIENTS WITH 
ACTIVE ARTERITIS ON TAB
Lge Sex Diagnosis
Length of 
History 
(months)
ESR Relapses/Year Follow-up (weeks)
J6 F GCA 2 7A 0 A
72 F GCA 1 71 1.8 119
’2 F GCA 12 71 A.O 103
’3 F GCA A 50 2.7 177
>2 F GCA 1 91 1.1 91
'0 F GCA 1 66 0 9A
'8 F GCA 6 62 - - ■
'2 F GCA 1 115 1.3 AO
'A F GCA 1 100 0 19
'1 F GCA 2 121 0 21
'8 F GCA 12 110 2.7 19
'7. F GCA 1 62 10.A 15
'6 F GCA 1 75 0 1A
7 F GCA A 85 0 6
3 M GCA 1 115 -
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TABLE 9
CLINICAL CHARACTERISTICS AND ESR OF PATIENTS WITH 
HEALED ARTERITIS ON TAB
j^ ge Sex Diagnosis
Length of 
History
(months)
ESR Relapses/Year Follow-up (weeks)
67 F GCA 2 91 1.2 178
72 F GCA 12 46 2.5 146
85 F GCA 1 61 1.2 136
76 F PMR 1 32 1.4 112
74 F PMR 1 120 1.9 107
76 M GCA 12 84 2.0 79
74 ' M PMR 2 77 1.2 86
66 F GCA 6 119 2.2 116
70 M GCA 4 44 0 56
83 M PMR 2 82 0 47
b F GCA 12 42 2.0 52
63 F GCA 2 32 - -
SI F PMR 1 52 1.5 34
,65 F GCA 6 72 4.0 20
S3 F GCA 1 85 3.7 14
79 F GCA 12 47 4.7 11
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TABLE 10
CLINICAL CHARACTERISTICS AND ESR OF PATIENTS WITH
NEGATIVE TAB
!
Age Sex Diagnosis
Length of 
History 
(months)
ESR Relapses/Year Follow-up (weeks)
69 M PMR 2 AO 1.2 174
69 F PMR 2 69 1.4 148
71 M PMR 2 108 0 43
63 F PMR 4 38 0.8 126
78 F GCA 1 79 1.6 96
76 M PMR 2 63 1.2 86
72 F PMR 6 48 1.4 77
60 F PMR 1 75 1.3 80
51 F GCA 1 91 2.6 60
60 F GCA 2 118 0 48
78 F PMR 4 62 0.8 69
52 F PMR 1 97 4.2 62
78 M PMR 1 110 1.7 60
60 F PMR 1 68 2.9 18
60 M PMR 2 66 1.9 53
. 56 F PMR 2 55 0 41
69 F PMR 2 82 2.9 36
78 F PMR 1 85 7.7 27
62 F GCA 2 50 6.9 30
67 F PMR 2 60 4.7 11
66 F PMR 2 106 3.1 17
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Age
The ages of patients with active, healed or negative 
biopsies were significantly different (p < 0.01) due to the 
difference between the negative biopsy group compared with 
patients with active or healed biopsies. Mean ages and 
standard errors are shown in Figure 8.
Length of History
The duration of symptoms before TAB was longest in 
those with healed biopsies and shortest in those with 
negative biopsies but the difference between the subgroups 
just failed to reach significance at the 5% level. (These 
results with means and S.E. are shown in Figure 9).
Statistical analysis showed no significant difference 
in sex, presenting ESR, relapses and follow-up in each group. 
This held both when 'positive' (i.e. active and healed) 
biopsies were compared with negative, and when the 3 
histological groups were compared. Mean values with SE for 
ESR and relapses in each histological group are shown in 
Figures 10 and 11.
Histology on Other Patients
Of the 26 positive biopsies from patients with active 
untreated disease, 19 showed active GCA and 7 healed 
arteritis. All these patients had presented acutely with GCA 
to general physicians or ophthalmologists. One of the 
patients on steroids experiencing a flare-up had active 
arteritis? in the other, the biopsy was normal. (A 
pretreatment biopsy in that case had shown healed
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AGE RELATED TO HISTOLOGY
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Figure 8
Mean age at diagnosis. Patients with negative biopsies 
were significantly younger (66.4 years) than those with 
active biopsies (74.7 years) or healed biopsies (73.6 yrs. 
S.E. not shown (all <1.86).
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HISTOLOGY
Figure 9
Mean history length (months). Bars = S.E.
ESR RELATED TO HISTOLOGY
100-1
ACTIVE HEALED NEGATIVE 
HISTOLOGY
Figure 10
Mean ESR (mm/hr). Bars = S.E. There was no significant 
difference Between histological subgroups.
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Figure 11
Mean number of relapses. Bars = S.E. There was no 
significant difference between histological subgroups
arteritis). Of the 2 post mortem specimens from patients 
with known GCAf one showed active disease in the temporal 
.arteries and the other healed arteritis in the temporal and 
also carotid arteries. Both were apparently asymptomatic and 
on steroids at the time of death, which was due to infection 
in one case and CVA in the other. Ten negative biopsies were 
examined from patients in whom PMR or GCA had been wrongly 
suspected. All showed fibroelastic intimal thickening 
compatible with age, 2 showed IEL degeneration, 1 medial 
degeneration and 1 calcification. The final diagnoses were 
rheumatoid arthritis (2 cases) chronic myeloid leukaemia (1 
case) and metastatic carcinoma (2 cases). In 3 patients 
headache settled spontaneously and in 2 muscular symptoms 
resolved spontaneously.
Immunoperoxidase Results
Immunoglobulin and complement deposits were seen in 7 
biopsies, 4 of which had active arteritis and 3 healed 
arteritis. No immunoglobulin or complement deposits were 
seen in 2 further biopsies with active arteritis, 9 with 
healed arteritis or any of the negative biopsies, 4 of which 
were from patients with clinical PMR/GCA. These results are 
shown in Table 11.
Active GCA
There was positive staining for IgG, IgM and C3 in 4 
biopsies and IgA was seen in 3. The deposits were found 
within plasma cells, as well as in extracellular locations 
within the media and deeper layers of the intima. There were 
patchy deposits of immunoglobulins along the surface of the
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TABLE lj_
IMMUNOPEROXIDASE STAINING IN TEMPORAL ARTERY BIOPSIES
Active Healed Negative
IgG k 2 -
IgA 3 1 -
IgM 4 - -
C3 4 - -
Numbers indicate positive immunoperoxidase 
stains in each histological category
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I EL and in 1 specimen IgG was seen within giant cells 
adjacent to the IEL. These deposits on the IEL and within 
giant cells were associated with positive staining for C3. 
All 4 patients had clinical GCA. (Figure 12).
Healed Arteritis
Immunoglobulin deposits were seen in only 3 of the 12 
specimens showing healed arteritis. Two were positive for 
IgG and one for IgA. No C3 was seen. The deposits were 
extracellular and mostly near to the IEL in the intima and 
media. Two of these patients had PMR clinically and one GCA 
and this biopsy was IgG positive.
Normal Arteries
There were no significant deposits of immunoglobulins 
in the 14 negative biopsies. Some specimens showed weak 
positive staining for immunoglobulins in the layers of intima 
bordering on the lumen of the artery and in the adventitia, 
around blood vessels supplying it. These appearances were 
felt to be due to non-specific diffusion of plasma globulins. 
Electron Microscopy Results 
GCA Patients
Routine histology had shown classical acute GCA in 2 
patients and chronic inflammatory changes in the third with a 
suggestion of active arteritis nearby.
Case 1
Light micrographs from lum sections of the Araldite 
blocks prepared for electron microscopy confirmed florid 
active arteritis with obliteration of the lumen and
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IMMUNOPEROXIDASE STAINING OF TEMPORAL
ARTERY BIOPSY FOR IgG
IgG
Figure 12
Deposits of immunoglobulin G (IgG) around the internal 
elastic lamina and inner layers of an artery with active 
arteritis, (x 80)
fragmentation and destruction of the internal elastic lamina 
(IEL) (Fig. 13).
Electron microscopy showed gross disintegration of the 
IEL. The elastin was irregular and 'frayed' on the intimal 
side (Fig. 14). Inflammatory cells were prominent in the 
media and intima, which were more cellular than normal. 
Degenerating material, possibly IEL, was seen in the intima. 
Plasma cells with increased endoplasmic reticulum were noted. 
The lumen was occluded and lymphocytes were seen in this 
area.
Case 2
The light microscopy sections confirmed the findings of 
routine histology, with acute GCA, severe damage to the 
elastic lamina and extensive inflammatory infiltration in the 
media. Intimal thickening was less prominent in the 
Araldite section, illustrating the variation from one region 
of the artery to another.
Electron microscopy showed that the IEL was 
degenerating and 'frayed' on the intimal side (Fig. 
15). Degenerated material, probably IEL, was present in the 
intima (Fig. 16). Smooth muscle cells, which occurred in both 
intima and media, had abnormally diffuse basement membranes, 
swollen mitochondria and a stellate configuration (Fig. 17). 
The endothelial cells surrounding the lumen were generally 
normal although a few were disrupted.
Case 3
Standard histology on the artery from this patient 
suggested active GCA nearby but showed only inflammatory
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ACTIVE ARTERITIS ON TEMPORAL ARTERY BIOPSY
Intima
Figure 13
Light micrograph from a temporal artery biopsy prepared 
for electron microscopy, showing obliteration of the 
lumen |— ►) with intimal proliferation,fragmentation of 
the internal elastic lamina (IEL) and inflammatory 
infiltrate (x 170).
ELECTRON MICROGRAPH OF IEL IN ACTIVE GCA
M e d ia
Intima
Figure 1A
Frayed internal elastic lamina (IEL) on the intimal 
aspect ( x 8500).
ELECTRON MICROGRAPH OF DEGENERATION OF THE IEL
IN ACTIVE GCA
Figure 15
Fragmentation and degeneration of the internal elastic 
lamina (IEL) with gap (*) (x 8500).
Media*
Intima
ELECTRON MICROGRAPH WITH DEGENERATING MATERIAL
IN THE INTIMA
Intima
Figure 16
Degenerated material (D) in the intima, possibly from 
the internal elastic lamina (IEL) which is fraying on
the intimal aspect (x20000).
ELECTRON MICROGRAPH OF ABNORMAL SMOOTH MUSCLE CELLS
Figure 17
Abnormal smooth muscle cells (SM) in the media (M) with 
a stellate configuration, and swollen mitochondria (Ml) 
(x 20000). IEL = Internal elastic lamina.
infiltration in the sections examined. Light microscopy of 
the Araldite sections also showed a marked inflammatory 
infiltrate with patchy IEL fragmentation and destruction, and 
moderate intimal hyperplasia.
Electron microscopy showed a disintegration of the IEL 
which was extremely severe in places (Figs. 18 and 19). 
Smooth muscle cells appeared to be in the process of moving 
from the media through gaps in the fragmented IEL (Fig. 20) 
and into the intima. Many looked abnormal with swollen 
mitochondria and loss of their usual cuboidal shape and 
smooth edged basement membrane.
Normal Controls 
Case 4
Standard histology showed intimal hyperplasia 
compatible with age but no arteritis, and a similar picture 
was seen in light micrographs of Araldite sections. 
Electron microscopy showed that the IEL tended to 'fray' on 
the intimal side but was intact and less granular than in 
the patients with GCA (Fig. 21). Smooth muscle cells were 
regularly shaped, with a smooth basement membrane and 
pavement-like appearance in the media. Small amounts of 
degenerating material, possibly smooth muscle basement 
membrane, were seen in one section.
Case 5
This post-mortem control of an elderly man with 
ischaemic heart disease showed intimal thickening compatible 
with ageing in the light micrographs (Fig. 22) but no signs
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ELECTRON MICROGRAPH WITH INTERNAL ELASTIC LAMINA DISINTEGRATION
Figure 18
Disintegration of the internal elastic lamina (IEL) with 
breakdown particularly on the intimal aspect in active 
GCA (x 8500).
ELECTRON MICROGRAPH WITH 
INTERNAL ELASTIC LAMINA DISINTEGRATION
Intima
Figure 19
Higher power of disintegration of the internal elastic lamina 
(IEL) from the same patient as in Figure 18 (x 20000).
ELECTRON MICROGRAPH OF SMOOTH MUSCLE CELL
MOVING THROUGH IEL
M ed i a
Intima
Figure 20
Smooth muscle cell moving through a break[ 1 in internal
elastic lamina to the intimal side in active GCA (x S500)
ELECTRON MICROGRAPH OF NORMAL TEMPORAL ARTERY
Media
|Pi£; f
Intim a
Figure 21
Internal elastic lamina (IEL) from a normal control, which 
is intact, less granular and with only minor intimal fraying 
(x 20000).
LIGHT MICROGRAPH OF NORMAL AGE CHANGES IN TEMPORAL ARTERY
Figure 22
Post-mortem control showing intimal thickening (i) hut norma 
internal elastic lamina (x A30).
of arteritis. The electron micrographs demonstrated a less 
cellular intima than that in acute GCA. The IEL looked 
generally regular and even, but slightly. - ragged on the 
intimal aspect. No significant destruction was seen and 
smooth muscle and medial cells were normal (Fig. 23). Some 
post-mortem artefacts were seen with swelling of the 
endothelial cells.
Case 6
The third control was a 3 month old baby who was a 'cot 
death1. Light micrographs showed clearly the lack of intimal 
thickening in the young, with the IEL virtually bordering on 
the lumen (Fig. 24). In electron micrographs the IEL 
appeared smooth and less granular than in both adult 
controls and GCA and it was of interest that Gram-negative 
bacteria were seen in the lumen, close to the endothelial 
surface (Fig. 25). Normal closely-packed collagen fibres 
were recognisable in the media, but there was evidence of 
post-mortem osmotic damage to the smooth muscle cells (Fig. 
26).
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ELECTRON MICROGRAPH OF NORMAL TEMPORAL ARTERY (p m )
Intima
Figure 23
Post-mortem control, showing normal internal elastic lamina 
(IEL) with slight intimal fraying, and normal cells in the 
media (M) ( x  8500).
LIGHT MICROGRAPH OF TEMPORAL ARTERY FROM A BABY
Figure 2A
Temporal artery Biopsy from a cot death case aged 3 months, 
with no intimal thickening and the internal elastic lamina 
(IEL) Bordering on the lumen (x A30).
ELECTRON MICROGRAPH OF TEMPORAL ARTERY FROM A BABY
Figure 23
Cot death case showing smooth internal elastic lamina (IEL) 
Bordering on the lumen, which contains Gram-negative Bacteria 
(arrowed) (x 8500).
ELECTRON MICROGRAPH OF TEMPORAL ARTERY FROM A BABY
Figure 26
The same cot death case showing normal collagen fibres (arrowed) 
in the media (x 12000).
3.2.4. DISCUSSION 
Histological Classification
The incidence of positive TAB in this' study was 60%, 
similar to the results in previous Scandinavian studies. If 
PMR and GCA are examined separately, 82% of TAB on patients 
with GCA (with or without PMR) were positive but only 23% TAB 
from patients with PMR alone were positive. This highly 
significant difference agrees with previous retrospective 
reports, although the incidence of positive biopsies in PMR 
only is somewhat lower than the 31% reported by Bengtsson and 
Malmvall (1981a). Although Hall et al. (1983) reported 
arteritis on TAB in 94% of patients, these were all GCA 
cases. The high incidence was almost certainly related to 
their practice of taking biopsies of 4 cm (median) , and if 
initial specimens were negative, proceeding to biopsy the 
other temporal artery.
When the number of healed biopsies was compared to the 
number with active biopsies, there was again a significant 
difference between PMR and GCA patients. Fifty-eight per 
cent of positive biopsies were active rather than healed in 
GCA patients, but all the positive biopsies in PMR patients 
showed healed rather than active arteritis. This contrasts 
sharply with the results of Allsop and Gallacher (1981) who 
rarely reported healed arteritis despite a similar definition 
of this category. However, differences in histological 
classification or in patient selection may account for the 
discrepancy. Both these authors, and Mambo (1979) included a 
separate classification of biopsies where no, or only
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occasional, giant cells were seen. This seems illogical, as 
the same artery may have giant cells and active inflammation 
in one section, and no giant cells in another section of 
acute inflammation.
The biopsies of the 26 patients who had been referred 
to physicians and ophthalmologists with acute visual symptoms 
or florid temporal arteritis had a higher proportion of 
active compared to healed biopsies (73%). This may 
represent the level of acute clinical activity in these 
patients, and also none had PMR only. However, in the 
prospective study of 52 biopsies, using the initial ESR and 
number of relapses on follow-up as a measure of disease 
activity, there was no significant difference in these 
parameters when active biopsies were compared with healed or 
negative, or when positive (active and healed) were compared 
with negative biopsies.
There was a trend towards a longer mean history in 
those with healed biopsies (mean 4.5 months) compared with 
those with active biopsies (mean 2.8 months) and with 
negative biopsies (1.7 months). Despite the differences 
between the groups this just failed to reach significance (at 
the 5% level). This suggests that a histological healing 
phase may occur in at least some sections of arteries from 
patients with a longer history. However, it is of interest 
that in post mortem studies active arteritis was still 
present years after the initial presentation.
There was a significant difference in age when the
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active biopsy and the healed biopsy groups were compared with 
the negative group and when all positive (active and healed) 
were compared with negative. This was not explained by the 
age of those with GCA (mean 72.0, SE 1.4) compared to those 
with PMR (mean 69.4, SE 1.79). There was no significant 
difference in the ages of patients with active biopsies 
compared with healed.
These results suggest that TAB is a worthwhile test, 
particularly in patients with clinical GCA. The incidence of 
positive biopsies was high (82%) and provides definitive 
evidence of the diagnosis before patients embark on what may 
be several years of potentially hazardous treatment with 
steroids. Although in this study the incidence of positive 
TAB in PMR was low, if the investigation can be readily 
carried out it remains a safe procedure which may demonstrate 
histological arteritis.
'Healed' arteritis is a recognisable histological 
entity and is seen in a third to a half of positive biopsies 
in our hands. It does not appear to help in predicting the 
course of PMR/GCA.
Steroids appear to have a variable effect on the 
changes of acute arteritis and the reasons for this variation 
remain unclear.
Pathogenesis of Arteritis
There are 2 main hypotheses about the pathological 
changes in GCA. The first proposes that damage to elastin is 
the initial ,event, the second that smooth muscle cell damage 
and activity are responsible. The evidence for elastin damage
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centres on the recognition that elastin is not antigenically 
inert, the unique fragmentation of the IEL,■'animal studies 
demonstrating similar reactions to elastin degradation, and 
the immune deposits which have been recognised close to the 
damaged IEL by immunofluorescence intially and in this study 
with immunoperoxidase staining.
A third mechanism was proposed by Minick, Alonso and 
Rankin (1977), who tried to relate the changes in GCA to 
those in atherosclerosis. They observed that immunological 
stimulation leads to fibrous intimal thickening, and that 
initial endothelial injury and platelet interaction with 
artery wall occurs in immune complex arterial lesions and in 
graft rejection, leading to intimal thickening in both. 
However, in graft arteriosclerosis (due either to an Arthus 
reaction mediated by cytotoxic antibodies or cell mediated 
damage involving lymphokines) the damage is largely confined 
to the intima, and the IEL remains intact. This therefore 
appears to be a different mechanism of arterial damage from 
that occurring in GCA.
There has been no supporting evidence for a fourth 
theory (O'Brien 1978) that actinic damage to elastin, 
particularly on the outer exposed side of temporal arteries, 
leads to elastolysis and GCA. We found no evidence of the 
asymmetrical elastin damage he describes.
Reinecke and Kuwabara (1969) felt smooth muscle cell 
destruction was occurring early in the disease with elastica 
being formed from the basement membrane of these cells? they
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did not find giant cells close to the IEL and felt elastin 
was not the site of primary insult. These findings were 
.based on light and electron microscopy studies? our light 
microscopy studies did not confirm random positioning of 
giant cells but found them close to the IEL as others have 
done, and containing IgM on one occasion.
The immunoperoxidase studies showed Ig and complement 
deposits in some active biopsies, and occasional Ig deposits 
in healed biopsies. This was less sensitive than standard 
histology in detecting arteritis and does not support the 
view of Waaler et al. (1976) that immune deposits seen in 
cases of very mild inflammation were useful in confirming the 
dignosis. As in immunofluorescene studies by Liang et al. 
(1974) Park and Hazleman (1978) and Bonnetblanc et al. 
(1978), extracellular immune deposits were often seen 
adjacent to the IEL. Intracellular staining was also seen, 
probably in relation to plasma cells. The results contrast 
with those of Gal lacher and Jones (1982) whose 
immunoperoxidase studies showed almost entirely intracellular 
Ig staining, no complement, and no IC deposition by the IEL.
Electron microscopy studies of arteries from GCA 
patients showed marked IEL fragmentation and destruction. 
Although some 'fraying' on the intimal side was seen in 
controls, the IEL was otherwise even and intact. 
Degenerating material which appeared to be IEL was seen in 
all 3 cases of active GCA in both the intima and media, but 
no phagocytosis of the elastic lamina was seen. In one 
biopsy where routine histology suggested arteritis nearby,
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marked changes were seen by electron microscopy with 
breakdown of the IEL. It is possible that-the EM section 
coincided with an active segment of arteritis. However, in 
light micrographs from an Araldite section, as in the 
routine histology section, the IEL did not appear grossly 
disrupted.
Abnormal smooth muscle cells apparently moving through 
gaps in the IEL were observed in biopsies from patients with 
GCA but not in controls, although in one control, normal 
smooth muscle cells were seen close to a gap in the IEL. 
Smooth muscle cells in biopsies from controls were regularly 
and compactly arrayed in the media with an even basement 
membrane. Others have described degenerating material in 
GCA patients which they felt was basement membrane (Kuwarara 
and Reinecke 1970, Albert et al. 1982) but in my patients the 
degenerating material seen closely resembled IEL in varying 
stages of disintegration, which was seen in all patients. 
We did not see giant cells or phagocytosis of the 
degenerating material although some histology sections 
contained giant cells. The endothelial cells were 
occasionally broken down but were usually normal.
This study therefore confirms previous descriptions of 
IEL destruction and also smooth muscle cell abnormalities. 
The question remains as to whether the primary abnormality 
exists in the IEL or in smooth muscle cells. The former 
seems more likely, for several reasons. Firstly, others have 
shown that the condition affects arteries which contain
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elastin; intracerebral arteries containing smooth muscle 
cells but minimal elastin are rarely affected. Secondly, in 
this study immunoperoxidase staining showed that Ig and 
complement were most often deposited beside the IEL or in 
giant cells which may have been phagocytosing it. Thirdly, 
the degenerating material seen in acute GCA appeared to be 
IEL not smooth muscle basement membrane. The IEL changes 
were far more prominent than the smooth muscle cell changes. 
From the appearances in one control EM, smooth muscle cells 
in normal arteries appear to move towards and probably 
through natural ageing splits in the IEL.
However, no further clues emerged from the EM study as 
to why the IEL breaks down. Although changes were more 
obvious in the EM than in routine histology in one case, EM 
does not appear to be a more useful way of diagnosing GCA.
It is curious that although all studies including ours, 
have noted degenerating fibrillar material, there are no 
reports of phagocytosis of this material by giant cells. 
This may have been missed given the small number of studies 
performed.
On the basis of standard histological, immunoperoxidase 
and electron microscopy studies, our results support the 
first hypothesis: that elastic lamina destruction is the
primary event in the arteritis seen in GCA. It remains 
unclear whether the immune deposits seen represent passive 
lodging or<a specific reaction to an arterial wall component. 
As numbers were small, further EM studies are needed.
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3.3 HEPATIC ABNORMALITIES
3.3.1 INTRODUCTION
The reported incidence of laboratory abnormalities of 
liver function in patients with PMR/GCA shows considerable 
variation. Elevation of serum alkaline phosphatase has been 
reported in 10 - 100% of PMR/GCA patients (Hall and
Hargreaves 1972, Mowat and Hazleman 1974, Malmvall and 
Bengtsson 1978, Chuang et al. 1982). Hall and Hargreaves 
pointed out that levels returned to normal after treatment 
with steroids. Buerk and Smith (1972) felt that raised 
alkaline phosphatase was more common in PMR than GCA. 
Isoenzyme studies have confirmed the hepatic origin (Gibbs 
1974, Von Knorring and Wasatjerna 1976). The last-mentioned 
authors also observed a striking correlation between the 
degree of increase in alkaline phosphatase activity, ESR and 
the clinical severity of PMR in their patients. Some 
patients had constitutional symptoms and a high ESR and 
alkaline phosphatase before myalgic symptoms developed? they 
felt these systemic features might be due to subclinical 
hepatic disease. Serum albumin is often low (Fauchald et 
al. 1972, Dickson et al. 1973), although Hamilton et al. 
(1971) found normal albumin levels in all their PMR/GCA 
patients. Some authors report mildly elevated transaminases 
in around 20-40% of patients (Wadman and Werner 1972(a), 
McCormack et al. 1978, Chuang et al. 1982) but Malmvall and 
Bengtsson (1978) found transaminases elevated in only 10% 
PMR/GCA patients. These abnormalities do not appear to 
contribute to symptoms of PMR/GCA, nor is hepatomegaly noted
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clinically in most cases. Their cause and relationship to 
the pathogenesis of the condition have yet to be adequately 
explained. A limited number of liver biopsies have been 
carried out in PMR/GCA and most are normal or show minor 
nonspecific changes. There are two published reports of 
arteritis, one in the hepatic artery at post-mortem 
(Heptinstall, Porter and Barkley 1954), and one of arteritis 
of the portal tract arteries and septal vessels (Ogilvie, 
James and Toghill 1981). Hepatic granulomata have been
reported (Long and James 1974, Kosolcharoen and Magnin 1976, 
Litwack, Bohan and Silverman 1977, McCormack, Astarita and 
Foroozan 1978, Fainaru, Friedman and Friedman 1979). Von 
Knorring and Wasatjerna (1976) found lymphocytes and 
increased alkaline phosphatase activity in the bile 
canaliculi, and suggested that parenchymal inflammation was 
present. Leong and Alp’s (1981) findings of hepatocyte 
necrosis with accompanying portal and lobular inflammation 
supported this. McCormack et al. (1978) found intrahepatic 
cholestasis and suggested this could have been due to patchy 
immune complex deposition in the hepatic arteries. Primary 
biliary cirrhosis has been reported in association with 
PMR/GCA (Robertson, Batstone and Loebl 1978, Hamblin 1981, 
Sattar et al. 1984) but in some cases the diagnosis rested on 
elevation of serum alkaline phosphatase and positive anti- 
mitochondrial antibody with no histological confirmation. 
Electron microscopy was carried out by Terwindt and Knoben 
(1966) in an early report of abnormal liver tests in PMR?
88
the abnormalities were nonspecific and chiefly affected the 
mitochondria. Light microscopy was normal.
There are few reports of radionuclide liver scans in 
PMR/GCA. Normal scans have been reported in 8 patients (Long 
and James 1974, Ghose, Shensa and Lerner 1976, Litwack et al. 
1977, McCormack et al. 1978, Leong and Alp 1981, Ogilvie et 
al. 1981, Jones 1983). We have reported abnormal liver scans 
in 6 patients (Jones et al. 1984) showing hepatomegaly in all 
6, patchy tracer distribution compatible with diffuse disease 
in 5, and focal defects suggestive of metastatic disease in 
3. There are 2 further reports of scans showing focal 
defects (Mann and Toole 1972, Ghose et al. 1976). There are 
no reports of follow-up liver scans in PMR/GCA.
This section describes a prospective study of liver 
function tests and isotope liver scans before and after 
treatment, including blood flow studies to document liver 
involvement in PMR/GCA and explore its significance.
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3.3.2 PATIENTS AND METHODS
All 74 patients with active untreated PMR/GCA as 
described earlier were included in this study. Past medical 
history, drug history and alcohol intake were recorded, and 
patients were examined for hepatomegaly and stigmata of liver 
disease. Serum albumin, alkaline phosphatase, bilirubin and 
ALT were measured before treatment and regularly during 
follow-up.
9^mTechnetium (Tc) sulphur colloid liver scans were 
carried out on 29 consecutive patients with active untreated 
GCA. Follow-up scans were carried out after 6-21 months 
(mean 12.4) on 15 of these patients. Flow studies were 
performed in 26 of the pretreatment scans, and in 13 of the 
follow-up scans. Scans were reported 'blind' by a Consultant 
in Nuclear Medicine.
Scintigraphy Method
Patients were positioned supine over a large field of 
view gamma camera with high sensitivity collimator. 150 MBq 
of 99mTc sulphur colloid were administered as a rapid 
intravenous bolus. Sequential posterior frames were recorded 
for 5 minutes, initially at 2 second intervals and later at 6 
second intervals. During later conventional static imaging 
30 second anterior and posterior images of liver and spleen 
were recorded. The data were analysed using a Varian V77 
computer. Regions of interest were drawn around liver and 
spleen on the anterior and posterior late views and the total 
relative uptake in each organ calculated from the geometric 
mean of the anterior and posterior counts. The arterial
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component of the hepatic uptake was identified using the 
method described by Wraight, Barber and Ritson (1982). The 
arterial fraction of hepatic flow was then calculated, 
applying correction for the colloid removed from the portal 
circulation by the spleen. The normal range was 0.1-0.3. 
The rate of clearance of tracer from the cardiac blood pool 
was measured as an estimate of total liver blood flow, and an 
index of total hepatic flow calculated (Wraight et al. 1982). 
The normal range for flow index was 0.28-0.42. The normal 
values for the arterial fraction of hepatic flow and and the 
flow index were calculated from a population who were younger 
than most of the PMR/GCA patients. There was no evidence 
that values altered with age.
Normal Values
(a) Laboratory tests Alkaline phosphatase 30-135 IU/L
Albumin 30-51 g/L
(b) Scans Isotope scans may become slightly
patchier with age; this was 
allowed for when these were reported.
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3.3.3 RESULTS 
Clinical
No patients had significant hepatomegaly or stigmata of 
chronic liver disease.
Liver Function Tests (LFTs)
27 of 70 patients (38.6%) had elevated alkaline 
phosphatase levels before treatment. The mean values for each 
subgroup were PMR 128 IU/L (SE 10.56), GCA 136.94 (SE 12.42). 
The range was 60-375 IU/L. These were not significantly 
different. When the arteritis patients were separated into 
those with and without PMR, mean alkaline phosphatase levels 
were 142.35 IU/L (SE 13.92) and 131.19 (SE 11.71) (no 
significant difference). The proportion with abnormal values 
was slightly higher in the group with GCA (15/33 ; 45%) 
compared with PMR (12/37; 32%) but this was not significantly 
different. The mean level of elevated values was 192 IU/L. 
Serum albumin was reduced in 21 of 73 patients (28.8%). 
Eleven of these had PMR (28%), and 10 GCA (29%) including 3 
with GCA/PMR. Mean levels were: PMR 31.1 g/1 (SE 0.62) and
GCA 31.29 (SE 0.80). These were not significantly different? 
values for GCA only were 30.33 g/1 (0.83) and for GCA/PMR 
32.37 g/1 (0.79) (not significantly different). The mean 
time for both values to return to normal was 2.6 weeks. 
Temporal Artery Biopsies
The incidence of positive TAB was not significantly 
different in patients with abnormal LFTs compared to patients 
with normal LFTs.
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Late Abnormalities
Four patients with normal pre-treatment values 
•developed elevated alkaline phosphatase levels 8-79 weeks 
after treatment was started. In one case the level returned 
to normal after several months; the patient had recurrent 
dyspeptic symptoms but no flare of GCA and albumin levels 
remained normal. In 3 other cases alkaline phosphatase 
remained modestly elevated throughout follow-up, probably 
related to Paget's disease in one case, and to a flare-up in 
GCA activity in another. The cause in the third case was 
unclear. One patient had transient elevation of 
transaminases some months after treatment was started with no 
evidence of a recurrence of GCA.
Isotope Liver Scans
Seven patients (24%) had abnormal liver scans with 
patchy uptake. Four of these had GCA and 3 PMR only. Five 
had a raised alkaline phosphatase before treatment. Follow- 
up scans were carried out in 15 cases 11-18 months after 
treatment (mean 14.2). All the abnormal scans remained 
patchy although in 2 cases the liver was smaller. One 
further patient whose initial scan showed slight hepatomegaly 
had developed patchy changes. All the follow-up scans were 
carried out when the patients were clinically well and LFTs 
were normal.
The arterial fraction of total liver flow (A/P ratio) 
was within the normal range in all PMR patients before 
treatment but reduced in 4 GCA patients. All these values 
became normal after treatment. The mean level for the entire
93
group before treatment was 0.15 (SE 0.01).
When PMR and GCA were examined separately, the means 
were 0.17 (SE 0.01) and 0.13 (SE 0.01) respectively. These 
were significantly different (0.05 > p > 0.02) (Figure 27). 
Follow-up scans in 7 GCA patients gave a mean value of 0.14.
Seventy-five per cent of those with reduced A/P ratios 
had abnormal LFTs compared with 39% of the entire group. 
Patchiness of liver scan did not relate to abnormal A/P 
ratios.
The flow index values were within the normal range for 
the whole group (0.325) and PMR and GCA as subsets (0.329, SE 
0.032 and 0.323, SE 0.025) with no significant difference 
between the two. Three values were above normal (2 PMR, 1 
GCA) and 6 values were reduced (3 PMR, 3 GCA). Follow-up 
scans were carried out in 4 patients with abnormal flow index 
values, and they all returned to normal. There was no 
correlation between the presence of abnormal total hepatic 
flow values, and abnormal LFTs, or A:P ratios or patchy 
tracer uptake.
ARTERIAL : TOTAL HEPATIC BLOOD FLOW IN PMR AND GCA
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Figure 27
The ratio of arterial : total hepatic blood flow in 12 patients 
with PMR and 15 with GCA. Bars show S.E. The mean for GCA was 
significantly less than for PMR (0.05 > p>0.02).
3.3.4. DISCUSSION
Elevated serum alkaline phosphatase occurred in about 
40% of patients, the middle range of previous reports. 
Abnormalities were not significantly more common in GCA 
patients compared with PMR nor in GCA/PMR, and were not 
related to arteritis on TAB. The elevation was modest in 
most cases, and of the group means, only GCA without PMR was 
greater than normal. These findings support the concept of 
PMR and GCA as one disease but do not help our understanding 
of the cause of hepatic abnormalities. Levels fell to normal 
after treatment, and appear to reflect disease activity. As 
levels were not significantly different or abnormal more 
often in any one subgroup, it is difficult to explain the 
range of frequency of abnormal alkaline phosphatase levels in 
other studies by patient selection.
Low serum albumin levels were common and occurred 
equally frequently in each subgroup. Reduced levels are 
likely to be due at least partly to a negative acute phase 
reaction rather than true liver dysfunction. Again it is of 
note that levels returned to normal rapidly after treatment.
The occurrence of abnormal radionuclide scans in 
PMR/GCA was confirmed, with patchy tracer uptake +^mild 
hepatomegaly in about one quarter of the cases scanned. 
Abnormal scans were equally common in PMR and GCA as separate 
subgroups. Although the percentage with elevated alkaline 
phosphatase in the group scanned (40%) was similar to that in 
the total group (38%), levels were raised in a much higher 
percentage o f those with abnormal scans (71%). However,
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numbers involved are small and this may not be significant. 
Although alkaline phosphatase levels returned to normal after 
treatment, the patchy changes on scans persisted. This is an 
unexpected finding - follow-up scans have not been carried 
out previously but it was assumed that scan abnormalities 
reversed on treatment. It is recognised that the structural 
effects of GCA of the upper limb arteries rarely, if ever, 
disappear and it is possible that involvement of liver is 
similarly persistent, causing the relatively minor scan 
abnormalities described.
The significantly lower arterial fraction of total 
hepatic flow in patients with GCA but not PMR is interesting. 
This has not been measured before in GCA. Abnormal values 
returned to normal after treatment, although the mean
remained lower than in PMR. These findings would be
compatible with hepatic arteritis in GCA, causing reduced 
percentage of arterial flow. Several values were within the 
normal range, but it is possible that some patients have 
clinical temporal arteritis alone without hepatic
involvement. The absence of any low values in the PMR group 
is compatible with the low incidence of GCA on TAB of these 
patients. Patients with low A:P ratios were also more likely 
to have abnormal LFTs.
Interpretation of the flow index studies is more 
difficult, and it seems likely that overall these are normal. 
Isolated increases and decreases may represent liver
dysfunction and these abnormalities disappeared after
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clinical improvement. Results were similar in each subgroup. 
Values are known to be low in cirrhosis (where portal flow is 
.reduced). There is no reason why portal "flow should be 
reduced in PMR/GCA.
To summarise these results: patients with GCA have 
reduced ar ter ia 1: tota 1 flow ratios and this could be 
explained by hepatic arteritis. Patients with reduced A:P 
flow ratios and also those with abnormal scans are more 
likely to have elevated alkaline phosphatase levels. 
Abnormal alkaline phosphatase and albumin levels returned to 
normal with clinical improvement on treatment. Flow ratios 
became normal (although the mean remained lower than in PMR) 
but abnormal isotope liver scans remained abnormal. This 
may be because visible scan defects take longer to resolve 
than flow abnormalities, and a degree of arteritis may 
persist. It is also possible that the patchy changes on scan 
are not due to arteritis, but to other pathology such as 
granulomata, which have been documented in PMR/GCA, as 
discussed earlier.
It is also unclear whether alkaline phosphatase is a 
marker for hepatic involvement (as suggested by the elevation 
to around 70% in those with abnormal scans and reduced flow 
ratio) or whether it is a nonspecific marker of disease 
activity, rather like acute phase proteins. The isoenzyme 
studies classifying it as of liver origin are few and 
relatively outdated. The fact that it is elevated equally 
commonly in PMR and GCA, and that elevation was not related 
to the presence of histological arteritis, might favour a
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nonspecific role. Alternatively abnormal liver function in 
PMR/GCA as expressed by scan and flow ratio abnormalities, 
might be taken to represent more active arteritic disease in 
the liver? it would not therefore be suprising if elevation 
of alkaline phosphatase was more common in these groups.
There seems little doubt that the liver is affected in 
PMR/GCA? no evidence emerged over the 3 year follow-up of 
other pathology causing these abnormalities. Further 
investigation of the histological changes in the liver is 
clearly needed.
The clinical implications of these findings are also 
important. In patients presenting with nonspecific features, 
the findings of abnormal liver function tests and abnormal 
radionuclide scans may mislead the physician into suspecting 
malignancy. Even if PMR/GCA is suspected, additional 
pathology may be sought. Treatment with steroids may be 
delayed, putting the patient at risk of complications such as 
blindness.
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3.4 ABNORMALITIES IN JOINTS
3.4.1 INTRODUCTION
Although PMR was traditionally viewed as a condition 
affecting muscles and not as a form of arthritis, several 
authors have proposed that joint involvement is common and 
contributes significantly to symptoms. The reported extent 
of joint disease ranges from virtually nil to an axial 
synovitis as the cause of the pain and stiffness of PMR, with 
transient peripheral synovitis.
In Bruce's original report on 'senile rheumatic gout' 
(1888) he clearly separated the condition from recognised 
arthritic conditions such as gout and rheumatoid arthritis, 
although he did note mild peripheral joint swelling in two 
cases. The early reports of the twentieth century also 
emphasise the rarity of joint involvement (Cooke et al. 1946, 
Kersley 1956, Paulley and Hughes 1960). Bagratuni (1953) 
defined the condition as 'anarthritic rheumatism' and Barber 
(1957) commented on 'the absence of objective joint changes'. 
No erosions were seen on X-rays and there was no juxta 
articular osteoporosis. Gordon (1960) reported joint swelling 
but felt it was due to osteoarthritis. Dixon et al. (1966) 
noted that joint involvement was rare and repeated this view 
in 1983, stating that 'true synovitis does not occur'. 
Small, asymptomatic knee effusions were noted in 8 of 18 PMR 
patients but there was no joint inflammation or destruction, 
and the white cell count in the synovial fluid was low 
(Wilske and Healey 1967). Hamilton et al. (1971) reported 
that objective evidence of joint inflammation was unusual,
although patients complained of shoulder, hip and knee 
arthralgia. Five of 95 patients had signs of peripheral 
joint involvement in Bengtsson and Malmvall's study (1982) 
and no patient had arthritic involvement of the hips or 
shoulders. Corrigan et al. (1974) noted a polymyalgic onset 
in rheumatoid arthritis presenting in the elderly, and felt 
there was a clinical overlap between the two conditions. 
Myles (1975) found painless knee effusions in 6 of 84 
patients but did not find axial synovitis. Sorensen and 
Lorenzen (1977) noted arthralgia but no evidence of arthritis 
in their series of 63 PMR/GCA patients. All these authors 
emphasise the profound proximal muscle pain and stiffness 
which occurred in their patients in the absence of axial 
synovitis either clinically or on radiographs. Peripheral 
joint swelling was unusual, and where present, was transient 
and mild.
Other authors believe that axial synovitis causes the 
proximal muscle pain, stiffness and tenderness which occurs 
in PMR and find synovitis to be common. Coomes and Sharp 
(1961) described patients whose symptoms suggested PMR, who 
had painful central joints with limited movement and in some 
cases swelling. Central polyarthritis was diagnosed, and to 
demonstrate that this might cause PMR-like pain, they 
injected saline through anaesthetised skin into the shoulder 
girdle joints, subacromial bursa, manubrio-sterna1 joint, 
interosseus sacro-iliac ligaments and the atlanto-axial 
spinal ligament. This caused referred pain in various sites
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around the neck, chest wall, upper arm, shoulder top, 
forearm, thumb, posterior scalp, lumbar region and outer 
.groin, felt 'over the muscle masses'. The authors therefore 
suggested that PMR was a form of arthritis affecting 
predominantly the spine and limb girdles, and noted that 
consistent muscular abnormalities had not been described. 
However, the following year Russell (1962) reported finding 
changes of GCA in a medium-sized artery in a deltoid muscle 
biopsy, from a male with GCA who subsequently developed PMR. 
In 1964 Gordon, Rennie and Branwood reported 6 shoulder joint 
biopsies from PMR patients which showed minor non-specific 
infiltration and suggested that synovial and periarticular 
inflammation caused muscle and periarticular symptoms in PMR. 
Andrews ( 1965) reported a series of 44 PMR patients; 
biopsies of the acromioclavicular joint in 7 cases showed 
'arthrosis' in 5 (this was not defined further) and pannus in 
1? 1 was normal. Muscle biopsies in these cases were
normal and so were plain radiographs of hands, feet, lumbar 
and cervical spine and sacro-iliac joints. The degree of 
morning stiffness was noted to be greater than that found in 
rheumatoid arthritis. Andrews felt that PMR syndrome might 
have various causes, including central arthritis and 
rheumatoid arthritis. Bruk (1967) reported palpable
synovial thickening or effusion in at least two-thirds of 80 
cases, often with central joint tenderness and limitation of 
spine and shoulder girdle movement. The sterno-clavicular 
joints were thickened in 40% of cases and biopsy of 5 showed 
chronic non-specific synovitis; X-rays showed erosive
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changes, especially of the sterno-clavicular joints, and/or 
sclerosis of the sacro-iliac joints in 17 patients. Muscle 
biopsies were normal in 17 cases, and muscle pain and 
tenderness were usually abolished by injection of local 
anaesthetic into appropriate tender focal areas in central 
joints, tendons and ligaments. These abnormalities occurred 
equally commonly in those with and without histological 
evidence of arteritis. Henderson, Tribe and Dixon (1975) 
documented peripheral synovitis in 5 of 88 cases on clinical 
grounds, radiologically and on examination of synovial tissue 
and fluid. Isotope scans (O'Duffy, Wahner and Hunder 1976) 
were reported to show abnormalities in 24 of 25 PMR patients, 
especially of shoulders but also over knees, wrists and 
hands, although joint swelling if present was minimal and 
transient. A follow-up study by the same group in 1980 
showed 13 of 16 scans were still abnormal with radiological 
abnormalities of the sacro-iliac joints and symphysis pubis 
in 7 of 18 cases. Miller and Stevens (1978) reported 
swelling and/or tenderness of the sterno-clavicular joints in 
15% of 39 PMR patients.Chuang et al. (1982) reported 
synovitis in 11 of 96 cases but the shoulders were affected 
in only 2 cases and the sterno-clavicular joints in 1 case. 
Tomograms ofsterno-clavicular joints were reported to show 
erosions in 11 of 25 patients (Paice et al. 1983) with 
abnormal joint scans in 20 of 22 cases. Soft tissue swelling 
was reported overthe sterno-clavicular joints (7 cases), 
knees (4), 'inanubrio-sternal joints (2) and wrists (1). Eight
of 12 patients with abnormal sterno-clavicular joint scans 
had erosions on tomography compared with 3 patients with 
normal scans. Follow-up scans and tomograms were still 
abnormal, though changes were less marked in most cases. 
Douglas, Martin and Morris (1984) carried out arthroscopy 
and biopsy of the shoulder joints of 19 PMR patients; 17 had 
synovitis on direct inspection but changes histologically 
were mild. Five isotope scans were performed; the shoulders 
were abnormal in one case and the sterno-clavicular joints in 
another. Chou and Schumacher (1984) found joint swelling, 
usually of the knees, in 10 of 15 PMR patients. Sterno­
clavicular erosions were seen in one patient. Radiological 
osteoarthritis of the knee was seen in 4 patients; 
examination of synovial fluid from 7 knees and one shoulder 
showed a white cell count of 300-5700/mm3. Synovial biopsy 
demonstrated mild synovial proliferation in 5 cases. Healey 
(1984) carried out a long-term follow-up study of 246 PMR/GCA 
patients and reported synovitis in 31%, especially of the 
knee, followed by the wrist. Where synovial fluid was 
obtained, the white cell count was usually >4000/mm . No 
erosions were seen on X-ray and no joint deformity developed. 
The role of arteritis in causing muscular symptoms was again 
raised by Bussiere et al. (1984) who reported the case of a 
woman with classical GCA and arteritis on TAB. She developed 
features of PMR 3 months later and muscle biopsy showed 
vasculitis of a small artery, with almost complete occlusion 
of the lumen, fragmentation of the IEL, an inflammatory 
infiltrate and necrotic and fibrinous deposits.
Controversy thus exists over whether synovitis occurs 
at all in PMR, which sites if any are affected, and whether 
axial synovitis causes the clinical features. In this 
section I have examined and assessed the extent of joint 
involvement in PMR using clinical findings, radiological 
changes, radionuclide scans and, in a few cases, 
thermography.
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3.4.2 PATIENTS AND METHODS 
Clinical
Symptoms and signs of joint disease were recorded on 
presentation and during follow-up in the 74 patients 
described in this thesis, a total of 847 assessments. 
Radiology
Twenty patients with PMR for approximately 3 years, 
still requiring treatment, had plain films of pelvis, hands 
and oblique sterno-clavicular views taken. Tomograms of the 
sterno-clavicular joints were carried out in 22 patients 
with PMR for at least 2 years. Age and sex-matched in­
patients with no rheumatic complaints affecting the upper 
half of the body had sterno-clavicular tomograms as controls. 
X-rays of 32 pairs of sterno-clavicular joints from 
consecutive post-mortems in patients over 60 years were 
taken. These films were all reported by the same consultant 
Radiologist.
Six patients had plain films of pelvis, hands or 
shoulders before treatment.
Isotope Scans
Radionuclide scans were carried out in 15 patients with 
active untreated PMR and 4 with GCA only. Nine were carried 
out using 99m technetium pertechnetate; 10 mCi was injected 
intravenously and patients were scanned 20 minutes after 
injection using a gamma camera. Ten patients had 99m 
technetium diphosphonate scans? 100 mCi of isotope was 
injected and scanning was carried out 4 hours later with a
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rectilinear scanner. Twelve patients undergoing brain scans 
but with no evidence of PMR or joint disease were used as 
controls for the pertechnetate group. Scans were graded for 
activity from 1-4 by a consultant in nuclear medicine, 
reporting the scans without knowledge of the diagnosis. 
Thermography
Thermographs were taken using an AGA thermovision 680 
medical system to detect infra-red emission from shoulders, 
elbows, hands, hips, knees and feet in 16 patients with 
active untreated PMR/GCA. Thermography was carried out in a 
draught-free room at 20.5°C +0.5°C and recordings were made 
after a 15 minute equilibration period in the room.
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3.4.3 RESULTS 
Clinical Results
Throughout the study, twenty-five patients complained 
of joint pain and had documented tenderness or swelling in 31 
sites, but in only 1 patient was this a new feature on 
presentation. Tenderness on examination was noted in 30 
joints and swelling in 8 (Table 12); the knee was most 
commonly affected (10 cases) followed by the shoulder (9 
cases) and hand (7 cases).
Of these twenty-five patients three had joint pain with 
tenderness or swelling which coincided with activity of 
PMR/GCA. One woman had wrist synovitis for some months 
before developing florid GCA with some features of PMR, and 
wrist and MCP tenderness recurred 4 weeks after steroids were 
started. At that stage her GCA was not controlled clinically 
(although her ESR and CRP had fallen to normal) so her 
steroids were increased with symptomatic improvement. 
Another c o m p l a i n e d  of b i t e m p o r a l  h e a d a c h e  and 
sternoclavicular aching 71 weeks after starting treatment for 
PMR; her ESR and CRP were normal but her steroids were 
increased and both features settled quickly. The third woman 
had PMR which was difficult to control and she often felt 
stiff and complained of proximal muscle aching. She was one 
of the only 2 patients who were given Azathioprine as a 
steroid-sparing agent. She had acromio-clavicular tenderness 
noted one week after presentation. On one occasion two and 
half years after starting treatment her sterno-clavicular 
joints were tender; the other features of her PMR were not
TABLE 12
JOINT ABNORMALITIES DOCUMENTED PRE AND POST TREATMENT
JOINT NO, OF CASES
Knee 10
Glenohumeral 5
Acromioclavicular k
Small joints hand 7
Wrist 2
Sternoclavicular 2
Neck 1
3!
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different from usual and her ESR was elevated at 73 mm/hour, 
as it had been for some weeks.
Two women complained on one occasion of shoulder pain 
(with stiffness in one case) and gleno-humeral tenderness was 
noted. Both had no other features of active disease and ESR 
and CRP were normal. One had been taking steroids for 3 
weeks and the other for 65 weeks.
Eleven patients had clinical and radiological 
osteoarthritis affecting joints noted to be painful, swollen 
or tender. There were well-documented changes in the knees 
(4 cases) and the shoulder (1 case) before the development 
of PMR/GCA. In the other patients, degenerative changes 
were noted after treatment was started. Patients complained 
of pain on one or sometimes two occasions; this never 
corresponded with a flare in activity of PMR/GCA. Joints 
affected were hands (4 patients), shoulders (4), knees (1), 
wrist (1) and neck (1).
Two patients had effusions aspirated, one 23 weeks 
after starting treatment and the other 31 weeks after 
treatment. Neither had any other evidence of activity of 
PMR/GCA and ESR and CRP were normal. X-ray showed a 
possible bony fragment in one case.
Two patients developed swollen knees but no effusions. 
In one case this occurred 148 weeks after treatment had 
started in a woman who had discontinued steroids 11 weeks 
previously. The other patient had swelling of the knee noted 
73 and 86 weeks after starting treatment when he was reducing
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prednisolone from 5 to 2 mg/day. ESR and CRP were normal in 
both cases.
Five patients complained of mild joint pain on one 
occasion only and were noted to have slight tenderness but no 
swelling, affecting the acromio-clavicular joint in 3 cases 
(one of whom had hand aching), the hand (1 case) and the 
knee (1 case). None of these patients had active PMR/GCA. 
ESR and/or CRP were normal in all cases. Symptoms occurred 
between 19 and 158 weeks after starting treatment.
Thus of 25 patients with joint abnormalities noted 
from the 847 assessments, only 3 appeared linked to PMR/GCA 
activity? 4 cases of knee swelling may have been related. 
Radiological Results 
Pre-treatment (6 patients)
There were degenerative changes in the hip joints (3 
patients), the hands (5 patients) and the shoulders (5 
patients).
After treatment (20 patients)
Sterno-clavicular joints (oblique views) ; 1 patient had
erosions.
Pelvis: No erosions or sclerosis of the sacro-iliac joints
or symphysis pubis were seen. Six had degenerative changes 
affecting the hip joints.
Hands: No erosions were seen. 15 had degenerative changes.
Sterno-Clavicular Tomograms
Tomograms were performed on 22 patients with a mean age 
of 71 years. Twelve had PMR only, 4 GCA only and 6 both. The 
disease duration ranged from 1-7 years (mean 3.1 years). One
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patient had definite erosions on the medial inferior aspect 
of the clavicle. One had 'destructive lucencies' of the right 
clavicle and sternum with less marked changes in the right 
sterno-clavicular joint. The medial inferior aspect of the 
left clavicle was irregular in one patient, and 'roughening' 
of the medial inferior clavicles was seen at the ligament 
insertion site in one patient. The other films were reported 
as normal. Thus erosions were seen in 2 patients and 
irregularities without definite erosions in 2 patients. 
Patient Controls
Four patients with non-rheumatic complaints had 
tomograms of the sterno-clavicular joints. All were normal. 
We were unable to X-ray more patients for logistical regions. 
Post-Mortem Sterno-clavicular X-rays
Definite erosions were seen in one of the 38 sterno­
clavicular joints (Figure 28). The patient was an 80 year 
old man who died from left ventricular failure? there was no 
history of PMR/GCA or any joint disease and there was no 
evidence of these at post-mortem.
Isotope Scan Results 
Diphosphonate Scans (10)
Increased uptake was seen over the sterno-clavicular 
joints (1 patient) and right shoulder (1 patient). 
Degenerative changes were seen in the lumbar spine (1 
patient). There was no evidence of significant joint 
involvement in the other scans, though Paget's disease was 
noted in one case and an unexplained area of increased uptake
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STERNOCLAVICULAR JOINT EROSIONS IN A 
IN A NORMAL CONTROL
Figure 28
Post-mortem radiograph from an 80 year old man, showing 
erosions (e) of the sternoclavicular joints.
in the proximal humerus in another.
Pertechnetate Scans (9)
Comparison of the pertechnetate scans from PMR patients 
and controls showed no significant differences between the 2 
groups. Although some scans from both showed modest 
increases in uptake these did not correlate with the clinical 
picture.
Thermography (16 patients)
Eleven had PMR only and one of these developed GCA 
within 1 week. Four had PMR and GCA, and 1 had GCA only.
Increased heat patterns were seen in 6 patients over 
both shoulders (3 cases), one shoulder (2 cases), both hips 
(2 cases), one hip (1 case), both temples (3 cases) and one 
temple (1 case). One patient with PMR had a cold shoulder.
The thermographic abnormalities did not always 
correspond with the clinical abnormalities for either 
shoulder/hip girdle or temporal arteries. Increased 
temporal artery uptake was seen in several normal controls 
and this part of the study was not continued.
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3.4.4 DISCUSSION 
Clinical Findings
The results show 5 cases of peripheral synovitis (1 
wrist and 4 knees) of which only 1 appeared related to 
PMR/GCA. There were 2 patients with tender sterno-clavicular 
joints. Five other patients had transient joint 
abnormalities unrelated to any clinical or laboratory 
parameters of activity of PMR/GCA. Other complaints of 
recurring or persisting joint pain were due to degenerative 
joint disease, as would be expected in this age group. 
Clinical axial joint abnormalities were therefore present in 
2.7% of patients on 0.2% of the total assessments. It seems 
unlikely from these results that the pain and stiffness in 
PMR is due to an axial synovitis. Peripheral joint synovitis 
occurred in at most 6.7% patients and does not appear to be a 
common or significant feature of PMR/GCA.
What are the reasons for the discrepancies between 
these results and other studies? In some cases, 'arthralgia* 
was equated with synovitis. Henderson et al.'s (1975) 
criteria for synovitis were swelling of the joints or tendon 
sheaths containing fluid with an increased number of white 
cells, or synovial biopsy showing inflammation. Stiff, 
limited or painful joint movement, or small effusions of 
clear fluid were not accepted as being diagnostic of 
synovitis. These criteria were not met by Bruk (1967) or 
O'Duffy et al. (1976). In other reports, synovitis did not 
always coincide with other features of PMR and many have been 
due to another cause such as osteoarthritis (Gordon 1960,
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Henderson et al. 1975). The concept of referred pain was 
used as strong evidence for a central cause of PMR symptoms 
“by Coomes and Sharp (1961) but the evidence for this was 
presumptive. In some cases the pain occurred in sites not 
commonly involved in PMR (the anterior chest wall, or 
posterior lumbar regions) after injection of soft tissue 
structures or central joints.
Varying diagnostic criteria may also contribute to some 
of the differences. Bruk (1967) specified joint or soft 
tissue swelling as inclusion criteria, and did not require 
the ESR to be elevated. These unusual criteria would have 
excluded patients in this series and many others, yet his is 
one of the most quoted studies as evidence of synovitis 
in PMR. Although Healey (1983) felt that PMR should be 
reclassified as 'benign seronegative rheumatoid arthritis', 
pointing out that the first five ARA criteria for rheumatoid 
were often fulfilled, he went on to suggest that the ARA 
criteria should be revised, as they were too broad to 
specify rheumatoid arthritis.
Most studies agree that peripheral synovitis occurs in 
a minority of patients; this was usually reported without 
evidence of central arthritis and does not suggest that the 
clinical picture in PMR is due to joint inflammation. No 
cases of deforming arthritis have been reported, again 
suggesting that synovitis, where present, is not severe. 
Radiology
Our results showed sterno-clavicular erosions in 2 of
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22 PMR patients and 1 of 38 post-mortem controls. No sacro­
iliac or pelvic abnormalities were seen and there were no 
peripheral erosive changes. We therefore found no 
radiological evidence for either axial synovitis causing the 
clinical features of PMR, nor for accompanying peripheral 
synovitis.
There are several factors which might explain the 
discrepancies between these results and those of other 
workers, such as Paice et al. (1983) who found sterno­
clavicular erosions in 11 of 25 PMR patients and in none of 
16 controls. Firstly their patients were younger than ours 
(mean 59.5 v 71.4 years) and it is possible that some had 
erosive rheumatoid disease. Alternatively the erosions may 
have been incidental - 5 patients with erosions had 
clinically normal joints and 5 without erosions had 
clinically abnormal joints. Sterno-clavicular erosions may 
occur in the elderly because of degenerative change and this 
may explain isolated erosions in one series (Chou and 
Schumacher 1984). The erosions in our post-mortem study 
occurred in an 80 year old and were probably degenerative. 
However, it is also possible that our patients might have 
had a higher incidence of erosions if the history had been 
longer (more than half of those with erosions in Paice's 
group had been untreated for more than a year) or, less 
likely, that some erosions might have healed, as our patients 
had been treated for 2-3 years when examined.
Bruk (1967) gives the only report of erosive pelvic 
abnormalities; we found no evidence of this and I have
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already discussed his atypical diagnostic criteria for PMR. 
We did not find sacro-iliac sclerosis or symphysis pubis 
osteitis as reported by O'Duffy et al.(1980) and it is 
noteworthy that these abnormalities also occurred in their 
controls.
Authors reporting radiological abnormalities have 
mentioned the difficulties in interpretation because of the 
frequent occurrence of degenerative disease in this age group 
(Gordon 1960, Bruk 1967, O'Duffy et al. 1980). Degenerative 
changes were common in this study as would be expected in 
this age group. Over-interpretation of such changes may 
explain some of the abnormalities in other series.
It is also well recognised that abnormalities in the 
sacro-iliac joints are subject to considerable inter-observer 
differences in reporting (Macrae, Haslock and Wright 1971, 
Hollingsworth et al. 1983) and this has to be taken into 
account in assessing the sacro-iliac abnormalities reported 
by Bruk (1967) and O'Duffy et al. (1980).
Isotope Scans
The results of this study showed increased sterno­
clavicular uptake in one patient and increased uptake over 
one shoulder in another patient. The other 17 scans showed 
no significant joint involvement, again suggesting that PMR 
is not due to central arthritis.
There are only 2 other reports of isotope scans in PMR 
and both reported significant abnormalities; again their are 
plausible explanations for these inconsistences.
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O'Duffy et al. (1976, 1980) may have been looking at a 
different patient population. Their diagnostic criteria did 
not specify shoulder and hip girdle stiffness. Twelve of 
their 25 patients were successfully treated with aspirin or 
NSAIDs. On follow-up in 1980 16 of 23 patients questioned 
felt their condition was still active and clinicians agreed 
in 10 of 19 cases seen, and noted joint swelling, tenderness 
or reduced movement in 15 cases. The scan abnormalities were 
largely in shoulders and hands: only one in 8 had increased
sterno-clavicular uptake. Although in 38 instances clinical 
abnormalities correlated with those on scan, in 43 they did 
not (34 positive scans with no clinical abnormality and 9 
with clinical abnormalities but normal scans). The control 
scans were normal but the mean age was not given and may have 
been relatively low as the group were 'over 50 years'. The 
authors admit that hip and sterno-clavicular scans were 
difficult to interpret and excluded them from the follow-up 
study. They also found difficulty in assessing PMR activity 
because of co-existing degenerative joint disease in about 
half the patients. O'Duffy et al. (1980), however, feel 
that central arthritis is the cause of PMR, despite the 
atypical clinical course of these patients, the high 
incidence of degenerative disease, the difficulty in 
interpreting axial joints on scan and the lack of correlation 
between clinical and scan findings.
Paice et al.'s study (1983) is also of questionable
validity. They excluded patients over 70 years because
(
degenerative changes caused difficulties in interpreting
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scans in that age group, so their PMR patients are 
atypically young (mean 59.5 years). In contrast to O'Duffy 
et al. (1980) they had no difficulty in interpreting 
sterno-clavicular joint scans, which they found to be 
abnormal in 12 of 22 cases. They also found a surprisingly 
high number with abnormal elbow uptake (15 cases) and hand 
uptake (14 cases), not areas usually affected by PMR. 
Control scans were apparently done but the results are not 
given. It is possible that over-reporting of abnormalities 
and co-existing degenerative disease contributed to the high 
rate of abnormalities reported here.
Thermography
Thermography in a limited number of our cases showed 
increased uptake (often asymmetrical) over the shoulders. We 
did not see increased uptake over peripheral joints, and we 
have already demonstrated that thermography is a sensitive 
means of detecting synovitis in peripheral joints which 
correlates well with clinical findings and isotope scans (De 
Silva et al. 1986). Shoulder thermographs give variable 
results depending partly on body fat content? areas of 
increased heat may occur in shoulder arthritis and tendinitis 
but results do not correlate well with clinical findings. 
Thermography has not been used previously to assess PMR. 
These results support the clinical findings that peripheral 
synovitis is unusual, and do not lend support to the theory 
that axial synovitis causes PMR, as shoulder abnormalities 
were not present in most cases. However, it is not a
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reliable method of assessing shoulder, sterno-clavicular or 
hip joint disease.
In summary, there is no convincing clinical evidence 
that synovitis is a normal occurrence in PMR although 
peripheral joint pain and swelling is sometimes found. It is 
well recognised that late onset rheumatoid arthritis may 
mimic PMR (Dimant 1979, Weinberger 1980, Deal et al. 1985) 
and this may explain some of the reported abnormalities.
If synovitis does occur in some patients, it appears to 
be low grade, and it is therefore difficult to understand how 
it could cause the severe pain, stiffness and muscle 
tenderness seen in PMR. It seems unlikely that buttock and 
thigh pain and stiffness are due primarily to joint 
involvement, given the absence of joint tenderness or 
restriction of hip or lumbar spine movement. There is no 
resemblance to the synovitis of rheumatoid arthritis. PMR 
does not cause juxta-articular osteoporosis and erosions? 
flexion contractures and tendon rupture are not seen and 
tests for rheumatoid factors in serum or joint fluid are 
negative. The dramatic, rapid and usually permanent reponse 
to small doses of corticosteroids is also quite unlike the 
picture seen in rheumatoid arthritis. Sterno-clavicular 
joint abnormalities are found in a small number of cases. 
One would expect a much higher rate of abnormality in PMR if 
this caused the clinical features. There is one report of 
mild histological synovitis in the shoulders (Douglas et al. 
1983). This is interesting but one would expect very marked 
synovitis if this were the cause of the intense pain and
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stiffness which occur in PMR. We did not find isotope scan 
abnormalities and the 2 previous reports of these are open to 
question in several respects. Radiological evidence of 
central arthritis rests on the atypical series of Bruk (1967) 
and one report (Paice et al. 1983) of sterno-clavicular 
erosions. These may occur in the normal elderly population.
I do not feel PMR is a disease of the joints, as 
proposed by O'Duffy et al. (1980). The evidence rests on 
dubious reports of clinical synovitis, radiological 
abnormalities which were either insignficant, unconfirmed or 
both, mild histological synovitis and 2 reports of differing 
isotope scan abnormalities.
The findings of arteritis in skeletal muscle are 
isolated (Russell 1962, Bussiere et al. 1984) but it remains 
possible that arteritis in muscles causes PMR symptoms. 
Nonspecific abnormalities on muscle biopsy have also been 
demonstrated (Brooke and Kaplan 1972, Fassbender and 
Annefeld, 1982). Central arthritis as the cause of the 
proximal pain and stiffness in PMR must be given the Scots 
verdict of 'not proven'. The occasional existence of mild 
peripheral synovitis is interesting but does not suggest that 
PMR is a disease of the joints.
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3.5 IMMUNE COMPLEXES IN PMR/GCA 
3.5.1 INTRODUCTION
There is controversy over whether circulating immune 
complexes (CIC) are elevated in PMR/GCA. Raised levels have 
been found by Papaioannou et al. (1980), Park et al. (1981), 
Espinoza et al. (1982), Benlahrache et al. (1983) and 
Youinou et al. (1985) but others have reported normal CIC 
(Radda et al. 1981, Malmvall et al. 1981). Differing methods 
may explain some of the variation in results - Park et al. 
(1981) using the PEG-CC assay, demonstrated elevated IC in 
44% of active untreated patients with PMR and GCA and in 23% 
of inactive treated cases. The ^^I-Clq binding assay and 
PEG-C4 assay also detected IC but the ^^I*conglutinin 
binding assay did not. Espinoza et al., (1982) using the 
Raji cell assay, demonstrated elevated IC in over 90% of 
patients. The solid phase Clq enzyme linked immunosorbent 
assay used by Malmvall et al. (1981) detected IC in only 
2/15 cases of GCA investigated. Levels have not correlated 
well with disease activity (Park et al. 1981). Papaiannou et 
al. (1980) found CIC levels were higher in patients with 
clinically active GCA than in those with PMR.
The modest elevation in CIC without alteration in 
complement levels, the chronic granulomatous lesions in 
affected arteries and the absence of other serological 
abnormalities are not typical of immune complex-mediated 
disease. However, the proximity of inflammatory cells and 
immune complexes to elastic tissue may be significant. 
Further work to support an immunological basis to PMR/GCA has
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included studies of T cell subsets (Benlahrache et al. 1983, 
Banks et al. 1983, Chelazzi and Broggini 1984) but the role 
of cell mediated immunity remains in dispute. It has been 
proposed that a T8 defect leads to CIC production and 
deposition in arteries (Benlahrache et al. 1983).
Immune complexes are a heterogenous population with 
varying sizes, immunoglobulin composition and complement 
fixing abilities. The variation in composition affects 
removal, deposition and their possible pathological 
activities. Each IC assay detects the presence of different 
components of the complex and therefore may reflect the 
presence of different IC populations. However, a knowledge 
of the nature and source of CIC in PMR/GCA may contribute to 
understanding of the pathogenesis, in particular to the 
significance of immune deposits in arteries as discussed 
earlier. This section therefore examines the levels of CIC 
in PMR/GCA patients, using 3 different methods. 
Characterisation studies of these complexes were then carried 
out.
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3.5.3 PATIENTS AND METHODS 
(a) CIC Levels
CIC were measured in 69 of the 74 patients with active 
untreated PMR/GCA described earlier. 37 had PMR only, and 32 
GCA, 18 of whom also had PMR. 3 assays were used, and IC 
were measured using at least 2 assays in 55 patients.
IC Assays
(1) Polyethylene Glycol Complement Consumption Test (PEG-CC
Test)
Immune complexes were measured by the PEG-CC test as 
described by Harkiss and Brown (1979). This was performed as 
a routine by the Clinical Immunology laboratory and results 
were expressed as 'percentage complement consumption' (normal 
range 0-24%).
(2) *^I-Clq Binding Test (Zubler et al. 1976)
1 oc ,
x^j-dq binding immune complexes were measured by 
the method of Zubler et al. (1976). Duplicate samples (50 
pi) of test serum, normal human serum (negative control) or 
normal human serum with 10 pg, 20 pg or 30 pg added heat 
aggregated IgG (positive control) were mixed with 150 pi of 
0.2 M EDTA pH 8.3 + 0.4% Tween 20 and incubated at 37°C for 
30 minutes. All tubes were placed on ice and 30 pi of ^^5j_ 
labelled Clq added followed by 1 ml of 3% polyethylene glycol 
(PEG). The contents of all tubes were mixed and placed on ice 
for 60 minutes. For trichloroacetic acid controls 20 pi of 
125 i-iabelled Clq was added to 150 pi of normal human serum 
and then precipitated with 20% trichloroacetic acid (1 ml) 
and allowed to stand on ice for 60 minutes. All tubes were
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centrifuged at 1500 g for 20 minutes. The supernatant was 
removed and the drained pellets counted for a g a m m a
■counter. Results were expressed as percentage ^^I-Clq 
precipitated compared with the radioactivity precipitated in 
the trichloroacetic acid control tubes. Normal range < 6%.
(3) PEG-C4 (Digeon et al. 1977)
Immune complexes were measured using the PEG-C4 assay 
described by Digeon et al. (1977). In this assay complement 
component C4 bound to circulating immune complexes is 
precipitated from serum with 3% polyethylene glycol (PEG) and 
then assayed by radial immunodiffusion. 100 pi serum was 
diluted 1/5 in borate buffer (0.1 M, pH 8.4) and mixed with 
an equal volume of 6% PEG in borate buffer at 4°C. After 
incubation for 18 hours at 4°C, samples were centrifuged for 
10 minutes at 1500g. The supernatant was discarded and the 
precipitate was washed twice with 500 pi of 3% PEG. 50 pi 
0.1M glycine-HCl (pH 3) was then added and the precipitate 
resuspended and incubated for 30 minutes at 37°C. Samples 
(20 pi) were plated out into anti C4 radial immunodiffusion 
plates in duplicate with C4 standards at dilutions of 1/4, 
1/8, 1/16, 1/32 and 1/48 then kept humidified for 48 hours. 
(Anti-C4 IgG and C4 standards were from Atlantic Antibodies).
The amount of precipitable C4 in the immune complexes 
was quantitated by reference to the standard curve plotted of
o
diameter^ v concentration. Normal range <1 mg/100 ml.
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Characterisation of CIC 
Patients
Studies were carried out on 15 of the above patients, 
all of whom had elevated IC levels in at least 2 of the 3 
assays. Nine had PMR and 6 GCA, 4 of whom also had features 
of PMR. Only 1 patient was male. The mean age at onset was 
68 years (52-81). Temporal artery biopsies were carried out 
in 9 cases and 5 showed the histological changes of GCA. 
Seventeen samples of sera were obtained.
Preparation of Immune complexes
The IC in two aliquots (750 pi) from each sample were 
concentrated by overnight precipitation at 4°C with an equal 
volume of 6% PEG in 0.1 M borate buffer pH 8.3, 75 mM NaCl. 
The precipitate was collected by centrifugation at 2000 g for 
10 minutes at 4°C and then washed twice with 1.0 ml 3% PEG. 
The precipitate was dissolved in 1.0 ml complement fixation 
diluent (CFD).
IC were then isolated by incubation of an aliquot with 
300 pi of 1:5 suspension of either anti-Clq-Sepharose or anti- 
C3c-Sepharose for 2 hours at 22°C. The Sepharose-bound 
complex was washed with CFD, then 500 pi of 0.5 M Tris HC1 
buffer pH 6.8, containing 2.5% (w/v) SDS, 8% (v/v) glycerol, 
0.01% (w/v) bromophenol blue and 20 mM Dithiothreito1 was 
added, heated at 100°C for 3 minutes and then loaded on to an 
SDS polyacrylamide gel.
SDS Gradient Polyacrylamide Gel Electrophoresis
The gels (125 x 140 x 0.75 mm) contained 10-22% total 
aery lamide g r a d i e n t  w i t h  2.5% (w/v) N, N -
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methylenebisacrylamide and an upper gel containing 4.5% total 
acrylamide and 2.5% N, N-methylenebisacrylamide and were 
.polymerised by 0.017% (w/v) ammonium persulphate and 0.015% 
(v/v) N,N,N 'N'-tetramethylethylene diamine (TEMED). The 
upper gel had three wells; the two end wells were 5 x 20 mm 
and the centre well 115 x 20 mm. The buffer system used was 
as described by Laemmli and Favre, 1973.
Two gels were run in parallel using the LKB 2001 
vertical electrophoresis apparatus. The centre wells were 
loaded with IC purified by either anti-Clq-Sepharose or anti-
1 2 c
C3c-Sepharose. I-standards containing phosphorylase A
(Mr=100,000) , transferrin (Mr=78,000) bovine serum albumin 
(Mr=68,000), ovalbumin (Mr=43,000), carbonic anhydrase 
(Mr = 29,000), soya bean trypsin inhibitor (24,000) and 
lactalbumin (Mr=14,000) were loaded into the outside wells. 
Electrophoresis was carried out at 150 V until the marker dye 
reached the bottom of the gels.
A 2 cm strip of each gel containing one of the standard 
wells was removed, fixed in 40% (w/v) trichloroacetic acid, 
stained in 0.5% (w/v) Coomassie brilliant blue G in 40% (v/v) 
methanol, 5% (v/v) acetic acid, destained and dried on to 
filter paper.
Transfer to Nitrocellulose
The unfixed portion of each gel was placed in transfer 
buffer, (25 mM tris, 192 mM glycine, 20% (v/v) methanol) for 
10 minutes before being placed in the plastic holder with 0.2 
/im nitrocellulose sheet (Schleicher and Schuell, Anderman &
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Co. Ltd., Kingston-Upon-Thames, Surrey, U.K.). The 
nitrocellulose was marked with the sample identification, gel 
orientation and position of the standards. Transfer was 
carried out in Bio-Rad transplot cell at 0.1A overnight.
Unoccupied sites on the nitrocellulose were blocked 
using a buffer (50 mM tris/HCl, pH 7.2, 5 mM EDTA, 150 mM 
NaCl, 0.05% Nonidet P40, 0.02% NaN^) containing 0.25% (w/v) 
gelatin for a minimum of 5 hours at 4°C.
Identification of Proteins
6 mm strips of nitrocellulose were cut avoiding the 
standards position. Individual strips were incubated in 5 ml 
of different specific antisera diluted 1:100 in blocking 
buffer for 1 hour at 4°C. A plastic box 280 x 150 x 40 mm, 
with compartments 20 x 150 x 40 mm (Engineering and Design 
Plastics, Cherry Hinton, Cambridge. U.K.) was used. The 
strips were washed with 5 changes of blocking buffer.
If the antisera had been raised in goats these strips 
were incubated in rabbit anti-goat antisera (Atlantic 
antibodies, American Hospital Supplies U.K. Ltd.) which had 
been passed through a human IgG-Sepharose column and then 
washed as before.
IOC
All the strips were incubated m  goat anti-rabbit
antiserum (Atlantic antibodies). 100 Ci was used in the 
labelling of approximately 3.5 mg of protein then diluted to 
7 x 10^ cpm/ml. The strips were washed then aligned with the 
piece of nitrocellulose containing the 1^5j standards and 
autoradiographed at -70°C overnight.
Initially, 10 specific antisera were used: rabbit anti-
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human IgG and Clq (Dako Patts, Dako Ltd, High Wycombe UK) and 
C3c (The Behring Corporation) and goat anti-human IgA, IgM, 
Clr, Cls, C4, properdin and factor B (Atlantic antibodies). 
Then 5 additional antisera were used: goat anti-human C
reactive protein, <% 2 macroglobulin, factor H ( ft 1H) , Cl 
esterase inhibitor and rabbit anti-human C4 binding protein 
(Miles Scientific Ltd., U.K.).
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3.5.3 RESULTS 
Immune Complex Levels 
PEG-CC Assay
CIC were measured by the PEG-CC assay in 35 PMR and 32 
GCA patients. The range was 0-63.1% for the entire group 
(normal range 0-24%). Levels were elevated in 16 PMR patients 
(46%) and 17 GCA patients (53%). Mean levels were 23.4% (SE 
2.25) for the PMR patients and 28.2% (SE 2.25) for the GCA 
group. These were not significantly different.
PEG-C4 Assay
CIC were measured in 26 PMR and 24 GCA patients. The 
range was 0-11 mg/100 ml (normal < 1). Levels were increased 
in 25/26 PMR patients (96%) and 21/24 GCA patients (86%). 
Mean values were 4.59 mg/lOOml (SE 0.446) for PMR and 3.76 
mg/100 ml (SE 0.531) for GCA? these were not significantly 
different.
Clq Binding Assay
CIC were measured in 25 PMR and 26 GCA patients. The 
range was 2.6-14.5 % (normal range <6%). Levels were
increased in 11 PMR patients (44%) and 9 GCA patients (35%). 
Mean levels were 6.14% (SE 0.63) for PMR and 5.21 (SE 0.45) 
for GCA. These were not significantly different.
Comparison of Assays
There were 45 samples where all 3 assays were carried 
out. Results were elevated in all 3 in 9 cases, in 2 of the 
3 assays in 14 cases and in only 1 assay in 22 cases. In the 
14 cases where 2 of the 3 were abnormal, PEG-CC was normal in 
5 cases, PEG C4 in 2 cases and Clq binding in 7 cases. Where
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only 1 assay gave an increased CIC level (22 cases) this was 
.PEG C4 in 19 cases, PEG-CC in 2 cases and Clq binding in 1 
case.
Characterisation of Immune Complexes
The dried gels had very few visible protein bands after 
staining with Coomassie brilliant blue. Individual proteins 
were identified using specific antiserum and an 125j 
labelled probe after Western Blotting. (Figs. 29 and 30). 
The relative molecular mass (Mr) of the proteins was 
calculated from the autoradiographs by reference to the
I O C
mobility of the I labelled standards. The number of
positive staining samples is shown in Table 13 and where 
multiple protein bands were present in complement components 
this is shown in Table 14. The overall results are shown in 
Table 15 where the number of positive samples identified 
are shown for both the anti-Clq-Sepharose and the anti-C3c- 
Sepharose adsorbents. Minor differences were observed but in 
general the results for either adsorbent were similar. In 
some samples differences were observed in both the number and 
size of protein bands identified. For example 11/17 samples 
had 3 protein bands identified with the Clq antiserum (Mr 
37,000, Mr 32,500 and Mr 24,500), whilst the other six 
samples had only either one or two of these protein bands 
visible. Similarly multiple protein bands were observed on 
the immunoblots for other complement components such as Clr, 
Cls, C3 and C4, and the relative numbers identified are 
shown in Table 14.
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AUTORADIOGRAPH OF IMMUNE COMPLEX COMPONENTS
(ANTI Clq SEPHAROSE)
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Figure 29 Immune complex components identified after 
anti Clq Sepharose by autoradiography of
^^I-labelled Western blots.
AUTORADIOGRAPH OF IMMUNE COMPLEX COMPONENTS
(ANTI C3c SEPHAROSE)
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Figure 30 Immune complex components identified after 
anti C3c sepharose by autoradiography of
^^I-labelled Western blots.
TABLE 13
IDENTIFICATION OF PROTEINS ON NITROCELLULOSE BLOTS USING
SPECIFIC ANTISERA
(a) 17 Samples
Antiserum to Anti Clq 
Sepharose
Anti C3c 
Sepharose
IgG 3 2
IgA 7 9
IgM 17 17
Clr 16 13
Cls 16 14
Clq 17 14
C3 14 16
C4 13 12
Properdin 4 5
Factor B 0 3
0>) 10 Samples
Antiserum to Anti Clq Anti C3c
Sepharose Sepharose
C-Reactive
protein 10 9
OC Macro­
globulin 7 2
Factor H 3 4
5 A h M f S ! se 5 3
C4 Binding 
protein 0 0
(Numbers = number of samples with positive bands)
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TABLE Ik
IDENTIFICATION OF PROTEIN SUBUNITS WITH ANTISERUM TO
Clr, Cls, Clq, C^. and C,x ON WESTERN BLOTTING OF IC FROM 
THE SERA OF PATIENTS WITH GCA (7 ) OR PMR ONLY (lO) 
(Numbers = samples with positive staining)
r
GCA PMR
No. Anti Clq Anti C3c Anti Clq Anti C3c
Bands Sepharose Sepharose Sepharose Sepharose
P I  v 1 1 k 0 1uir 2 5 2 9 7
Total ■ 6 6 9 8
Cls 12
k
2
k
0
5
3
7
3
Total 6 k 10 10
-
1 3 k 1 k
Clq 2 2 1 0 1
3 2 0 9 k
Total 7 5 10 9
1 k 1 3
2 1 5 . k 1
3 1 5
C3 k 1 1
5 1
7 1
9 1
Total 5 7 9 9
1 3 2 7 k
C4 2 2 2
3 1 1 2
5 1
Total 3 3
..
10
_____________________ _
9
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TABLE 15
IDENTIFICATION OF PROTEINS ON NITROCELLULOSE BLOTS WITH
THE PATIENTS SERUM CLASSIFIED AS GCA OR PMR 
(a) 7 Samples GCA, 10 Samples PMR
GCA PMR
Antiserum to Anti Clq Sepharose
Anti C3e 
Sepharose
Anti Clq 
Sepharose
Anti C3c 
Sepharose
IgG 1 0 2 2
IgA 2 2 5 7
IgM 7 7 10 10
Clr 7 6 9 8
Cls 6 k 10 10
Clq 7 5 10 9
C3 5 7 9 9
C4 3 3 10 9
Properdin 1 1 3 k
Factor B 0 1 0 2
(b) 5 Samples GCA, 5 Samples PMR
Antiserum to Anti Clq Sepharose
Anti C3c 
Sepharose
Anti Clq 
Sepharose
Anti C3c 
Sepharose
CRP 5 5 5 4
eLMa c r o g 1 ohu 1 i n 3 2 4 0
Factor H 1 1 2 3
CEI 1 0 4 3
C4bp 0 0 0 0
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Five additional antisera were used to investigate a 
further 10 immunoblot pairs (Table 13 b). C-Reactive protein 
(CRP) was present in all but one of the sera tested but no 
C4 binding protein (C4 bp) was identified. The anti Clq- 
Sepharose IC showed positive staining for 0C2macro9l°kulin i-n 
7/10 samples, Factor H in 3/10 samples and Cl esterase (CEl) 
inhibitor in 5/10 samples. Similar results are shown for the 
anti C3c-Sepharose IC.
Table 15 separates the serum samples into those from 
patients with polymyalgia rheumatica alone (10) and those 
with giant cell arteritis (7) and then examines the relative 
distribution of the various immune complex components. Few 
differences were seen in the components which were often 
present e.g. IgM and Clr, and where some differences occurred 
the numbers were too small to be able to draw any firm 
conclusions.
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3.5.4 DISCUSSION
Using the standard PEG-CC assay, CIC were elevated in 
about 50% of patients. These results support the work of 
Park et al. (1981) where immune complexes were modestly 
elevated in 44% of patients. There was no significant 
difference between those with PMR compared with GCA. All 
patients had active untreated disease so no comment can be 
made on whether levels were related to disease activity. 
However, follow-up studies (Chapter 5) showed that only 10% 
of patients had elevated CIC during relapse when the disease 
process was almost invariably less active than on 
presentation.
Considerable variation emerged over the number of 
patients with increased CIC when different assays were used. 
The PEG C4 assay detected raised CIC levels in almost every 
case. The Clq binding assay results were similar to those 
with the PEG-CC assay. The mean levels were around normal 
for both these assays, but definitely elevated in the PEG-C4 
assay. No significant differences emerged between PMR and 
GCA patients irrespective of the assay used.
The unexpectedly high number of cases with elevated CIC 
measured by the PEG-C4 assay must reflect detection of 
different complexes than those measured with the other 
assays. Discrepancies with borderline PEG-C4 positive sera 
compared with the Clg binding assay have been noted by Digeon 
et al. (1977). This assay appears excessively sensitive and 
does not correspond with other series.
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These results support the hypothesis that IC formation 
is involved in the pathogenesis but circulating immune 
complex measurements may be of less relevance than IC 
deposits. It is possible that circulating immune complexes 
are quickly deposited and that serum levels are not directly 
related to events in arteries. Elevated CIC in this series 
were not more common in patients with histological arteritis 
but IC deposition does appear to be related to arteritic 
changes in TAB (Chapter 3) and may play a crucial part in 
the pathogenesis of the disease.
The measurement of CIC does not appear to contribute in 
diagnosis or management of PMR/GCA.
Characterisation Studies
We have used a new and rapid method for the analysis of 
IC (Smith, Cawston and Hazleman 1985) which allows small 
volumes of sera to be processed and the individual components 
of the IC identified.
Only those sera with raised IC contained a mixture of 
immunoglobulins, complement components, acute phase proteins 
and proteinase inhibitors.
All the IC investigated contained IgM but only a few 
contained IgG and both of these immunoglobulins can activate 
the classical complement pathway (CCP). IgA was present in 
more IC than IgG and although IgA does not activate the CCP 
some subclasses can activate the alternative complement 
pathway (ACP).
A number of complement components were present in the 
IC. Clq was obviously present in all samples where the anti-
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Clq affinity adsorbent was used to purify the complexes and 
was also present in most of the complexes purified by the 
anti C3c adsorbent. Clr, Cls, C3 and C4 were also present in 
many samples. Cl esterase inhibitor (Cl inactivator) which 
binds tightly and rapidly to cause dissociation of Clr and 
Cls from the IC was also found, and tended to be more common 
in PMR patients. Factor B was identified in only 3 IC, all 
purified with anti-C3c-Sepharose. In the ACP it forms the C3 
convertase C3bBb with activated C3 (C3b). Properdin, which 
binds to C3b and stabilises the C3bBb complex and maintains 
the C3b positive feedback loop, was found in 9 IC.
Factor H was identified in several IC. It is a control 
protein for the CCP and ACP, potentiating the action of C3b 
inactivator on C3b while preventing the binding of other 
proteins to C3b. Two IC contained both factor H and 
properdin.
Other investigations of IC components showed CRP was 
present in all the IC studied. CRP may be capable of 
inhibiting ACP activation and stopping C3b binding to 
surfaces. oC 2 inacroglobulin, a serum protease inhibitor, was 
found in some IC and this could suggest that these complexes 
are in the process of inactivation and are therefore inert.
It is possible that some serum components could bind 
non-specifically to the IgG-Sepharose (eg.. Clq or rheumatoid 
factor) via the Fc portion of the coupled IgG. Obviously the 
use of (Fab)2 antibodies would overcome this problem. 
However, the levels of non-complexed Fc binding materials
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will be minimised by the PEG precipitation and washing and we 
have not found that PMR/GCA sera contain raised levels of 
rheumatoid factor.
There are some differences in the components identified 
in IC purified using the different affinity matrices. This 
was expected and is likely to reflect differences in the 
degree of complement activation, the complement activation 
pathway, the presence of inhibitors, the degree of 
solubilisation and the removal of the complexes.
There were also differences between those patients who 
had polymyalgia rheumatica only and those who had giant cell 
arteritis. The presence and/or number of the polypeptide 
chains of Clr, Cls, Clq, C3 and C4, properdin, factor 
factor H and Cl esterase inhibitor appeared to be different 
although it was difficult to determine the significance of 
this or draw firm conclusions because of the small numbers. 
The IC in PMR and GCA differed from the IC previously 
analysed, by the same method, in rheumatoid arthritis 
patients' sera (Smith et al. 1985). RA IC do not contain 
properdin and factor B, and have a population purified by 
anti Clq-Sepharose unable to activate the CCP, indicated by 
the absence of C3 and the presence in only 1/7 of Clr or Cls.
The method we have developed allows the rapid and 
reproducible analysis of immune complexes in multiple samples 
which are available in small amounts. In addition, it is 
possible to separate the immune complexes by this method and 
store nitrocellulose strips to allow identification of 
further components as new anti sera become available. This
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may clarify the role of CIC in PMR/GCA.
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C H A P T E R  4 
A PROSPECTIVE STUDY OF THE CLINICAL AND LABORATORY FINDINGS
IN ACTIVE UNTREATED PMR/GCA
4.1 INTRODUCTION
The classical features of PMR/GCA are well-recognised 
but the variety of presentations and the range of frequency 
of symptoms, signs and laboratory abnormalities are 
considerable.
It is stated in major rheumatology textbooks (Dixon 
1978, Hunder and Hazleman 1981) that females are affected 
more often than males in a ratio of about 3:1; this 
difference is not due to their increased life expectancy. 
However, Paulley and Hughes (1960) reported 36 males and 40 
females in their series and Whitfield, Bateman and .Cooke 
(1963) also found equal numbers of men and women in a series 
of 72 cases. Fainaru et al. (1979) reported 45% males in 47 
patients and although Chuang et al. (1982) found an incidence 
of 1.7:1 female:male with higher incidences for women in 
every decade, the incidence differences were not 
statistically significant. In contrast, Bengtsson and 
Malmvall (1981a) found GCA occurred twice as often in women 
and PMR was also significantly more common. Coomes et al. 
(1976) reported a ratio of 3.4:1 (F:M) and Von Knorring's
series (1979) showed even more marked differences, with only 
6 men in a series of 53 PMR/GCA patients. Post mortem 
studies (Ostberg 1973) found a female:male ratio of 2.4:1.
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The age incidence is less controversial: most studies
agree that PMR/GCA is rare under 60 years and increasingly 
common in each decade thereafter (Bengtsson and Malmvall 
1981a, Chuang et al. 1982); GCA was rarely found in younger 
patients in comparison to PMR. Coomes et al. (1976) found 15 
patients with PMR under 60 years in their series of 102; 
Meadows (1966) found 80% of his GCA patients were over 70 
years.
4.1.1 CLINICAL FEATURES 
Arteritic
Headache was present in 18% of Kogstad's cases (1965)
but Whitfield et al. (1963) reported headache in 96% of
patients. Fauchald et al. (1972) found 59% of TAB positive 
cases did not have headache. However, most series with a 
large proportion of PMR patients had a lower incidence of 
headache, while in GCA-dominated series headache usually 
occurred.
The incidence of visual symptoms, and in particular
blindness, also varies. Whitfield et al. (1963) reviewed the
early literature and found ocular involvement reported in one 
third to half the cases. In their own series, 40/72 had 
permanent visual loss, partial in 21 cases but total in 15, 
12 of whom became blind in both eyes. Meadows (1966) 
reported blindness in 57.5% GCA cases; about two-thirds of 
these were bilateral. A further 15% had ophthalmoplegia. 
Hamilton et al. (1971) noted visual loss in 50% PMR/GCA 
cases. Some later series reported a lower incidence of 
visual loss. Fauchald et al. (1972) reported visual symptoms
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in only 7% of 94 patients, 61 of whom had GCA. Malmvall and 
Bengtsson (1978) reported reversible visual symptoms in only 
12% of GCA patients; none became blind. However, Fainaru et 
al. (1979) found visual disturbance in 47% patients and 
blindness in 30%. Fifteen (25%) patients from the Mayo 
clinic had visual symptoms before diagnosis of GCA? in 3 (5%) 
there was complete loss of vision (Huston and Hunder 1980).
Temporal artery tenderness is documented in some 
series, ranging from 33% (Sorensen and Lorenzen 1977) to 69% 
(Huston et al. 1978). Fauchald et al. (1972) found temporal 
artery tenderness in 17/44 (39%) GCA patients and 4/29 (14%) 
PMR patients.
Systemic Features
These occur in both PMR and GCA. Malmvall and 
Bengtsson (1978) found anorexia in 'most1 GCA patients? 19/68 
(28%) lost more than 2 kg. Weight loss was noted in 68% 
of the GCA series of Fainaru et al. (1979) but in only 15% of 
Chuang et al's PMR patients (1982).
Few series give data on malaise. 'Nearly half' of 
Whitfield et al's group (1963) had 'general failure of 
health'. Malaise was reported in 'most' patients by Hamilton 
et al. (1971) and 34% of patients in a study of GCA (Fainaru 
et al. 1979) complained of excessive fatigue.
'Occult' presentation is well recognised, with fever, 
nonspecific malaise, weight loss or anaemia of unknown cause 
(Healey and Wilske 1980, Calamia and Hunder 1981). There are 
case reports documenting unusual presentation of PMR/GCA from
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almost every system and some of these are shown in Table 16. 
Jaw claudication, tongue ischaemia and occasionally necrosis, 
and large artery involvement, particularly aortic, subclavian 
and axillary, are well recognised (Salisbury and Hazleman 
1981, Kyle et al. 1987) although presentation with such 
features is unusual.
Musculoskeletal Features
The cardinal features of PMR are proximal muscle pain 
and stiffness, most marked in the mornings. Occasionally the 
forearms and calf muscles are also affected (Barber 1957, 
Mowat and Hazleman 1974). The reported incidence of muscular 
features varies; obviously specific studies of PMR report a 
high incidence of muscle pain and stiffness (100% Chuang et 
al.1982). Biopsy positive GCA series have reported PMR in 
17-25% (Fainaru et al. 1979, Jonasson et al. 1979, Calamia 
and Hunder 1980).
In series including both PMR and GCA patients, a 
greater variation in PMR incidence has been documented. 
Fauchald et al. (1972) found PMR in 90.4% of patients though 
symptoms were mild in about half of these. Sorensen and 
Lorenzen (1977) noted PMR in 59% of a mixed group of PMR/GCA 
patients. Von Knorring (1979) noted that all his patients 
with GCA went on to develop PMR. Knudsen et al. (1982) in a 
mixed series of PMR/GCA found classical muscle pain and 
stiffness in all those who presented with PMR and in 43% 
biopsy positive GCA cases? only 14% of the GCA patients had 
no muscle symptoms at all. The question of joint 
involvement, central and peripheral, is controversial and has
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TABLE 16
UNUSUAL PRESENTATION OF PMR/GCA
r--------- 1— :-----------------------
Syncope due to carotid sinus 
hypersensitivity
Cocksedge et al 1984
Periorbital and facial swelling Cohen et al 1982
Tongue necrosis Barford and 
Bretiau 1984
Upper limb claudication Fraya et al 1982
Incidental finding on routine 
hysterectomy Petrides et al 1979
Radiculopathy Shapiro et al 1983
Diplopia Healey and Wiske 1980
Ear pain Coppeto 198 A
Interstitial lung disease Karam and Fulmer 1982
Stroke Small 1984
Angina Paulley 1980
.1---
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been discussed fully in Chapter 3.
4.1.2 LABORATORY INVESTIGATIONS 
ESR
The ESR is almost always elevated and may be extremely 
high, over 100 mm/hour. Most studies report a raised ESR in 
95-100% patients (Paulley & Hughes 1960, Huston et al. 1978, 
Chuang et al. 1982). However, a recent study (Ellis and 
Ralston 1983) found 22.5 % cases with an ESR <30 mm/hour, and 
there are well documented cases of biopsy positive GCA with a 
normal ESR (Whitfield et al. 1963, Rynes, Mika and 
Bartholomew 1977, Malmvall and Bengtsson 1978, Dare and Byrne 
1980). Cases where the ESR has been elevated initially but 
normal on repeat testing, and vice versa, have also been 
reported (Jones and Hazleman 1981). In addition it is known 
that the ESR in any one individual can show variation at 
different times of the day or over periods of a few days 
(Mallya et al. 1982). Although some have reported a raised 
ESR in the elderly with no demonstrable cause for this (Boyd 
and Hoffbrand 1966, Hayes and Stinson 1976), Bottinger and 
Svedberg (1967) found a range of 0-20 mm/hour for males and 
0-30 mm/hour (females) in 2,500 healthy people over 50 years.
The ESR is affected particularly by fibrinogen and also 
by plasma globulins and other acute phase proteins. It is 
therefore not surprising that immunoglobulins and acute phase 
proteins are elevated in acute PMR/GCA. C-reactive protein, 
which precipitates the C-polysaccharide of the pneumococcus, 
was described in 1930 (Tillet and Francis 1930) and was later
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noted to relate to ESR, although in some patients this 
correlation was poor (Hedlund 1947, McConkey, Crockson and 
Crockson 1972). The acute phase proteins such as 
orosomucoid, oC ^ antitrypsin, haptoglobin and CRP rise in a 
nonspecific way during the acute phase of most inflammatory 
and infective conditions. CRP may rise by several hundred 
fold within hours of an insult (Pepys 1983).
Acute Phase Proteins
There is little information on whether ESR or acute 
phase proteins are more useful in PMR/GCA, both for diagnosis 
and assessment. Haptoglobin was elevated in 87% and the ESR 
was elevated in 100% of PMR/GCA patients (Malmvall and 
Bengtsson 1978). Eshagian and Goeken (1980) found the CRP to 
be elevated in 10 of 11 patients with biopsy-positive GCA; 
CRP correlated with ESR in untreated cases. Park et al. 
(1981) compared ESR with CRP, oC^antitrypsin, haptoglobin and 
orosomucoid in 108 PMR/GCA patients. All the acute phase 
proteins were positively related, with the highest 
correlation between CRP and orosomucoid, (r=0.72) and CRP and 
ESR (r=0.66). ESR was the best indicator of disease 
activity.
Mallya et al. (1985) studied 13 PMR patients and found 
ESR and CRP to be elevated on presentation in all of them? 
both measurements correlated strongly with minutes of morning 
stiffness and pain scores? CRP gave slightly higher 
correlation coefficients.
Other studies have commented on abnormal protein 
electrophoresis but have not measured specific acute phase
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proteins.
Immunoglobulins
Immunoglobulin levels have been reported to be elevated 
by Malmvall et al. (1976). Both IgG and IgA were increased 
in GCA patients compared to levels in a control group. IgA 
was significantly higher in male GCA patients, but IgA levels 
in GCA women were not significantly different from controls. 
There was no significant difference in IgM levels between 
patients and controls. Results in biopsy-positive patients 
were similar to those with negative biopsies. There are no 
other studies of immunoglobulin levels in PMR/GCA.
Anaemia
Secondary anaemia is a well recognised feature of 
PMR/GCA but has been found with variable frequency. As 
discussed in the clinical section, patients may present with 
anaemia. Whitfield et al. (1963) found anaemia in almost 
half the patients. Seventy-nine per cent of Wadman and 
Werner's series (1972a) of GCA patients were anaemic. 
Malmvall and Bengtsson (1978) noted haemoglobin (Hb) less 
than 12 g/dl in 55% patients: 7 had a Hb less than lOg/dl.
Huston et al's (1978) results were similar - 42 (66%) GCA 
patients had Hb levels below 12 g/dl and in 6 patients the 
level was less than 10 g/dl. Knudsen et al. (1982) found 
anaemia in only 30% of patients; there was no significant 
difference between PMR and GCA. Forty-seven per cent of 
Chuang et al's 1982 series of PMR patients had a low Hb. In 
contrast to these studies, Mallya et al. (1985) did not
1^7
record significant anemia in their PMR patients, but noted 
that the Hb level after 14 days of treatment was 
significantly higher than on presentation. In most cases 
anaemia is mild.
Platelets
Thrombocytosis, presumed to be part of the inflammatory 
process in PMR/GCA, was reported by Hamrin (1972) and 
Bengtsson and Malmvall (1978),who found platelet counts 
greater than 350 x 10^/L in 35% patients. Eight patients had 
levels over 500 x 10^/L. Bergstrom et al. (1979) 
demonstrated an increased platelet production rate in active 
GCA with a normal platelet life span. Eighty-four per cent 
of biopsy positive patients had platelet levels greater than 
370 x 10^/L (Calamia and Hunder 1980). However, Hamilton et 
al. (1971) found only 4% of patients with thrombocytosis. 
Thyroid Function
An association with both hypo and hyperthyroidism has 
been noted (Thomas and Croft 1974) and in a series of 250 
patients with auto-immune thyroid disease, seven cases of 
PMR/GCA were found (Dent and Edwards 1978). Dare and Byrne 
(1980) reported thyroid disease in 6 of 25 GCA patients.
Liver Tests
Varying abnormalities have been reported and are 
discussed fully in Chapter 3.
Immune Complexes
Reports of increased CIC show differing levels and are 
also discussed in Chapter 3.
Thus the variation in clinical and laboratory
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abnormalities is considerable, and I emphasie again the 
factors which may contribute to this. PMR/GCA has been 
reported in the literature for only 40 years or so, and our 
understanding of the condition has changed over this period. 
Recent studies are therefore likely to present a different 
spectrum from those of 20 years ago. Secondly, because of 
the variety of symptoms, patients present to many different 
specialists (e.g. rheumatologists, neurologists, physicians). 
Different series will therefore reflect the bias of the 
specialty concerned. Thirdly, the diagnostic criteria for 
both PMR and GCA vary in different units. In some cases, the 
criteria used to define polymyalgia rheumatica were not 
given, in others 'myalgia' was described. Some studies 
include patients with PMR only (Kogstad 1965, Chuang et al. 
1982), and others varying proportions of both PMR and GCA 
(Fauchald et al.1972, Sorensen and Lorenzen 1977, Bengtsson 
and Malmvall 1978). Some GCA studies included only biopsy 
positive cases (Hamilton et al. 1971, Fainaru et al. 1979, 
Jonasson et al. 1979) and other patients with clinical GCA, 
irrespective of histology (Wadman and Werner 1972a, Huston 
and Hunder 1980).
Another source of inaccuracy is that almost all these 
studies were retrospective. The only large prospective study 
was that of Bengtsson and Malmvall (1978) who reviewed 90 
patients, 68 of whom were seen prospectively, but this series 
took 10 years to collect.
Laboratory abnormalities may vary for all the above
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reasons, as it is unclear if these differ in PMR and GCA. A 
further problem is the definition of normal range - some 
units do not define anaemia, and the sex variation in Hb 
levels was not considered in most studies. Thrombocytosis 
was diagnosed if platelet counts were over 350 x 10^/L in 
some series, which others regard as within normal limits.
In this chapter I will present the clinical and 
laboratory findings on presentation in 74 patients with 
active untreated PMR/GCA. Patients have been studied 
prospectively and have been classified in 3 groups? those 
with PMR only, those with GCA only, and those with Both. The 
aim of this part of the study was to obtain an accurate 
picture of clinical and laboratory features of the condition 
and of the nature of the overlap between PMR and GCA.
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4.2 PATIENTS AND METHODS
The clinical features of the 78 patients described in 
Chapter 3 with active untreated PMR/GCA have been recorded, 
and laboratory tests carried out on 74 of them.
Diagnostic Classification
A full history was taken and detailed examination 
carried out. A diagnosis of PMR/GCA was made if the 
diagnostic criteria of Jones and Hazleman (1981) were 
fulfilled, as set out below.
PMR
(1) Pain and stiffness of the muscles of the shoulder and 
hip girdle in the absence of true muscular weakness.
(2) Duration of at least 2 months, unless treated within 
this period.
(3) Morning stiffness of at least 1 hour.
(4) An ESR of >30 mm/hr (Westergren) or CRP >0.6mg/dl.
(5) Absence of evidence of rheumatoid or other inflammatory 
arthritis.
(6) Absence of malignant disease.
(7) Absence of objective evidence of primary muscle disease.
(8) A prompt and dramatic response to corticosteroid 
therapy.
GCA
(1) Positive temporal artery biopsy or cranial artery 
tenderness.
(2) One or more of the following:
headache, visual disturbance,jaw pain, cerebrovascular 
insufficiency, and ESR >30 or CRP >0.6 mg/dl.
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(3) Prompt and dramatic response to steroids.
Patients were classified as:
(1) PMR (features of PMR only)
(2) GCA (features of GCA only)
(3) GCA/PMR or Both (features of both PMR and GCA)
4.2.1 CLINICAL FEATURES
The following information was abstracted after the 
initial history and examination were carried out. 'None' or 
'Not Known1 was recorded if applicable.
History
Sex
Age at onset 
Referral source 
Peak symptoms
Time from onset to hospital presentation.
First specific symptom: Headache
Temple/scalp tender
Muscular
Visual
Masseter pain 
Tongue pain 
Other
Malaise, Anorexia 
Weight loss
Headache - Character: Throbbing
Constant
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- Site:
Frequency:
Predominant 
Visual symptoms:
Muscular symptoms:
Other
Right temple 
Left temple 
Bitemporal
Scalp pain alone (incl. facial) 
Right temple and scalp pain 
Left temple and scalp pain 
Bitemporal and scalp pain 
Daily
Several days/week 
Several days/month 
Less often
Lights
Spots
Blurred/decreased vision
Field defect
Blindness
Diplopia
Orbital pain
Pain only
Tender only
Stiff only
Pain and tenderness
Pain and stiffness
Pain, stiffnes and tenderness
Stiffness and tenderness
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Muscles predominantly 
involved:
Muscles involved (side):
Joint features
Joints predominantly 
involved:
Joint side involved:
Other vascular disease:
Proximal upper limb 
Distal upper limb 
Proximal lower limb 
Distal lower limb 
Combination of above 
Generalised
Unilateral
Bilateral
Pain
Pain and stiffness
Pain, stiffness and swelling
Hands/wrists
Elbows
Shoulders
Feet/ankles
Knees
Hips
Spinal
Combination
Unilateral
Bilateral
Hypertension 
Ischaemic heart disease 
Cerebrovascular disease 
Claudication
15^
Other disease at/ 
before presentation:
Family History:
Drugs taken on 
presentation:
Examination
BP(diastolic) 
Temporal arteries:
Arterial ulcers 
Venous thrombosis 
Other
Diabetes mellitus 
Thyroid disease 
Malignancy 
Hepatitis 
Other
GCA
PMR
Diabetes mellitus 
Thyroid disease 
Hepatitis
Carpal tunnel syndrome
Malignancy
Other
Analgesics
Aspirin
NSAID
Other
Normal
Tender
Tender and red 
Tender and thickened
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Thickened, non tender
Retinopathy
-Bruits
Muscles: Normal movement
Movement reduced by pain 
Stiffness on movement 
Tenderness
Joints: Normal
Tender but no synovitis
Synovitis
Effusion
4.2.2 LABORATORY INVESTIGATIONS
The following blood tests were carried out:
(a) Haemoglobin and platelet count
(Coulter count in a routine clinical laboratory)
(b) ESR
(Westergren method in routine clinical laboratory)
(c) Liver tests and plasma glucose 
(Multichannel analyser S.M.A. II)
(d) Immunoglobulins G, A and M, orosomucoid haptoglobin 
and oL ^ antitrypsin
(Immunoturbidimetry on a multistat III l.L. instrument)
(e) C-Reactive protein 
(Beckman rate nephelometer)
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.(f) CPK
(Standard enzymatic method)
(g) Thyroid function tests 
(RIA)
(h) Rose Waaler 
(Standard SCAT)
(i) Autoantibodies 
(Immunofluorescence technique)
(j) Circulating immune complexes 
PEG-CC 
PEG-C4
Clq binding assay 
(Method details given in Chapter 3.)
Temporal artery biopsy was carried out in 61 patients. 
Electrocardiography and X-rays were carried out in selected 
cases.
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4.3 RESULTS
4.3.1 CLINICAL FEATURES 
Diagnosis on Presentation
Of the 78 patients, 39 had PMR only, 19 GCA only and 20 
PMR/GCA. There were 17 men, 12 of whom had PMR, 2 GCA and 3 
PMR/GCA. Clinical data was available on all these patients 
and laboratory data on 74 patients (39 PMR, 18 GCA and 17 
PMR/GCA).
Age
The mean age was 71.4 years with a range of 52-86. PMR 
patients were slightly younger (mean 68.3 years SE 1.41); 
the means for GCA and PMR/GCA were 74.7 (1.87) and 70.9
(1.42) respectively. There was a significant difference 
between PMR and GCA (0.02<p<0.05) .
The mean age of the male patients was 73.7 years 
(SE 1.46) and of the woman 69.6 years (SE 1.10); these were 
not significantly different.
Peak Symptoms
The onset of the illness was acute (reaching a peak 
within 1 week) in 21 cases. 7 of these had PMR only, 6 GCA 
only and 8 PMR/GCA. 13 patients were unsure when their 
symptoms became maximal. The majority estimated that their 
symptoms took up to 3 months to peak? in four cases 
symptoms reached maximum severity after 9-12 months.
Time From Onset To Presentation (Figures 31,32 and 33)
Sixty-three per cent of GCA patients presented within 2 
months and 69% with PMR presented within 4 months. Fifty 
per cent with PMR/GCA presented within 4 months, but almost a
158
DELAY IN PRESENTATION PMR
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0-2 3-4 5-6 7-8 8-12 >12
MONTHS
Figure 51
The duration of symptoms in months before PMR 
patients presented to hospital. Blocks show 
number of patients.
DELAY IN PRESENTATION GCA
10 -
0-2 3-4 5-6 7-8 9-12 >12
MONTHS
Figure 32
The duration of symptoms (months) before 
GCA patients presented to hospital. Blocks 
show number of patients.
DELAY IN PRESENTATION PMR/GCA
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0-2 3-4 5-6 7-8 9-12 >12
MONTHS
Figure 33
The duration of symptoms (months) before 
PMR/GCA patients presented to hospital. 
Blocks show number of patients.
third presented more than a year after onset, usually because 
initial symptoms of PMR had faded and the subsequent 
development of GCA precipitated hospital referral. GCA 
preceded the development of PMR in only 2 cases of PMR/GCA. 
Exacerbation of headache in one of these patients led to 
hospital referral. One woman with headache typical of GCA 
for one year finally consulted her doctor when she developed 
PMR and marked scalp tenderness. One patient with PMR for 
one year attended her doctor when she suddenly loss the sight 
in one eye.
First Specific Symptoms
These are listed below for each subgroup 
PMR (39 patients)
Muscular
GCA (19 patients)
Headache 
Blindness 1 eye
Scalp tenderness without headache 
Masseter pain
39 patients
Cheek pain and swelling
PMR/GCA (20 patients)
Muscular
Headache
Scalp tenderness
Wrist pain and swelling
14 patients 
2 patients 
1 patient 
1 patient 
1 patient
8 patients 
7 patients 
2 patients 
1 patient
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Arm claudication* 1 patient
Jaw claudication 1 patient
Clinical Features at Presentation
Table 17 shows which clinical features were present by 
the time of hospital assessment.
Malaise, Anorexia
Most patients complained of malaise and about 50% of 
anorexia; there was no significant difference in each 
subgroup.
Weight Loss
Between one-third and one-half of patients 
reported weight loss. Most lost 1-5 kg but 9 lost between 6 
and 17 kg. Those who lost weight in each subgroup were 15/39 
PMR (2 unsure), 5/19 GCA (1 unsure) and 10/20 Both.
Headache
Ninety per cent patients with GCA or PMR/GCA complained 
of headache; by definition none of the PMR group had 
significant headache. This was equally common in both 
groups.
*GCA of the myometrial arteries was found on routine 
hysterectomy; shortly afterwards she developed arm 
claudication. See Appendix 2 for full case report on this 
very unusual case.
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TABLE 17
Frequency of Clinical Features Before Hospital Presentation
Symptom/Sign PMR (%) GCA (%) Both (%) All (%)
Malaise 26 (67%) 14 (74%) 16 (80%) 56 (72%)
Anorexia 17 (44%) 9 (47%) 10 (50%) 36 (46%)
Weight loss 15 (38%) 5 (26%) 10 (50%) 31 (40%)
Headache - 17 (89%) 18 (90%) 35 (45%)
T.A. tenderness - 10 (53%) 12 (60%) 23 (28%)
T.A. thickened/ 
pulsation j 9 (23%) 5 (26%) 4 (20%) 18 (23%)
Visual symptoms - 8 (42%) 7 (35%) 15 (19%)
Blindness - 3 (16%) 1 ( 5%) 4 ( 5%)
Muscle pain &/ 
or stiffness &/ 
or tenderness 39 (100%) 0 ( 0%) 20(100%) 59 (76%)
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Character
GCA
Eleven patients described constant pain? 2 of these also 
experienced superimposed bursts of sharp pain. One described 
stabbing pain, 1 slight pain, 1 bursting pain and 3 were 
unable to describe their headache.
PMR/GCA
Seven complained of constant pain, 2 described 
intermittent bursts of pain and one sharp pain. Eight were 
unable to describe their headache.
Site
Bitemporal headache with scalp pain was by far the most 
common site in both groups. Details are shown in Table 18. 
Very few patients complained of pain localised only to the 
temple.
Frequency
GCA
Fifteen patients experienced headaches daily, and 2 were 
unsure of how often headache occurred.
PMR/GCA
Eight experienced daily headaches, 5 on several days per 
week, 3 had headaches at least once per week and 2 were 
unsure.
One patient presented with headache to her General 
Practitioner but had no complaints when seen in hospital 
other than vague malaise? temporal artery biopsy was 
positive.
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TABLE 18 
MAIN SITE OF HEADACHE
.. - ■ 11 ■' 1 11 ■■■'---- 11 —■ 1 "
Main Headache Site GCA. PMR/GCA
Right temple 0 1
Left temple 1 2
Bitemporal 3 1
Scalp pain alone 3 1
Right temple and scalp pain 2 k
Left temple and scalp pain 2 3
Bitemporal and scalp pain 5 6
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Visual Symptoms
These were present in 19% overall and in 38% of GCA _+PMR. 
The predominant complaint was transient blurring; many 
patients were unsure whether this was unilateral or bilateral 
but 3 complained of bilateral visual blurring. Two 
complained of orbital pain and one of bilateral intermittent 
tunnel vision. In addition, 4 patients became blind in one 
eye and in 2 of these cases this was the presenting feature. 
One patient who presented with PMR experienced one transient 
episode of visual blurring which I felt was not significant; 
however, she later went on to develop definite features of 
arteritis so this may have been relevant.
PMR Symptoms
Sixteen of the PMR patients noted painful, stiff muscles 
and in a further 23 tenderness was also present. In the 
PMR/GCA group, 4 experienced pain only, 3 stiffness only, 7 
pain and stiffness and 6 pain, stiffness and tenderness. The 
distribution of muscles affected is shown in Table 19. In 
the PMR group, shoulder, upper arm, hip and thigh muscles 
were by far the commonest combination (77%). Three patients 
complained of proximal shoulder girdle pain, stiffness and 
tenderness and as the illness fulfilled the diagnostic 
criteria in every other respect were included. One woman had 
proximal arm and leg symptoms affecting the right shoulder 
and both hips, but in all the other cases symptoms were 
bilateral, although sometimes more marked on one side. 
Significant peripheral joint involvement occurred in only 1 
patient at the onset of the conditon, affecting her wrist.
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TABLE 19 
MUSCLE GROUPS AFFECTED
Muscles Affected PMR (39) PMR/GCA (20)
Proximal arm and proximal leg only 30 9
Proximal arm and entire leg 2 1
Proximal arm, proximal leg and low back 1 0
Proximal arm and distal leg 1 1
Proximal arm and buttock/low back 1 0
Proximal arm 3 5
Proximal leg 0 3
Generalised 1 1
Numbers = number of patients with specific muscle group affected
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The joint findings are discussed in detail in Chapter 3.
Other Vascular Disease
These results are shown in Table 20. Previously 
diagnosed hypertension was common; there were 5 patients 
with known ischaemic heart disease and the other conditions 
were even less common.
Past Medical History
Previous illness, other than vascular disease is shown in 
Table 21. Sixteen (41%) of the PMR only patients had been 
entirely healthy before, as had 5 GCA (26%) and 4 PMR/GCA 
(20%). Seven patients (9%) had a history of thyroid disease, 
2 others had pernicious anaemia and 1 vitiligo. All the 
diabetics were type II, treated with diet and also drugs in 
some cases. The musculoskeletal disease was degenerative in 
8 of the 11 cases. Two had had prolapsed intervertebral 
discs. There was one burnt out case of probable rheumatoid 
arthritis. Four patients had experienced carpal tunnel 
syndrome.
Family History
None of the patients had relatives who had suffered 
from PMR/GCA, although one had a spouse who had been 
affected. Ten had close relatives with diabetes and 11 with 
malignant disease. One woman had a daughter with thyroid 
disease. Seven had had relatives with 'rheumatism', one of 
which was rheumatoid arthritis. There were 2 with relatives 
with pernicious anaemia. The others were mostly cerebrovas­
cular or cardiovascular disease.
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TABLE 20
INCIDENCE OF OTHER VASCULAR DISEASE IN PMR/GCA
•' —
PMR GCA PMR/GCA
Hypertension 8 (21) 5 (26) 11 (55)
Ischaemic heart disease - 2 (11) 3 (15)
Cerebrovascular disease 2 (5) 2 (11) -
Intermittent claudication 1 (3) - i (5)
Venous thrombosis 2 (5) 1 (5) i (5)
Arrhythmias 2 3 (15) i (5)
Other 2 (5) - -
Figures in brackets = % 
Numbers = patients affected
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TABLE 21
PAST MEDICAL HISTORY (EXCLUDING VASCULAR DISEASE)
PMR GCA PMR/GCA
Diabetes 1 2 1
Thyroid 3 1 3
Other auto-immune 3 - -
Musculo-skeletal 5 2 k
Carpal tunnel syndrome 3 - 1
Malignancy 1 1 1
Gastro-intestinal/Renal/
Gynaecological 10 5 9
Respiratory 2 3 3
Psychiatric - 2 2
Other 6 3 1
Numbers = patients affected
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Therapy
Many patients had already received treatment from their 
G.P. Analgesics had been used by a higher percentage of GCA 
patients (42%) and PMR/GCA patients (45%) than PMR only 
(26%), but 64% of PMR patients had been prescribed aspirin or 
non-steroidal anti-inflammatory drugs compared with only 16% 
of GCA and 30% of PMR/GCA patients.
Examination 
Blood Pressure
Diastolic BP ranged from 70 to 130 mmHg. The 
distribution in each subgroup is shown in Figs. 34, 35, and 
36.
Retinopathy
One patient had an arterial occlusion and one had a 
branch retinal vein occlusion with retinal oedema and 
haemorrhages. Grade I or II hypertensive changes were seen in 
5% of patients with known hypertension.
Bruits
Table 22 lists these. Three patients had 2 bruits, and 
2 had 3. Precordial murmurs were less common in those with 
PMR only, and carotid bruits not heard in any patient with 
PMR/GCA, but the distribution was relatively even, given the 
small number of affected patients.
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BLOOD PRESSURE AND PMR
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Figure
Diastolic BP on presentation in PMR patients. 
Blocks = number of patients.
BLOOD PRESSURE AND GCA
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Figure 35
Diastolic BP on presentation in GCA patients 
Blocks = number-of patients.
BLOOD PRESSURE AND PMR/GCA
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Figure 36
Diastolic BP on presentation in patients with both 
PMR and GCA. Blocks = number of patients.
TABLE 22
BRUITS ON PRESENTATION (NUMBER OF PATIENTS)
CARDIAC 11 (3 PMR, .'4 GCA, k PMR/GCA)
CAROTID 10 (6 PMR, k GCA)
SUBCLAVIAN 7 (A PMR, 2 GCA, 1 PMR/GCA)
BRACHIAL 1 (GCA)
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Muscles 
PMR
Findings on examination for active movement corresponded 
to the history with painful or stiff movement especially 
shoulder abduction. However, full passive movement was 
possible in 87%.
PMR/GCA
Active movement was slightly restricted by pain and 
stiffness in 9 cases, 7 of whom also had muscle tenderness. 
Full passive movement was possible in all but one case.
4.3.2 LABORATORY INVESTIGATIONS 
Haemoglobin (Hb)
Twenty-five of 73 (34%) patients had Hb levels below the 
normal range for their sex; 8 of these were male so anaemia 
was present in 57% of the male patients and 29% of the women. 
This was a secondary anaemia in all but one case, a woman 
with iron deficiency.
The mean Hb levels in mg/dl with SE for each subgroup 
were: PMR 12.07 (0.23); GCA 12.44 (0.25); Both 12.37
(0.26). There was no significant difference between these 
values; levels below normal were much more common in PMR 
patients (44%) than GCA (22%) and Both (25%) but this was 
largely because almost all the anaemic male patients had 
PMR. The distribution for each subgroup is shown in Figures 
37, 38 and 39. For all groups this appears bimodal. 
Platelets
Platelet levels were elevated (>450 x 10^/1) in 26 of 61 
patients (43%). The mean levels were not signif icnat ly
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Figure 38
The range of Hh (g/dl) in GCA patients on 
presentation. Blocks show number of 
patients.
HAEMOGLOBIN DISTRIBUTION PMR/GCA
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Figure 39
The range of Hb (g/dl) in PMR/GCA patients 
on presentation. Blocks show number of 
patients.
different in each subgroup: PMR 425 x 109/L, (SE 22.8); GCA 
446 x 109/L (SE 39.1); Both 481 x 109/L (SE 38.1). Levels 
were raised in 40% PMR, 44% GCA and 46% Both.
ESR
The ESR was greater than 30 mm/hr (Westergren) in all 
cases, with a range of 32-138. The mean levels and SE for 
each subgroup were: PMR 70.21 (4.22), GCA 76.28 (4.96), Both
70.59 (5.95). These values were not significantly different. 
The distribution for each subgroup is shown in Figures 40, 41 
and 42.
Liver Tests
These are discussed in detail in Chapter 3. Alkaline 
phosphatase levels were not significantly different in each 
subgroup although the proportion with abnormally elevated 
values was greater in those with GCA or Both (47% and 44%) 
than in those with PMR only (32%). Only GCA patients had a 
mean value above normal.
Albumin levels were not significantly different in each 
subgroup (means in g/1 and SE: PMR 31.14, 0.62; GCA 30.33,
0.83; Both 32.37, 0.79) and although the proportion of
abnormally low results was higher in GCA (38%) most of these 
values were just below normal.
Blood glucose
Three patients (1 PMR, 1 GCA, 1 Both) had an elevated 
blood glucose; all were known to have Type II diabetes 
mellitus.
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Figure 40
The range of ESR levels in PMR patients oh 
presentation. Blocks show number of patients
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Figure 41
The range of ESR levels in GCA patients 
on presentation. Blocks show numher of 
patients.
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Figure 42
The range of ESR levels in PMR/GCA 
patients on presentation. Blocks 
show number of patients.
Immunoglobulins
IgG was elevated in 20 of 71 patients (14 PMR, 3 GCA, 3 
Both). Mean levels in each subgroup were not significantly 
different.
IgA was elevated in 11 of 70 patients (6 PMR, 3 GCA, 2 
Both). Mean levels were not significantly different in each 
subgroup.
IgM was elevated in 8 of 70 patients (5 PMR, 2 GCA, 1 
Both) with no significant difference in mean levels in each 
subgroup.
Mean values with SE for IgG, A and M are shown in Table
23.
Acute Phase Proteins
Orosomucoid (Normal range 0.5 - 1.0 g/1)
64/69 patients had elevated levels. The proportion with 
abnormal values and mean levels were not significantly 
different between each subgroup.
Haptoglobin(N.R. 0. 5 - 2 . 6  g/1)
54/69 patients had elevated levels; there was no 
significant difference in the proportion of abnormal values 
or mean levels between each subgroup. 
cC ^ Antitrypsin (N.R. 0.9 - 1.8 g/1)
49/69 patients had eleveated levels. The proportion of 
patients with abnormal results and the mean levels were not 
significantly different for each subgroup.
Mean levels and S.E. of the acute phase proteins for each 
subgroup are shown in Table 24.
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TABLE 23
SERUM IMMUNOGLOBULIN LEVELS ON PRESENTATION (MEAN + S.E.)
PMR GCA
1
-
BOTH
IgG 
(6-13 g/1)
11.86 0.42 11.21 0.64 10.89 0.76
I gA
(0.8-3.7 g/1)
2.72 0.16 2.85
CM•o 2.66 0.3
IgM
(0.4-2.2 g/1)
1.28 0.14 1.26 0.16 1.42 0.18
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TABLE 24
ACUTE PHASE PROTEINS ON PRESENTATION (MEAN VALUES + S.E.)
PMR GCA BOTH
Orosomucoid 
(0.5 - 1 g/1)
2.11 0.11 2.31 0.27 2.08 0.14
Haptoglobin
(0.5-2.6 g/1)
3.89 0 .18 4.36 0.42 3.93 0.36
of^anti trypsin 
(0.9-1.8 g/1)
2.3^ 0 .11 2.38 0.26 2.01 0.12
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C-Reactive Protein (N.R., <0.6 mg/dl)
CRP was elevated in 49/55 patients; all those with CRP < 
0.6 had an ESR >30 mm. The elevated values ranged from 0.6 - 
26.7 mg/dl. The distribution of elevated levels is shown for 
each subgroup in Figures 43, 44 and 45 and tended to be
bimodal in Both. This method of testing does not quantitate 
'normal' values, but mean values in mg/dl and SE of elevated 
CRP levels were: PMR 4.35 (0.63), GCA 7.94 (2.03); Both 5.49
(0.91). Levels in GCA patients were higher than those for 
PMR only.
Creatine Phosphokinase
CPK levels were normal.
Immune Complexes
These are discussed fully in Chapter 3.
Rose Waaler (RW)
One woman with GCA and a positive TAB had a RW titre of > 
512. She had no joint or muscle symptoms. All the other RW 
tests were negative.
Thyroid Function
One woman who was known to be hypothyroid but had not 
been taking her thyroxine tablets had a low T4 (47 nmol/1) 
and a raised TSH (14.9 1U/L). Four patients had slight 
elevation of TSH but normal T4 levels. One woman with known 
hypothyroidism, on treatment with thyroxine, had a slightly 
elevated T4. 7 patients had thyroid autoantibodies in
significant titres? 2 of these were known to have thyroid 
disease and 2 had marginally elevated TSH levels.
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The range of abnormal CRP values in PMR patients 
on presentation. Blocks show number of patients.
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Figure 45
The range of abnormal CRP levels in PMR/GCA 
patients on presentation. Blocks show number 
of patients.
Autoantibodies
Two patients had significant titres of parietal cell 
autoantibodies. Five had detectable antibody to antinuclear 
factor but at low titre only (1/25).
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4.4 DISCUSSION
This is the first large prospective study to examine in 
detail both clinical and laboratory findings in PMR/GCA. The 
patients were predominantly referred by general practitioners 
to the rheumatology department, and this will inevitably 
bias the results.
4.4.1 CLINICAL FEATURES
GCA with or without PMR was as common as PMR alone; 
this may be because PMR patients are less likely to be 
referred to hospital.
The overall ratio of females to males (4:1) is similar 
to figures quoted in the literature. However, the very low 
numbers of men in the groups with arteritis, with or without 
PMR, differs from other studies where the male:female ratio 
on the whole has been higher in GCA patients than in PMR. 
PMR patients were younger than those with GCA; PMR/GCA fell 
between the two. The difference was not accounted for by the 
males in the PMR group.
The phenomenon of acute onset was confirmed, but did 
not appear to relate to the pattern of symptoms. Patients 
with GCA tended to present earlier than those with PMR, not 
surprising in an age group where 'rheumatic' complaints were 
accepted as part of old age in many cases. There were 
several patients where PMR symptoms had lessened either 
spontaneously or sometimes with the use of nonsteroidal anti­
inflammatory drugs, and the later development of arteritis 
led them to consult a doctor. It was unusual for GCA to 
precede PMR, although simultaneous development of both was
178
common. It is possible that some who presented with GCA only 
might have developed PMR, but steroid treatment pre-empted 
this.
The initial features show a high incidence of headache and 
low incidence of visual symptoms in the GCA and PMR/GCA 
group. This pattern persisted till the time of hospital 
referral and treatment, with only 4 patients from the entire 
group losing the sight in one eye. Even if this number is 
considered as a percentage of patients with GCA or PMR/GCA, 
excluding the PMR group, it remains lower (10%) than in many 
other studies. Although weight loss and malaise were common, 
occult presentation was unusual, possibly because more 
typical features of PMR/GCA had developed by the time of 
hospital referral. One patient who presented with masseter 
pain had been admitted 2 months earlier with a diagnosis of 
vertebrobasilar insufficiency. Her ESR was elevated then and 
this may have been arteritic in nature. No other recent 
symptoms which might have been due to PMR/GCA were elicited 
either from the patients themselves or from hospital records. 
There was one extremely unusual presentation, the woman with 
myometrial GCA on routine hysterectomy who subsequently 
developed bilateral axillary GCA. PMR features conformed to 
those found in other studies; symptoms confined to the 
proximal muscle groups were most common although other areas 
were also involved in about 20% of PMR cases.
An association with thyroid disease was relatively 
common but other conditions occurred with a frequency to be
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expected in that age group.
Many PMR patients had been treated with NSAIDs before 
hospital referral but this did not control their symptoms. 
This supports the findings of Bengtsson and Malmval 1(198lc) 
and contrasts with those of Chuang et al. (1982) who feel 
that NSAIDs can be satisfactorily used to treat many PMR 
patients.
Abnormalities on examination are uncommon in PMR/GCA. 
Although diastolic blood pressure was greater than 100 mmHg 
in a number of patients, levels were usually less than 100 
thereafter and elevated initial findings were probably 
spurious and anxiety -related. Temporal artery tenderness 
occurred in about 60% of patients with arteritis but there 
was no physical sign which was of high sensitivity in making 
the diagnosis. Bruits were heard in a minority, unlike 
Mumenthaler's (1978) review where they occurred in 58% of GCA 
patients. Limitation of movement of the shoulder girdle was 
uncommon and extremely rare at the hips, although patients 
often had discomfort on shoulder abduction in particular. 
This relatively good joint movement in combination with 
muscle tenderness again emphasises the differences between 
PMR and joint disorders.
4.4.2 LABORATORY INVESTIGATIONS
These were not significantly different in each 
subgroup. Anaemia in male patients was an unexpected finding 
and the reason for this is unclear. It did not appear to 
relate to length of history or disease activity.
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Thrombocytosis was common, and although some previous 
studies have reported a similar incidence their upper normal 
value was lower than in this study.
Although the diagnostic criteria required either ESR or 
CRP to be elevated, both were raised in all but 6 cases, 
where the CRP was normal. Mean ESR values were not 
significantly different in each subgroup, but CRP was higher 
in patients with GCA only compared to PMR only. This just 
reached significance, and may have been spurious; 
alternatively it is possible that the higher CRP level in GCA 
reflects more active disease. The apparent bimodal 
distribution of Hb in all patients and possibly of CRP in 
PMR/GCA is interesting. This did not appear to relate to 
the length of history of to severity of symptoms. It is 
possible that it related to the extent of arteritis and that 
overt clinical features do not fully reflect the severity of 
underlying disease. This is supported by a study showing the 
extent of arteritis in the absence of symptoms relating to 
the vessels affected (Wilkinson and Russell 1972). Bimodal 
distribution of ESR occurs in other studies (although none of 
the other authors refer to it) with a trough between 80-89 
mm/hr (Hamrin 1972, Mowat and Hazleman 1974). This was seen 
only in GCA/PMR patients in this study. The distribution was 
not related to whether polymyalgia or arteritis was the more 
prominent feature - over half of the patients with an ESR < 
70 had clinically very active arteritis with minimal PMR. In 
the GCA group all but 3 patients had an ESR of 60 or greater, 
and in PMR patients there was a normal distribution of
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values. CRP values tended to be either less than 6 mg/dl or 
greater than 8 mg/dl in all subgroups. Although this might 
suggest 2 distinct populations, the lack of correlation of 
this with other clinical or laboratory features does not 
support this hypothesis. Further analysis of the course of 
the disease in relation to data on presentation is needed, 
but in this study relapse rate was not related to the 
presenting ESR (Chapter 5).
The other acute phase proteins, although usually 
elevated, did not appear to be more useful in supporting the 
diagnosis. ESR and CRP were elevated in 90-100% of cases. 
Although the percentage of patients with raised orosomucoid 
was also high (92%) follow-up studies showed this tended to 
remain elevated whereas CRP and ESR fell to within the normal 
range.
Rose Waaler tests and autoantibody tests were negative 
and did not support the view that PMR is a variation of 
rheumatoid arthritis (Corrigan et al. 1974) or that PMR/GCA 
is linked to autoimmune disorders (Dare and Byrne 1980).
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4.4.3 CONCLUSIONS
The overall picture in PMR/GCA is of a spectrum of 
•disease, where the classical features of proximal muscle pain 
and stiffness, with headache, visual symptoms and malaise are 
by far the most common. Loss of vision is unusual and the 
higher incidence of blindness quoted in some series probably 
reflects selection bias; for example in studies where 
patients were referred to ophthalmologists (Whitfield et al. 
1963). Patients rarely developed bilateral visual defects in 
contrast to the findings of Meadows (1966). The laboratory 
findings do not differ in each subgroup (except for a higher 
CRP in GCA) and in particular there are no clinical or 
laboratory features which distinguish the ’overlap' group of 
patients with both PMR and GCA. Previous studies have not 
examined this group as a separate entity from those with PMR 
only or GCA only. This study suggests that on the basis of 
the clinical and laboratory features at the onset of the 
condition, a clinical separation of GCA with PMR from GCA 
only is unnecessary. Patients were allocated to a particular 
subgroup by pre-treatment diagnosis and a few patients in 
either the PMR only or GCA only groups developed features of 
both during the course of the illness (see Chapter 5). This 
makes the initial separation somewhat artificial but as the 
numbers who changed diagnosis were small and the clinical and 
laboratory features similar, the overall results are unlikely 
to have been affected. Indeed, presenting systemic features 
and laboratory tests, excluding histology, emphasise the 
similarities between PMR and GCA not the differences.
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Although the varying incidence of clinical features may 
be due to selection bias of different specialties, this does 
not explain the range of reported sex ratios. The high 
proportion of women with GCA or PMR/GCA in this study and 
others contrasts with other forms of arteritis, and also with 
the proportion with PMR. Further epidemiological studies 
are needed to confirm this.
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C H A P T E R  5 
THE CLINICAL AND LABORATORY COURSE OF PMR/GCA
5.1 INTRODUCTION
5.1.1 CLINICAL COURSE
In Hutchinson's original report of GCA (1890) he 
emphasised that Mr. Rumbold made a complete recovery from his 
painful condition? similarly Bruce describing PMR as 'senile 
rheumatic gout' in 1888 was amazed at its 'complete 
curability even at a very advanced time of life'. Bagratuni 
(1956) describing PMR cases before corticosteroids became 
available, reported that symptoms persisted, sometimes with 
periods of remission, from 3 months - 35 years with a mean of 
5.25 years. Kersley (1956) prescribed short courses of 
corticotrophin in some patients and noted that some had a 
complete remission but in others the condition recurred even 
where steroids had been used. A later larger series by 
Bagratuni in 1963 found a mean disease duration of 7.1 
years; most were treated with, and responded to, 
salicylates. There are no such reports on the prognosis in 
GCA before steroids became available.
Since the 1950s, corticosteroids have been used to 
treat PMR/GCA. One of the earliest reports of their 
efficacy came from a series of 55 patients with GCA from 
the Mayo clinic in 1957 (Birkhead, Wagener and Shick). Most 
patients became asymptomatic within a few days of commencing 
cortisone treatment. In particular the use of cortisone 
reduced the incidence of blindness - none of the 55 patients
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treated with steroids developed bilateral blindness once on 
.treatment, compared with 11 of 53 patients who became 
bilaterally blind before the introduction of cortisone.
Since the routine use of steroids to treat PMR/GCA, 
further studies have been published describing the clinical 
course and duration of the disease. Widely differing 
patterns have been reported, partly reflecting the separation 
of PMR from GCA in some series, and varying criteria used 
both in diagnosis and assessment. Most of these studies have 
been retrospective reviews from case notes of all PMR/GCA 
patients seen by a variety of doctors over several years, 
making it difficult to obtain an accurate picture. In 
particular, it is often unclear - and probably not known - 
whether patients are still taking steroids by default or 
because attempted withdrawal has precipitated a relapse. In 
these largely retrospective studies, few details of the 
course of the condition are given.
Whitfield et al. (1963) made the important observation 
that relapses and sometimes visual loss occurred in patients 
taking an adequate prednisolone dose. Dixon et al. (1966) 
reported that 23 of 31 PMR/GCA patients still had 'active' 
disease after a mean of 14 months treatment. Paulsen and 
Iversen (1971) reported relapses in 11 of 16 PMR patients; 
the ESR was always greater than 25 mm during relapses, which 
did not occur more frequently in the first year of the 
illness. They found the ESR to be 'a reliable objective 
parameter of disease activity and of response to steroid
186
therapy'. Fauchald et al. (1972) reported that 9 of 94 
PMR/GCA patients relapsed while taking steroids. In every 
case this was felt to be related to too rapid a reduction in 
dose. A further 13 relapsed once steroids had been 
discontinued at a mean of 16 months. The nature of the 
relapses is not discussed but ocular involvement was 
apparently low, although about two thirds of the patients had 
GCA. Beevers, Harpur and Turk (1973) felt that many relapses 
in their series were due to spontaneous reactivation and not 
to a reduction in steroid dose. 30 relapses occurred in 
their 44 GCA patients at a mean of 10.4 months on steroids. 
There were also 18 cases of asymptomatic re-elevation of the 
ESR. Myles (1975) found 3 of 84 PMR/GCA patients had 
relapsed off treatment. Sorensen and Lorenzen (1977) 
reported blindness developing in 2 patients while on steroids 
but on a daily dose of only 2.5 mg prednisolone.
A study by Esselinckyx, Doherty and Dixon (1977) of 18 
PMR patients treated for a mean of 27 months, found that the 
initial ESR was not related to disease duration but did 
relate to the response to attempted steroid withdrawal. 
Relapses always included features of the initial presentation 
and they felt that symptoms were always specific enough to 
exclude a 'pseudorheumatism1 reaction to steroid withdrawal 
reported to occur in the normal population.
Studies from the late 1 970s onwards are more 
informative about the course of PMR/GCA. Huston et al.
(1978) reported relapses in 11 of 42 GCA patients. Ten of 
these occurred in relation to a reduction in steroid dose,
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and one when off steroids. Relapses often took the form of 
PMR rather than GCA. Spiera and Davison (1978) found PMR to 
be uncomplicated with only 1 of 56 patients developing GCA.
Von Knorring (1979) studied 53 PMR/GCA patients and 
found that 21 patients had 33 relapses while on treatment. 
Those with PMR initially all had PMR relapses; those with 
GCA relapsed as PMR and/or GCA. Sixty-four per cent of PMR 
relapses occurred on reducing prednisolone dose from 5 to 2.5 
mg, and 54% of GCA relapses when reducing prednisolone from 
7.5 to 5 mg/day. Five patients with definite relapses had an 
ESR < 30. Relapses also occurred frequently after steroid 
withdrawal - 71% within 1 year. Six relapsed after 2 years. 
Bengtsson and Malmvall (1981b) reported 94 flares in 38 
patients from a total series of 90. This occurred when the 
prednisolone dose was less than 10 mg in 90%. The most 
common symptoms were of muscular discomfort, irrespective of 
the initial diagnosis. The ESR was greater than 20 in 70% of 
flares, which were most common during the first year of 
treatment, and decreased each year thereafter. However, 4 
occurred after 4 or more years on steroids. Seventy-three 
per cent of those who relapsed off treatment did so within 3 
months of steroid withdrawal, but 2 patients relapsed more 
than a year later and 1 after 10 years off treatment. 
Twenty-seven per cent of patients never experienced flare-ups 
once on steroids. None of the patients lost their sight 
while taking steroids.
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A much higher relapse rate, with more serious 
complications, was reported by Jones and Hazleman in 1981. Of 
85 PMR/GCA patients, only 11 did not have a definite relapse 
while the steroid dose was being reduced. Forty occurred 
after at least a year of treatment and 23 after at least 2 
years. Visual or neurological complications developed in 
26%, and 55% of those presenting with PMR developed GCA 
later. Relapse after steroid withdrawal occurred in 7 
patients. Knudsen et al. (1982) found that 46% of 94 PMR/GCA 
patients had no recurrences after treatment for a mean of 30 
months. Details of the remaining 54% who presumably did 
experience relapses were not given. Chuang et al. (1982) 
described only 4 relapses in a series of 94 patients with 
PMR, occurring between 3 months and 2 years after starting 
treatment. These seemed to be associated with rapid steroid 
reduction. Thirty-nine of this atypical group were treated 
with aspirin or NSAIDs rather than steroids and the mean 
time on steroids was only 11 months. Behn, Perera and Myles 
(1983) described relapses once steroids had been 
discontinued? 30 of 170 PMR/GCA patients deteriorated within 
21 months of steroid withdrawal. Most occurred within 6 
months. However, no serious complications occurred after 
treatment had been started and no clinical features predicted 
who would relapse. The mean time of steroid withdrawal was 
31 months. In a study of 96 patients with PMR only, Ayoub, 
Franklin and Torretti (1985) reported that 56% had relapses, 
but only 1 'occurred as GCA.
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5.1.2 LABORATORY ASSESSMENT OF DISEASE ACTIVITY
Eshagian and Goeken (1980) felt that CRP was more 
sensitive than the ESR in assessing disease activity. On 
some occasions when patients had a flare-up clinically, the 
ESR was normal but the CRP elevated. Park et al. (1981) 
found ESR to correlate best with disease activity at varying 
stages, comparing it with CRP and other acute phase proteins. 
Mallya et al. (1985) found that CRP reflected disease 
activity more accurately than ESR over the first 2 weeks of 
treatment in a small study of GCA patients. In contrast, 
Paolaggi, Chaduat and Auquier (1985) found ESR to correlate 
better with disease activity than ososomucoid and haptoglobin 
during a follow-up period of GCA patients. Hickling et al. 
(1986) found that ESR, CRP and PV all rose during relapses 
but no one parameter predicted relapse in PMR.
An alternative method of assessment was proposed by 
Nalbandian et al. (1981). They thought that prostaglandin 
metabolism was disordered in PMR/GCA, and that measurement of 
urinary prostaglandin F, serum/urinary lysozymes, serum acid 
phosphatase and serum angiotensin converting enzyme would 
reflect disease activity and stage more accurately than the 
nonspecific ESR. This hypothesis remains untested.
The only consistent findings from these largely 
retrospective studies are that PMR/GCA is a relapsing 
condition, and that treatment with steroids reduces the 
number of complications. The number who relapse, the nature 
of the relapse, the relationship to alteration in steroid
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dose, predicting which patients relapse and which laboratory 
parameters correlate best with relapse is unclear from the 
small number of studies which have examined this.
5.1.3 DISEASE DURATION
The disease duration is also unclear. Barber, (1957) 
treating patients with aspirin or phenylbutazone in most 
cases, found a duration of 1-8 years in 12 PMR patients. 
Russell (1959) and Meadows (1966) felt that treatment could 
be discontinued after 1 year, but Gordon (1960) described the 
mean duration of PMR as 33 months. In Kogstad's (1965) group 
of 70 PMR patients, 13 of whom also had GCA, it was possible 
to discontinue steroids in 18 after 7-28 months of treatment 
(mean 18 months). Only 5 of Dixon et al.'s series (1966) of 
31 patients were in remission off steroids after 2-32 months 
treatment (mean 14). Fauchald et al. (1972) recommended a 
minimum of 2 years treatment based on their report of 94 
PMR/GCA patients of whom 13 had successfully come off 
steroids after a mean of 16 months. Myles (1975) reported 
similar results, with 14 of 84 PMR/GCA patients discontinuing 
steroids at a mean of 21 months (3 months - 3 years 6 
months). More than one-third were still taking steroids 
after 4 years. Coomes et al. (1976), following up Dixon et 
al.'s earlier study (1966) found 84% of 102 PMR/GCA patients 
still on steroids at 5 years. Sorensen and Lorenzen (1977) 
reported that 26 of 63 PMR/GCA patients had stopped steroid 
therapy at a mean of 2 years. The next large series (Huston 
et al. 1978) gave a different picture? in 42 GCA patients, 
treatment length ranged from 1-77 months (mean 7) with a mean
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follow-up period of 5 years. The authors felt it was unusual 
.for PMR/GCA to last for more than 2 years. Fainaru et al.
(1979), in a retrospective study, followed up 19 patients 
from an initial group of 47 with GCA. Fifteen were still 
taking steroids after 1-13 years, most for less than 5. Von 
Knorring (1979) found most patients needed treatment for 2-3 
years but some were still taking steroids after 5 years and 
one patient was still taking steroids after 9 years.
Most of the literature in the 1980s provided more 
evidence that at least 2 years treatment was often required. 
Bengtsson and Malmvall (1981b) in a large series of 90 
PMR/GCA patients followed for 3-10 years found 35 still 
needed treatment after a mean of 59 months. Thirty-seven had 
discontinued steroids at a mean of 27 months. Graham et al. 
(1981) found that one-third of their patients needed steroids 
indefinitely; these were largely patients with visual and/or 
neurological problems. Jones and Hazleman (1981) found that 
97% of patients needed treatment for at least one year. 
Twenty-one of the series of 85 PMR/GCA patients had been 
taking steroids for at least 3 years and only 7 had been able 
to discontinue steroids. Knudsen (1982) reported a mean of 
30 months treatment in 69 of 80 PMR/GCA patients, although 11 
with PMR had made a full recovery within one year.
American series have tended to.report shorter 
disease duration and this may partly reflect patient 
selection. Huston and Hunder (1980) found most of their 60 
GCA patients could discontinue steroids within 2 years, in
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contrast to British and Scandinavian literature. Chuang et 
al. (1982) recorded a median duration of 11 months in 96 PMR 
patients, with a duration of less than 2 years in 75%.
More recent papers by Behn et al. (1983) and Ayoub et 
al. (1985) have not supported these findings. Seventy-two of 
Behn et al.'s 176 patients had discontinued treatment at a 
mean of 31 months (3-103); 93 still required steroids.
Ayoub et al. (1985) reported that 31 of 70 PMR patients were 
able to discontinue prednisolone after 23.7 months, but on 
life table analysis 40% were likely to remain on steroids for 
more than 4 years. This was the only study which looked for 
factors which might predict disease duration? none were 
found.
Chuang et al. (1982) proposed that there were 2 
populations, one with a short self-limiting disease duration 
and one with a longer relapsing course, but no other study 
supported this hypothesis. Russell (1959) and Gordon (1960) 
both described an early active phase then a longer phase of 
reduced activity. It remains controversial whether steroids 
shorten the disease duration, the view held by Gordon (1960), 
or merely suppress (Birkhead et al. 1957, Whitfield et al. 
1963, Hamilton et al. 1971* Bengtsson and Malmvall 1981b).
The aim of this section is to study the course of 
PMR/GCA, to clarify the controversies that exist over the 
nature and frequency of relapses, whether relapses can be 
predicted, which laboratory parameters best reflect clinical 
relapse and how long treatment should be continued.
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5.2 PATIENTS AND METHODS
The seventy-four patients first seen with active 
untreated PMR/GCA and described earlier were followed up from 
4 weeks to three and a half years. On each visit, the 
following clinical features were recorded:
(1) Muscle pain, stiffness and tenderness.
(2) Joint pain and swelling.
(3) Headache.
(4) Visual symptoms.
(5) Temporal artery tenderness, loss of pulsation and 
thickening.
(6) Diastolic BP.
(7) Weight.
(8) Global assessment of whether the patient was better, 
worse or unchanged.
(9) Presence of intercurrent medical problems.
(10) Whether a relapse requiring an increase in steroid dose 
had occurred between visits.
(11) Prednisolone dose taken since last visit (mg).
(12) Planned prednisolone dose till next visit (mg).
(13) Whether the steroid dose was being altered and in which 
way.
(14) Number of weeks of treatment.
(15) Number of visits.
Patients were reviewed at 1-2 weekly intervals for 2 
months, then usually every 2-3 months. My global assessment 
(No. 8 above) was based only on clinical findings, not on 
laboratory results, and was classified in relation to the
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previous visit as follows:
(1) Improvement to normal.
(2) Partial improvement.
(3) Worse.
(4) Unchanged and well.
(5) Unchanged overall but with different PMR/GCA features.
(6) Unchanged with the same PMR/GCA features.
(7) Unwell with something completely separate from PMR/GCA. 
Thus there were 3 grades assessing the clinical state of 
PMR/GCA:
Grade 1 = Relapse (either as a new event or as a flare
persisting without improvement).
Grade 2 = Improved but still not back to normal.
Grade 3 = Well; symptoms occasionally present but not felt 
to be significant.
Laboratory Parameters
FBC, ESR, platelets were measured on every visit. C- 
reactive protein, orosomucoid, haptoglobin, CL ^ antitrypsin, 
IgG, IgA, IgM, alkaline phosphatase, albumin, glucose, immune 
complexes (Clq binding, PEG C4 and complement consumption) 
were measured on most visits. Methods are described in 
Chapter 3 and 4.
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5.3 RESULTS
5.3.1 CLINICAL DATA
74 patients presenting with PMR (39), GCA alone (18) 
and both PMR and GCA (Both) (17) were followed for 4-177 
weeks (mean 65.99, SE 5.53). Values for each subgroup were 
not significantly different (Table 25). The number of 
visits/patient was 2-33 (mean 11, SE 0.72) and did not differ 
significantly in each subgroup (Table 25). There were 847 
patient visits in total.
Change of Diagnosis
8 patients who presented with PMR developed GCA, 6 
within 5 weeks of starting treatment, 1 at 26 weeks and 1 at 
89 weeks.
4 patients who presented with GCA developed PMR, all 
more than 4 months after starting treatment, at 16 weeks, 27 
weeks, 67 weeks and 75 weeks.
Patients are classed under their initial subgroup, not 
the final diagnostic group.
Well Patients and Well Visits - Grade 3
Patients were classed as 'completely well1 on 481 of 
the 847 visits (56.8%). Examination on these occasions was 
normal. The values for each subgroup (Table 26) were 
significantly different (p < 0.001) due mainly to the
difference between GCA compared with Both. GCA patients 
were well on 68% of visits, PMR on 58% visits and Both on 
45%. 20 patients had no recurrence of symptoms after the
initial phase of illness (8 PMR, 8 GCA, 4 Both).
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TABLE 25
WEEKS OF FOLLOW-UP AND NUMBER OF VISITS
FOR EACH SUBGROUP
(Mean Values 
and S.E.)
PMR GCA BOTH
Follow-up (weeks) 
Number of visits
68.2 (7.3) 
11.3 (l.o)
57.7 (11.3) 
10.2 (1.5)
69.8 (12.9) 
13.2 (1.5)
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TABLE 26
NUMBER OF GRADE 5 (1 COMPLETELY WELL1) VISITS 
FOR EACH SUBGROUP
PMR GCA BOTH ALL
Number of 
Grade 3 Visits
Total Visits
255 (58*) 
440
125 (68*) 
183
101 (45*) 
224
481 (57*) 
847
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Other Illness
On 23 occasions patients were unwell with a different 
problem from PMR/GCA (4 PMR, 6 GCA, 13 Both).
Relapses
54 patients experienced 131 relapses, including 
unobserved episodes between visits requiring an increase in 
steroids and flares during the initial 8 weeks of illness. 
Details of each subgroup were not significantly different and 
are shown in Table 27 with the number of flares/patient. 
Most patients (63%) had 1 or 2 flares, but 11 had 4 or more. 
There were 90 observed relapses in 46 patients throughout the 
study (49 PMR, 18 GCA, 23 Both). Relapses in the first 8 
weeks are discussed in relation to the trial of differing 
steroid regimes over this period, described in Chapter 6. 
After the initial 8 weeks there were 69 observed new relapses 
occurring in 41 patients (23 PMR, 8 GCA, 10 Both). In 
addition to the 69 new relapses, there were 32 subsequent 
visits where symptoms remained as severe, i.e. 101 'Grade 1' 
visits after the first 2 months. There was no significant 
difference in each subgroup. There were 74 visits after the 
initial 2 months when patients improved from a definite 
relapse but were still not back to normal (Grade 2). There 
was a significant difference in the number of Grade 2 visits 
in each subgroup (p < 0.01), due mainly to the difference 
between patients with Both compared with GCA. (Table 28 shows 
details).
Eight patients (6 PMR, 2 Both) had relapses only at
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TABLE 27
NUMBER OF PATIENTS IN EACH SUBGROUP WHO HAD RELAPSES 
SHOWN AS NUMBER OF RELAPSES/PATIENT
Number of Patients
Number of 
Relapses
PMR (31) GCA (10) BOTH (13) All (54)
1 13 1 4 18
2 7 6 3 16
3 5 2 2 9
4 4 0 3 7
5+ 2 1 1 4
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TABLE 28
GRADE 1 VISITS (RELAPSES) AND GRADE 2 VISITS (ABNORMAL BUT 
IMPROVING) IN EACH SUBGROUP AFTER 2 MONTHS TREATMENT
Number of 
Grade 1 Visits
Number of 
Grade 2 Visits
Total
Visits
PMR 57 35 4A0
GCA 16 8 183
BOTH 28 31 22k
ALL 101 I k 8k7
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home. A total of 41 relapses occurring between visits were 
recorded in patients who were well when seen at the next 
visit.
The most common symptoms during relapses (as a 
percentage of all symptoms) were muscle pain (25%), muscle 
stiffness (21%), headache (18%) and temporal artery or scalp 
tenderness (13%). The frequency with which these occurred in 
each subgroup is shown in Table 29.
In these patients who had features of PMR and GCA,
either initially or during follow-up, relapses involving 
arteritis were more common than polymyalgic flares. Thirty- 
four relapses included arteritic features (15 also with PMR) 
and in 11 the relapse featured PMR only.
The number of visits after treatment had started when 
any abnormal symptoms or signs were present, including both 
flares (Grade 1) and visits where some improvement had 
occurred (Grade 2) totalled 264/847 (PMR 135/440, GCA 35/183,
Both 94/224). There was a significant difference in the
number of abnormal visits in each subgroup (p < 0.001). This 
was due mainly to the smaller percentage in GCA patients 
compared with Both.
There were 4 patients who were unwell (Grade 1 and 2) 
more often than they were well. Two complained of mild but 
persistent muscle aching, but were reluctant to increase 
their steroids. Two other cases were extremely difficult to 
control (1 PMR who developed GCA, and 1 PMR/GCA, who was 
never completely well, with persistent headache and temporal 
tenderness). These four patients contributed 24 of the
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101 new or ongoing relapses, after the first 2 months and 28 
of the 74 Grade 2 visits when symptoms were still present. 
One further patient became blind in one eye while on 
treatment; ESR and CRP were normal. One patient who 
presented with blindness in 1 eye with florid GCA on TAB died 
at home 8 weeks after starting treatment? post-mortem was 
not carried out.
When Relapses Occurred
Most new relapses occurred within the first 6 months 
(55%) and 72% within 1 year but there was a wide range (less 
than 2 months to more than 30 months). Details are shown in 
Table 30.
Length of Relapses
The length of relapse was calculated as the number of 
weeks from the visit where a flare was first noted to the 
first visit where symptoms and signs had completely settled. 
Patients who never fully improved, or where follow-up ended 
before this stage was reached, are excluded. Thirty-five 
per cent completely recovered within 4 weeks and a further 
23% within 8 weeks. Eighteen per cent still had symptoms at 
>16 weeks (Table 31).
Effect of Steroid Reduction and Dose
Forty-nine of the 90 observed flares occurred in 
association with attempted reduction in steroid dose. This 
proportion was not significantly different for each subgroup 
(PMR 29/49, GCA 8/18, Both 12/23). The steroid dose at the 
time of relapse ranged from 5-40 mg prednisolone/day (mean 10
20k
I
TABLE 30
TIME-POINT AT WHICH NEW RELAPSES OCCURRED 
IN EACH SUBGROUP
Number of Patients
Time (Months) PMR GCA BOTH ALL ($)
« 3 Ik 3 k 23.6
A-6 13 5 8 31.5
7-9 3 1 2 6.7
10-12 k 1 k 10.1
13-18 6 k 3 Ik,6
19-2A 3 2 0 5.6
25-30 3 1 2 6.7
>30 1 0 0 1.1
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TABLE 31
LENGTH OF RELAPSE (WEEKS) FOR EACH SUBGROUP
Number of Patients
Relapse length 
(weeks)
PMR GCA BOTH ALL (%)
14 5 5 3^.8
5-8 9 k 2 22.7
9-12 5 3 3 16.7
13-16 4 1 0 7.6
17-20 3 0 2 7.6
>20 5 1 1 10.6
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mg). Values for each subgroup showed a higher dose in 
relapsing patients with Both (13.63 mg) compared to GCA (9.75 
mg) and PMR only (8.38 mg) but this just failed to reach 
significance at the 5% level.
5.3.2. LABORATORY DATA 
Relapses, ESR and CRP
The ESR was abnormal (>30 mm) in 48.3% cases and CRP 
abnormal (>0.6 mg/dl) in 40.7% of Grade 1 visits. There was 
no significant difference in the percentage of abnormal 
values for each subgroup for either test, nor when ESR was 
compared with CRP (Table 32). On 13 occasions when the ESR 
was abnormal CRP was normal, and on 9 the CRP was abnormal 
and ESR normal.
Clinical Abnormalities, ESR and CRP
On visits when abnormal symptoms and signs were 
recorded, the ESR was abnormal in 43% cases and CRP in 35%. 
Subgroup details are in Table 33 and there were no 
significant differences in each. ESR and CRP disagreed in 
19% of clinically abnormal PMR visits, 45% GCA and 19% Both. 
Home Relapses
The ESR became abnormal on the visit immediately 
preceding a 'home flare', while the patient was still 
clinically well, on 9 out of 44 occasions (PMR 4, GCA 1, Both 
4). The CRP became abnormal on 10 out of 38 occasions. , The 
abnormalities coincided in 6 cases.
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TABLE 32
PERCENTAGE OF RELAPSES (GRADE 1 VISITS) VITH 
INCREASED ESR OR CRP FOR EACH SUBGROUP
1
ESR CRP
PMR
GCA
BOTH
41.7*
58.8*
54.5*
46.5*
29.4*
38.1*
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TABLE 33
OCCASIONS WHEN ABNORMAL CLINICAL FEATURES DOCUMENTED 
AND ESR AND/OR CRP ELEVATED
Number of Occasions($)
ESR CRP
PMR
GCA
BOTH
58 (43.3$) 
17 (50%)
28 (29.8$)
53 (44.5$) 
9 (28$)
17 (22.7$)
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Unexplained Abnormalities in ESR/CRP
There were 17 occasions (less then 3% of all visits) 
when the ESR was > 30 mm with no apparent cause and 27 when 
the CRP was > 0.6 mg/dl. Abnormalities during or immediately
preceding a relapse, or coinciding with any abnormal symptoms
or signs whether due to PMR/GCA or other disease were 
excluded. One patient had an ESR of > 70 mm on all but 2 
occasions, even when well, but a normal CRP on all but 4 of 
his 12 visits. Apart from this case and one reading of 53, 
the unexplained abnormal levels were all < 45 mm/hour.
ESR Absolute Values
During relapses the mean ESR was 26.3 mm (SE 2.3) for 
PMR, 42.1 (6.91) for GCA and 28.2 (2.9) for Both. There was 
a significant difference between the levels for PMR and GCA.
(0.02 > p > 0.01 ).
Relative Changes in ESR at Time of Relapse
13 of the 40 ESR levels greater than 30 mm during
relapses, had risen from normal (< 30) on the preceding 
visit (PMR 7, GCA 1, Both 5). The mean rise was 14 mm/hr. 
Twenty-seven were already over 30 mm (PMR 12, GCA 9, Both 6), 
one because of other illness.
Of the 45 normal ESR values, in 7 cases patients had 
increased their steroids before they attended hospital.
The ESR was not done in 2 cases.
Relative Changes in CRP at Time of Relapse
32 of 80 CRP levels in relapses were > 0.6 mg/dl (20 PMR, 5 
GCA, 7 Both). 19 had been normal on the preceding visit (13 
PMR, 2 GCA, 4 Both). 13 were already abnormal (7 PMR, 3 GCA,
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3 Both). Of these, one from each subgroup had become 
abnormal only on the visit preceding the relapse visit. Of 
the 48 normal values, 7 patients had already increased their 
steroids at home before the 'relapse' visit.
Thus during a clinical relapse 51% of ESR readings were 
abnormal (PMR 19/43, GCA 10/16, Both 11/18) and 44% CRP 
readings were abnormal, excluding episodes of intercurrent 
illness, or where the patient had increased the steroid dose 
prior to the blood test.
Other Laboratory Measurements
Forty per cent orosomucoid and 39% haptoglobin levels 
were slightly elevated during relapses but in almost half 
these cases values were chronically mildly elevated. 
Increased levels occurred particularly in the PMR only and 
Both subgroups, and infrequently in those with GCA only. oC^AT 
was elevated less frequently (27%), almost entirely in PMR 
cases, and again the increase was usually minimal.
Immune complexes were elevated during 9 relapses (10%) 
when measured by PEG-CC and alkaline phosphatase was elevated 
on 5 occasions. Immunoglobulin G was above normal in 3 
flares, IgA in 1 and IgM during 4.
Mean ESR and CRP in Relapsers and Non-Relapsers
There was no significant difference in the group or 
subgroups in the level of the presenting ESR (or CRP if 
abnormal) when patients who never relapsed were compared with 
those who did relapse.
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ESR and CRP in the First 2 Months of Treatment
A specific study was carried out of the correlation 
between clinical state, ESR and CRP over the first phase of 
treatment. 40 assessments of ESR,CRP and clinical state were 
made at 1 week and 70 assessments between 2 and 8 weeks, (the 
majority being at 2-3 weeks), on 63 of the patients (34 PMR, 
29 GCA, including 11 with Both).
There were 20 patients who were Grade 3, completely 
well, at one week but 9 of these still had an elevated ESR 
and 2 an elevated CRP. From 2 weeks onwards, 52 were 
completely well and by then only 4 had a raised ESR and 8 a 
raised CRP. Results for each subgroup are shown in Table 34.
After 1 week, there were 24 Grade 2 patients who had 
improved but still had symptoms. Eight of these had a normal 
ESR and 16 a normal CRP. From 2 weeks onwards, there were 
only 12 Grade 2 assessments, of whom 8 had a normal ESR and 7 
a normal CRP (Table 35) .
The correlation between abnormal ESR and abnormal CRP 
values was then examined; of 24 PMR patients with 
assessments at 0, 1 and 4 weeks, all had abnormal values
initially. Subsequent numbers with abnormal ESR and CRP are 
shown in Table 36a. Analysis of these results gave r=0.575 
(p < 0.01). For 20 GCA patients where clinical assessment, 
ESR and CRP were recorded at 0, 1 and 4 weeks, all had raised 
ESR and all but one a raised CRP initially with only 2 
abnormal levels by 4 weeks (Table 36b). Correlation of 
these elevated values gave r = 0.627 (p < 0.01).
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TABLE 3A
GRADE 3 (COMPLETELY WELL) PATIENTS WITH RAISED ESR OR CRP AT
(a) 1 WEEK
(t>) 2-8 WEEKS
(a) WEEK 1
Completely
Well fESR fCRP
PMR 9/25 A 1
GCA 11/21 5 1
TOTAL 20/A6 9 2
(L) AFTER
2 WEEKS
Completely
Well (es r f CRP
PMR 29/39 3 6
GCA 23/31 1 2
TOTAL 52/70 A 8
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TABLE 35
GRADE 2 (IMPROVED BUT STILL ABNORMAL) PATIENTS WITH 
NORMAL ESR OR CRP AT
(a) 1 WEEK
(b) 2-8 WEEKS
a) WEEK 1
IMPROVED ESR NORMAL CRP NORMAL
PMR 16/25 k 10
GCA 8/21 h 6
TOTAL 2A/A6 8 16
>) AFTER
2 WEEKS
IMPROVED ESR NORMAL CRP NORMAL
PMR 6/39 k 3
GCA 6/31 k A
TOTAL 12/70 8 7
21A
TABLE 36
NUMBER OF PATIENTS WITH ELEVATED ESR AND CRP LEVELS 
OVER THE FIRST MONTH OF TREATMENT 
PMR 24 PATIENTS
Time (weeks)
0 1 4
♦ esr 2k 12 1
f CRP 24 7 4
GCA 20 PATIENTS
00
Time (weeks)
0 1 4
tESR 20 9 3
f CRP 19 5 4
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5.3.3. DISEASE DURATION
Four PMR and 3 GCA patients managed to discontinue 
steroids without relapse. The times at which steroids were 
stopped are shown in Table 37. Steroids were stopped in 
one GCA patient after 70 weeks but a flare of both PMR and 
GCA at 100 weeks necessitated restarting them. When the 
number of steroid withdrawals remaining well were related to 
the number of patients still followed-up, only 2% of 54 
followed for 6 months - 1 year were off steroids, 6% of the 
39 followed for 1 year-18 months and 24% of those followed 
for 18 months to 2 years had discontinued steroids. The 
mean cumulative dose when steroids were discontinued was 
3.155 g (2.072-5.005 g). By the end of the study a further 
39 patients had exceeded this dose and were still requiring 
steroids.
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TABLE 37
TIMING OF STEROID WITHDRAWAL IN PATIENTS ABLE TO 
DISCONTINUE TREATMENT
Time(weeks) when 
Steroids withdrawn Diagnosi s
Total follow-up 
(weeks)
43 PMR 52
67 BOTH 67
70* GCA 146
76 GCA 94
83 PMR 89
89 GCA 127
101 PMR 135
137 PMR 148
*Steroids restarted at 100 weeks
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5.4 DISCUSSION
5.4.1 CLINICAL COURSE
These results suggest that PMR/GCA runs a relatively 
benign course. Although abnormal symptoms and signs were 
present on almost half the total number of patient visits, 
these were severe (Grade 1) on just over 10% of visits. One 
patient lost sight in one eye and 2 had chronically active 
disease which was relatively resistant to steroids and very 
difficult to manage. This small number of serious problems 
contrasts with the complications and prognosis described by 
others (Whitfield et al. 1963, Jones and Hazleman 1981). 
This may be partly because my patients were largely GP 
referrals, whereas Whitfield et al. saw patients with 
ophthalmological problems and Jones and Hazleman's group were 
drawn from all hospital specialties. The average follow-up 
period was about 15 months and most relapses occurred within 
the first six months, as found by the majority of studies. 
It therefore seems unlikely that the low complication rate is 
due to short follow-up.
The clinical course was different in each subgroup. 
Patients who presented with PMR/GCA did least well. They had 
significantly more episodes with documented abnormalities, 
both Grade 1 or 2. Even if the initial 2 months were 
excluded, they still had more Grade 2 visits, where they were 
improving but not well, than both the other groups. This was 
partly due to 2 patients who had an extremely high number of 
Grade 2 visits. The number of relapses (Grade 1 visits)
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after the first 2 months was not significantly different.
Patients presenting with PMR only were unwell (Grade 1 
and 2) on significantly more occasions than those with GCA 
alone. However, when the course after the first 2 months was 
analysed, neither relapses (Grade 1) nor 'improved but 
unwell' visits (Grade 2) were more frequent than in patients 
with GCA.
GCA patients were completely well (Grade 3) 
significantly more often than those with PMR only or both.
Thus patients with the combination of clinical features 
appear to be symptomatic more frequently than those with only 
PMR or only GCA, even if the first 2 months are excluded 
while the disease is coming under control. The differences 
between PMR only and GCA only, disappear when the first 2 
months are excluded, and may reflect the different steroid 
regimes used in each group (see Chapter 6).
It is possible that the combination of both PMR and GCA 
has a synergistic effect, causing more stress than either in 
isolation. It is of interest that relapses were more likely 
to feature GCA than PMR; this supports the view that GCA 
requires higher doses of steroid to control it. It also 
suggests that the pseudorheumatism effect seen on steroid 
reduction, which can be mistaken for a PMR flare, was not 
responsible for the increased number of abnormal visits in 
PMR/GCA patients.
As the number of visits per patient was not 
significantly different in each subgroup, these findings are 
not due to unwell patients being seen more often. Patients
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with arteritis, whether GCA only or both PMR/GCA, were all 
treated with the GCA regime initially so treatment 
differences do not explain the difference in results between 
these subgroups. It is also possible that these differences 
would be less marked if all arteritis patients (GCA and Both) 
were compared with PMR only. This may be why other studies 
have not found differences in the course of PMR and GCA.
These results support the view that relapses are most 
common in the first year, and this was true for all 
subgroups. The grumbling persistence of abnormal clinical 
features (Grade 2) after relapse was unexpected. The initial 
response to steroids was usually rapid, and it may be 
that larger increases in steroids at the time of later 
relapses would have led to more rapid recovery. Some 
patients, especially those with PMR, preferred to tolerate 
mild symptoms rather than increase their steroids further. 
The interval between visits, sometimes 3 months, may also 
have contributed to an over-estimation of the time when full 
recovery occurred.
Just over half the relapses occurred in relation to an 
attempt to reduce the steroid dose. This is a slightly lower 
proportion than reported by the other series to document this 
(Huston et al. 1978, Von Knorring 1979) and the mean dose was 
10 mg, which was higher than that recorded by Bengtsson and 
Malmvall (1981b). The level in PMR/GCA (Both) patients was 
somewhat higher than those with PMR only and GCA; 
this may relate to grumbling activity in the former group
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necessitating a higher steroid dose.
5.4.2 LABORATORY DATA
The ESR and/or CRP were abnormal in about half the 
relapses, and on a slightly lower proportion of visits when 
patients had improved but still had abnormal clinical 
features. When the ESR or CRP was abnormal, it had been so on 
the preceding visit in about half. Neither was helpful in 
consistently predicting relapse. This is not unexpected in 
the later stages of follow-up, when the interval between 
visits was often 3 months, which is almost certainly too long 
to pick up incipient relapses by looking at changing trends 
in ESR. However, a rise before a 'home relapse' did occur 
in about 25% of episodes, when the follow-up interval was 
shorter. There were hardly any abnormal ESR or CRP levels on 
visits when patients were completely well and did not proceed 
to relapse before or at the next visit. These results 
suggest that a raised ESR or CRP, if present, is significant 
but a normal value is of no help in excluding a relapse, at 
the time or in the near future. This is in contrast to 
Paulsen and Iversen's finding (1971) that the ESR was always 
> 25 mm during relapse; other studies rarely gave details of 
ESR during relapse.lt was also noteworthy that abnormalities 
did not always coincide, and it may be useful to perform both 
tests. During a relapse patients with GCA had a higher ESR 
than those with PMR only, supporting the view that GCA is the 
more aggressive condition.
Acute phase proteins were often mildly elevated and 
although further elevation during relapses occurred in about
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40%, this did not appear to be a more useful test than ESR or 
CRP, and supports the findings of Paolaggi et al. (1985) who 
found orosomucoid and haptoglobin but not ESR tended to 
remain elevated despite clinical improvement.
Elevation of alkaline phosphatase was rarely seen 
during relapses although it had occurred at the time of 
presentation in about one third. Immune complexes were 
rarely increased, and were not helpful as a measure of 
disease activity.
Over the initial phase of treatment, ESR was as good 
as,- or better, than CRP in reflecting clinical activity, in 
contrast to the findings of Eshaghian and Goeken (1980) and 
Mallya et al. (1985). Both studies were small, the first 
looking at GCA and the second largely at PMR. In this 
study, while it was true that CRP fell to normal more rapidly 
than the ESR at 1 week in patients who were completely well, 
both tests were equally accurate thereafter. In patients who 
had improved but were still abnormal at 1 week, CRP could 
have been misleading as it had fallen to normal in most 
cases, in contrast to the ESR. Abnormal values for each test 
correlated reasonably well. The results were similar for 
both PMR and GCA and were not subdivided further. Park et 
al. (1981) also found the ESR to reflect disease activity 
best of several acute phase proteins measured, including CRP.
As the ESR is a cheaper and more readily available 
test, it should be used in preference to CRP in monitoring 
disease activity. Although CRP may be more accurate in
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patients who are clinically well after 1 week of treatment, 
this group is rarely a management problem. CRP has a useful 
back-up role for cases where the ESR result is at variance 
with the clinical picture.
Thus ESR with CRP still appear to be the most useful 
laboratory parameters to measure but even these are of 
limited value in predicting the course of PMR/GCA, with a 
high rate of false negative values during relapse, but a low 
false positive rate.
5.4.3 DISEASE DURATION
Patients appear to require steroids for at least least 
2 years. In this study, only 7 of the 71 patients followed 
for at least 3 months (mean 15 months) were able to 
discontinue steroid therapy However, of those followed for 
2 years, 24% had been withdrawn from treatment. The 
follow-up period is too short to make definitive statements 
about treatment periods, but these figures suggest that 20- 
25% patients will be able to discontinue steroids after about 
2 years of treatment. Stopping therapy within 1 year is 
unusual. Clinical features or steroid dose did not predict 
which patients could discontinue steroids.
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5.4.4. CONCLUSIONS
The course of the disease was benign. Relapses were 
uncommon and PMR, GCA and overlap patients behaved in a 
broadly similar fashion after the first 2 months. Grumbling 
persistence of symptoms was more common in the overlap group 
although this was partly due to a few patients where disease 
control was difficult. Laboratory tests were similar in the 
subgroups during the period of follow-up and the ESR remains 
the best parameter with which to assess disease activity. 
The average disease duration is at least 2 years.
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C H A P T E R  6 
CONTROVERSIES IN THE TREATMENT OF PMR/GCA
6.1 INTRODUCTION
Many aspects of the treatment of PMR/GCA remain 
controversial, in particular:
(1) the initial dose of prednisolone needed to control the 
disease.
(2) whether PMR and GCA should be treated differently.
(3) the rate of reduction of prednisolone.
(4) the relationship between steroid dose and steroid side 
effects.
6.1.1 INITIAL TREATMENT OF PMR/GCA
Suggested prednisolone doses in the literature range 
from 10-100 mg prednisolone/day, with some authors proposing 
treatment of PMR with NSAIDs only (Goodman 1979, Chuang et 
al. 1982).
PMR
An initial dose of 10 mg/day for PMR has been advised 
by Myles et al. (1975), Mowat (1979), Dixon (1983) and 
Hubault (1983). Behn et al. (1983) noted that patients 
taking less than 10 mg prednisolone/day initially were more 
likely to need an increase than those taking 10 mg/day but 
found that 10 mg/day was satisfactory in most cases. Others, 
including major textbooks, have suggested using 10-20 mg 
prednisolone/day (Kogstad 1965, Huston and Hunder 1980, Byron 
and Hughes 1983). Ayoub et al. (1985) retrospectively 
studied the treatment given to 76 PMR patients, all with 
negative TAB, and found the mean initial dose was 22.8 mg
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prednisolone/day.
GCA
The literature recommendations for treatment of GCA 
vary far more widely than those for PMR. Whitfield et al. 
(1963) used 30-40 mg/day unless there were visual symptoms, 
when IM or IV ACTH was added. Kogstad (1965) used only 20 mg 
prednisolone/day. Huston and Hunder (1980) reported that 10- 
20 mg/day relieved symptoms but they used 40-60 mg/day to 
prevent blindness. Behn et al. (1983) found that 20 mg/day 
caused fewer relapses than an initial daily dose of less than 
20 mg. Some papers and textbooks recommend moderate doses of 
40-60 mg prednisolone/day (Hamilton et al. 1971, Sorensen 
and Lorenzen 1977, Mowat 1979, Jonasson et al. 1979, Byron 
and Hughes 1983). Others have used high doses of 
prednisolone. Wadman and Werner (1972a) proposed 60-80 mg 
prednisolone/day as did Cohen and Hurd (1981). Graham et al. 
(1981) used 80 mg prednisolone/day plus IV hydrocortisone 
although their series included many patients with visual or 
neurological features. Chuang et al. (1982) reported the 
use of 100 mg/day by some physicians. Model (1978) reported 
the use of 500 mg. methylprednisolone IV to successfully 
reverse blindness when 100 mg. IV hydrocortisone and 40 mg 
oral prednisolone failed to do so.
It has been suggested that PMR should be treated with 
higher doses of steroids comparable to those used in GCA, 
because of the risk of arteritis developing (Hamilton 1971, 
Fauchald et al. 1 972). Bengtsson and Malmvall (1981b)
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reported treating PMR/GCA patients with a mean of 33 mg, 
using this dose for both PMR and GCA in a retrospective 
study. Attempts to treat PMR/GCA with alternate day steroids 
have had limited success (Hunder et al. 1975, Bengtsson and 
Malmvall 1981c).
One limitation of all these studies is that no attempt 
was made to compare prospectively different steroid doses at 
the start of treatment, nor the rate of dose reduction in the 
early stages of treatment.
Rate of Steroid Reduction
Esselinkyx et al. (1977) studied steroid reduction in 
18 PMR patients once the prednisolone dose was stable 
(usually 10 mg/day, range 2.5-15 mg/day). There was 100% 
relapse if steroids were withdrawn abruptly over one week, 
usually with a rise in ESR. Withdrawal at the rate of 1 
mg/month was satisfactory where the ESR or PV was normal but 
a slower reduction rate (0.5 mg/month) was needed if the ESR 
or PV were still elevated. They felt the extent of the 
elevation of ESR might predict outcome on steroid withdrawal, 
by highlighting those with occult disease activity once 
they were asymptomatic. Weekly decrements of not more than 
10% were suggested by Calamia and Hunder (1980).
6.1.2 SIDE-EFFECTS
Retrospective series have reported side-effects such as 
Cushingoid weight gain, osteoporosis and fracture, diabetes 
mellitus, increased infection, poor skin healing, cataract, 
mood changes, and peptic ulceration or dyspepsia.
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Beevers et al. (1973) recorded a high incidence of 
major side effects (59%) in a study emphasising the need for 
prolonged treatment. Von Knorring (1979) reported 10 
possible steroid complications in 53 patients (19%). An 
Israeli review from several centres recorded side-effects in 
more than 50% (Fainaru et al. 1979); Bengtsson and Malmvall 
(1981b) reported 15 side-effects from a series of 90 patients 
(17%). Behn et al. (1983) recorded 27 complications of 
steroid therapy in 176 patients (15%) using 10-20 mg 
prednisolone/day. Complication rates of 22.7% were found by 
Ayoub et al. (1985) in 76 PMR patients whose mean initial 
dose was 22.8 mg prednisolone/day.
There are no studies relating side-effects to steroid 
dose in PMR/GCA. However, Spiera and Davison (1978) found 
minimal steroid complications in PMR patients treated with 10 
mg prednisolone/day, but substantial steroid toxicity in GCA 
patients where higher (although unspecified) doses were used. 
Graham et al. (1981) reported increased mortality in women 
taking maintenance doses of more than 10 mg prednisolone/day. 
Bengtsson and Malmvall (1981b) recognised the importance of 
examining side-effects in relation to steroid dose but found 
it impossible to study from their data. Ayoub et al. (1983) 
showed that patients treated with higher doses were likely to 
need treatment for longer (irrespective of initial disease 
activity).
Most of the information available on treatment comes 
from retrospective reviews not designed to examine the four 
problems listed above. It is important that these questions
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are answered because inadequate treatment of PMR/GCA may 
cause discomfort and disability for the -patient and, at 
worst, lead to serious complications such as blindness. On 
the other hand, treatment which is unnecessarily aggressive 
or prolonged may also cause morbidity and sometimes mortality 
because of the complications of steroid therapy. It is 
clearly important to determine whether steroid-induced 
complications are related to dose in PMR/GCA, as there would 
be no point in avoiding high dose steroids if side-effects 
were equally common when low doses were used.
In this chapter I will present studies carried out to 
try to answer the above questions.
The first section is a prospective study comparing 
treatment regimes in 74 patients with active untreated 
PMR/GCA over the first two months of treatment. The second 
section studies the amount of steroid taken by these patients 
in relation to steroid side-effects, and particularly weight 
gain, over follow-up periods of six months to three and a 
half years. The final section is a retrospective study of 
steroid related side-effects in 34 patients with PMR/GCA 
followed for 6-10 years, relating side-effects to the amount 
of prednisolone taken. This has been included because side- 
effects in the prospective group with relatively short 
follow-up in some cases may have underestimated side-effects.
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6-2 PATIENTS AND METHODS
6.2.1 PROSPECTIVE STUDY OF 'HIGH* V 'LOW' STEROID REGIMES
Seventy-four patients with active untreated PMR/GCA 
diagnosed between 1982 and 1985 on the criteria of Jones and 
Hazleman (1981) were included in the study. Thirty-nine 
presented with PMR and 35 with GCA, 17 of whom also had PMR. 
Four regimes were used for the first 2 months of treatment, 
separating PMR from GCA and using high and low dose schedules 
for each, to which patients were randomly allocated (Table 
38) .
There were 19 PMR 'high' patients who took 20 mg 
prednisolone/day for one month, reducing at 2 week intervals 
in the second month to 15 mg, then 10 mg prednisolone/day. 
Twenty PMR 'low' patients took 10 mg prednisolone/day for one 
month, then 7.5 mg and 5 mg prednisolone/day for 2 weeks 
each.
All GCA patients took 40 mg prednisolone/day for 5 
days. The 'high' group of 20 patients continued with 40 mg 
for 4 weeks which was reduced to 30 mg/day for 2 weeks then 
20 mg/day for 2 weeks. The low dose group (15 patients) 
reduced to 20 mg prednisolone/day for 4 weeks after the 
initial 5 days on 40 mg/day, then took 15 mg/day for 2 weeks 
followed by 10 mg/day for 2 weeks.
Patients were reviewed weekly initially then about 
every 2 weeks when clinical and laboratory parameters were 
recorded and patients were scored for disease activity as 
described in Chapter 4. If the disease process did not 
appear controlled or if new symptoms developed, the dose was
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TABLE 38
STEROID REGIMES FOR THE FIRST 2 MONTHS1 TREATMENT 
Prednisolone dose in mg/day for (a) PMR patients (b) GCA patients
PMR A Weeks 2 Weeks 2 weeks
High 20 15 10
Low 10 7.5 5
GCA 5 days A weeks 2 weeks 2 weeks
High AO AO 30 20
Low AO 20 15 10
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altered to achieve adequate control.
6.2.2. PROSPECTIVE STUDY OF STEROID SIDE-EFFECTS AND STEROID 
DOSE
Seventy-one patients were followed for up to three and 
a half years. Age, length of treatment, maximum daily 
prednisolone dose, mean daily dose and the cumulative 
prednisolone dose were calculated and steroid side effects 
and weight changes were recorded. Three of the 74 patients 
in the complete study were excluded because of follow-up 
periods of less than 12 weeks.
Statistical analysis was carried out using Student's t
test.
6.2.3 RETROSPECTIVE STUDY OF STEROID SIDE-EFFECTS AND 
STEROID DOSE
34 patients with PMR/GCA diagnosed and treated for at 
least 18 months were identified from a computerised 
diagnostic index. All fulfilled the diagnostic criteria of 
Jones and Hazleman (1981). Age, sex, diagnosis, length of 
follow-up, maximum daily prednisolone dose and cumulative 
prednisolone dose were recorded. An interview-administered 
questionnaire was used to record steroid-related side-effects 
(Appendix 3). Patients were then classified into three 
groups depending on the severity of side-effects:
(i) no side-effects
(ii) mild side-effects - either weight gain or steroid 
related skin changes
(iii) major side-effects e.g. fracture, diabetes mellitus, or
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the presence of both weight gain and skin changes.
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6.3 RESULTS
6.3.1 PROSPECTIVE STUDY OF 'HIGH' VERSUS 'LOW STEROID 
REGIMES
PMR High
Two of 19 patients were unable to remain on the 
1 high1 regime. Both experienced a flare-up of PMR symptoms at 
6 weeks, when they tried to reduce from 15 to 10 mg of 
prednisolone/day but were clinically asymptomatic over the 
final 2 weeks on 15 mg/day. In both, the ESR had fallen in 
the first month but rose in the second month when symptoms 
recurred on steroid reduction. The CRP behaved similarly.
PMR Low
Thirteen of 20 patients failed on the 'low'regime. Six 
had severe pain and stiffness 1-3 weeks after starting 
treatment but responded to an increase in prednisolone to 
15-20 mg/day. The other 7 patients relapsed in the second 
month, 2 on reducing to 7.5 mg/day and 5 on reducing to 5 
mg/day. All responded when reverting to the previous dose.
The ESR and/or CRP remained elevated or rose after an 
initial fall in 3 of the 6 cases who flared in the first 
month. In 2 other cases the dose of prednisolone was 
increased a few days before blood tests were taken, and ESR 
or CRP did not rise.
The 13 who failed included five patients who presented 
with PMR but developed GCA during the first 2 months of 
treatment. All developed headache and scalp tenderness and 
one had visual blurring. Two had already required an 
increase in steroid dose because PMR symptoms were not
controlled on the PMR low regime over the first three weeks. 
Symptoms and signs of GCA responded in all 5 cases to an 
increase in prednisolone. ESR rose in 3 cases when GCA 
developed? in the other 2, symptoms occurred in the first 2 
weeks when the ESR had not fallen significantly.
GCA High
Four of the 20 patients were unable to stay on the 
'high'regime. One woman who presented with loss of vision 
developed reduced visual acuity in the other with ischaemic 
changes on fundoscopy. Two developed increasingly severe 
headache, with visual blurring in one case. The fourth 
patient (described in detail in Appendix 2) had GCA of the 
myometrial and axillary arteries and required 60 mg 
prednisolone to relieve her arm claudication. All patients 
responded to higher doses of prednisolone. Only one patient 
had an increase in ESR and CRP when her GCA flared.
GCA Low
Six of the 15 patients taking 'GCA low' did not 
complete the schedule. Two developed visual blurring, with 
temporal artery tenderness in one case, and 4 had increasing 
headache, with muscle symptoms in 2 cases. Three relapsed in 
the first month and 3 in the second; all improved when the 
prednisolone dose was increased. Two of the patients who 
relapsed in the second month had a concomitant increase in 
ESR or CRP.
Eight of the 10 GCA patients who failed on the 
allocated regime had both GCA and PMR.
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TABLE 59
EARLY RELAPSES
Patients requiring prednisolone dose increased within the 
first two months of treatment
Dose Increased Total No. Patients
PMR Low 13 20
PMR High 2 19
GCA Low 6 15
GCA High k 20
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Table 39 summarises these results, showing that 65% 
of patients were not controlled on the PMR 'low' regime, 
compared with only 2 patients (about 10%) not controlled on 
the PMR 'high' regime. The GCA 'low' regime was inadequate 
for 6 patients (about 40%) and 4 patients were not adequately 
controlled on the 'high' regime, although 1 of these had an 
extremely rare presentation. The ESR and/or CRP rose in 11 
of 30 patients at the time they required an alteration of 
steroid dose. Most relapses in the PMR group occurred on 
dose reduction over the seventh and eighth weeks, but this 
pattern was not seen in the GCA patients.
6.3.2 PROSPECTIVE STUDY OF STEROID SIDE-EFFECTS AND STEROID 
DOSE
35 complications attributable to steroid therapy 
occurred in 29 patients (Table 40). In addition, 4 
patients, (all GCA 'high') complained of feeling generally 
unwell while taking 40 mg prednisolone/day. Their symptoms 
(agitation, insomnia, malaise and palpitations in 2 cases), 
had not been present before treatment and settled when the 
prednisolone dose was reduced to 30 mg/day.
The most common side-effect was fracture affecting 
vertebral body (5 cases), neck of femur (2 cases), wrist (2 
cases), fibula (1 case). All these patients had radiological 
osteoporosis. Two patients developed peptic ulcer 
perforations and one patient both duodenal and gastric 
ulcers. 2 patients with diabetes mellitus previously 
controlled with diet and drugs needed insulin -and 2 
controlled with diet alone needed oral hypoglycemics and
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TABLE AO
PROSPECTIVE STUDY, STEROID-RELATED SIDE-EFFECTS
Side-Effect Number of Cases
Fracture 10
Peptic ulcer A
Diabetes mellitus A
Dyspepsia 5
Cataract 2
Deep vein thrombosis 2
Grafts to lacerations 2
Severe ankle oedema 2
Pulmonary embolus 1
Severe bruising 1
Infection 1
Herpes zoster 1
Glaucoma 1
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insulin respectively. Five patients developed severe 
dyspepsia for which no cause was found other than oesophageal 
reflux. One woman developed 5 separate complications: 
a moderately large pulmonary embolus, occult urinary tract 
infection leading to pyelonephritis, glaucoma, cataract and 
2 calf vein thromboses. Patients who developed a cushingoid 
appearance and gained weight are discussed in a later 
section. Many patients complained of hair thinning and loss, 
which may be a previously unrecognised side-effeet of 
steroids.
Timing
Side-effects occurred from within one week of starting 
treatment and up to 3 years later.
In 16 patients whose side-effects arose within the
first 3 months, all but 2 had GCA. Dyspepsia, peptic
ulceration, oedema and loss of control of diabetes were the 
most common early complications. Two women developed 
vertebral collapse in the first 3 months but most fractures 
occurred after at least one year of treatment.
Diagnosis and Dosage
Only 5 of the 29 patients with side effects had PMR
alone and all were on the PMR 'high' regime. Of the
remaining 24, 22 presented with GCA and 2 with PMR developed 
GCA. Only 6 remained on the GCA 'low' regime over the first 2 
months. The three patients treated with more than 40 mg 
prednisolone/day all developed complications. The cumulative 
doses and maximum daily dose of prednisolone were therefore
239
higher in patients who developed steroid related side- 
effects, because almost all were taking 'high' regimes.
Weight
Weight change was classified in 4 ways:
(1) Persistent weight gain of more than 2 kg (40 patients).
(2) Weight gain of more than 2 kg during treatment but final 
weight unchanged from starting value (11 patients).
(3) Weight unchanged throughout ( +1 kg) (9 patients).
(4) Weight loss (11 patients).
(1) Persistent Weight Gain (40 patients)
This was by far the largest group. There were 33 
women, and half the group had PMR only, so the composition by 
sex and diagnosis closely resembled the entire group. There 
was a relatively large number of patients who either required 
an increase in steroid dose in the first 2 months or had been 
on a 'high' regime from the start - 16 of the PMR patients, 
and 18 of the GCA patients.
(2) Weight Gain of more than 2 kg but Weight Returning to 
pre-treatment Value
There were 11 patients in this category, of whom 2 were 
men. Five presented with PMR alone, again reflecting the 
composition of the complete group. Three of the PMR patients 
either required an increased dose of prednisolone in the 
first 2 months or were on the 'high' regime. However, only 2 
GCA patients needed an increased dose or were taking the 
'high' regime.
2k0
The mean maximum weight gain in the first group was 
5.75 kg compared with 3.64 kg in the second group. The mean 
follow-up period in the first group was shorter (62.7 weeks 
compared with 115.5 weeks). The mean cumulative 
prednisolone dose was greater in the second group and the 
mean daily dose was less in those who regained baseline 
weight (6.30 mg/day compared with 11.66 mg/day), reflecting 
the longer follow-up. The mean maximum daily doses were not 
different (29.63 mg and 28.18 mg).
(3) No Change in Weight (9 Patients)
9 patients remained within 1 kg of their starting 
weight thoughout the study. Three were male, a much higher 
percentage than in the total group, and 4 had PMR only, a 
proportion reflecting the overall numbers. All the PMR group 
finished up on the 'high' regime within the first 2 months, 
and all the GCA patients either started on the high regime or 
required their steroid dose increased because they developed 
GCA on top of PMR within the first 2 months. The follow-up 
period was shorter when compared with those who gained then 
lost weight (58.8 weeks v. 115.4 weeks) but almost identical 
to those whose weight gain persisted (Group 1). The mean 
daily dose and maximum daily dose were similar to those who 
gained weight; the cumulative dose was slightly lower.
2 h l
(4) Weight Loss
Eleven patients lost 2-16 kg in weight (mean 5.82 kg).
3 were male, and 7 had GCA, both higher proportions than in 
the total group. All the patients either required an 
increase in steroid dose over the first 2 months because of 
relapse or the development of GCA, or were already on a 
'high' regime. The mean daily prednisolone dose and mean 
maximum daily dose was higher then in the other groups but 
this was largely because of the short mean follow-up of 45.2 
weeks and the high percentage of patients on a 'high' regime.
Four patients lost large amounts of weight because of 
intercurrent illnesses (perforated duodenal ulcer in one 
case, pulmonary embolus, left ventricular failure and 
strangulated femoral hernia one case, bronchial carcinoma 
one case and palpitations and anorexia one case). One women 
lost 16 kg following depression after her husband's sudden 
death. Two diabetics lost 2 kg each probably because of 
deterioration in control and one woman on psychotropic drugs 
lost 7 kg 12-19 weeks after treatment with no obvious cause. 
The remaining three patients lost 2-4 kg.
The mean weight gain, mean maximum daily prednisolone 
dose, mean daily dose, mean cumulative dose and mean follow- 
up for each group are shown in Table 41. Figures 46 and 47 
show the maximum weight change and final weight changes in 
those followed for more than 1 year and for the entire group 
at the end of the study.
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Figure h6
The range of maximum weight gain in all patient 
followed for at least 1 year. Blocks = number 
patients.
FINAL WEIGHT GAIN
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KILOGRAMS
Figure k l
The final amount of weight gained in patients followed 
for at least 1 year, at the end of the study. Blocks = 
number of patients.
6.3.3 RETROSPECTIVE STUDY OF STEROID SIDE-EFFECTS 
AND STEROID DOSE
Thirty-five patients were assessed, 24 of whom were 
female. Twelve had experienced no side-effects and 11 had 
minor side-effects. Twelve complained of more numerous or 
major side effects, shown in Table 42.
The age ranged from 53 to 85 years (mean 74.3 years) 
with a follow-up of 1.5 to 11 years (mean 4.64 years) since 
starting steroid therapy. Steroids had been taken from 1.5 
to 10 years (mean 3.84 years). The maximum daily dose taken 
ranged from 5 mg to 80 mg Prednisolone and the total amount 
consumed ranged from 2.31 g to 30.6 g. These results are 
shown in Table 43. The maximum daily dose taken in each 
group was significantly different (p < 0.001). This was due 
mainly to the much lower levels in those with no side effects 
(11.8 mg) compared with the levels in those with minor side 
effects (34.3 mg) and major side effects (39.1 mg). 
However, it can be seen that those with most serious side 
effects had taken the largest daily doses. The cumulative 
doses in each subgroup were also significantly different (p < 
0.01) and again this was mainly because of the much lower 
dose consumed by those with no side effects (5.8 g) compared 
with the amount taken by those with minor side effects (10.3 
g) and major side effects (10.7 g).
The mean age, length of time on steroids and period of 
follow-up was not significantly different when the subgroups 
were analysed. Although the mean length of time on steroids 
tended to be shorter in those with no side effects (3.2
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years) compared with those with majorside effects ( 
years) this did not reach statistical significance.
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4.46
6-4 DISCUSSION 
6.4.1 STEROID REGIMES
This is the first prospective study to compare varying 
treatment regimes for PMR/GCA. The results differ from 
traditional views by suggesting that high dose steroid 
therapy is unnecessary in GCA and that low doses may be 
inadequate in PMR.
PMR
There was a high relapse rate in PMR patients treated 
with 10 mg prednisolone/day initially; in contrast almost 
all PMR patients were controlled on 20 mg/day. This does not 
support the views of Mowat (1979), Goodman (1979), Chuang et 
al. (1982), Dixon (1983), Hubault (1983) and Behn et al. 
(1983) all of whom felt that 10 mg prednisolone/day or even 
NSAIDs were adequate in treating PMR.
Ayoub et al. (1985), however, found in a retrospective 
study that about 23 mg prednisolone/day was used initially to 
treat PMR. Our results also suggest that 20 mg/prednisolone 
is necessary for many patients in the first month of 
treatment.
GCA
40 mg prednisolone/day was needed for the first month 
to control disease activity and all 5 patients who developed 
GCA required more prednisolone than the PMR schedule 
allocated, so we did not feel that low doses could be used in 
GCA. This contrasts with some reports where 10-20 mg 
prednisolone/day was used to treat GCA (Kogstad 1965, Huston 
and Hunder 1978, Behn et al. 1983).
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We did not find it necessary, except in 2 exceptional 
cases, to use very high doses of steroid’ as suggested by 
Wadman and Werner (1972a), Cohen and Hurd (1981), Graham et 
al. (1981) and Chuang et al. (1982). Threatened visual loss 
should be treated aggressively but only one patient in this 
study experienced this; routine prophylactic high dose 
steroids are not indicated.
The rationale for using higher prednisolone doses for 
PMR is that these patients are at risk of developing 
arteritis. This risk was found to be high by Jones and 
Hazleman (1981). In this study, prophylactically high doses 
in PMR were not used, although 5 patients did develop GCA in 
the first 2 months. However, control was achieved rapidly by 
increasing the steroid dose. This was feasible because 
patients were being reviewed frequently.
The rate of reduction of steroid dose is important and 
the results suggest that, in the second month, less than 10 
mg/day for PMR and less than 15-20 mg prednisolone/day for 
GCA was associated with an unacceptable relapse rate. 
Esselinkyx et al. (1977) demonstrated that abrupt steroid 
withdrawal over one week led to 100% relapse rates, but there 
are no other studies examining different steroid reduction 
rates in PMR/GCA.
6.4.2. SIDE-EFFECTS 
Incidence
The incidence of steroid related side-effects in the 
prospective group were higher (39%) than reported in
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retrospective series (von Knorring 1979, Bengtsson and 
Malmvall 1981b,Behn et al. 1983) If sustained weight gain 
is included the figure rises to 56%. The lower incidence of 
recorded side-effects in most studies is probably because 
these were retrospective, only major complications were 
noted and data was obtained in most cases from case records. 
However, it is possible that side effects in our study may 
have been over-recorded, given the expected incidence of some 
of these problems (e.g. osteoporotic fracture) in this age 
group. In the retrospective group, major or multiple side- 
effects were reported by about 1/3 of patients, with 2/3 
noting skin changes or weight gain. The higher incidence 
despite the retrospective nature of the study is probably 
because an interview technique was used to elicit specific 
side-effects, which had troubled the patients but were not 
usually recorded in the notes.
It has also been shown that individual sensitivity to 
steroids is genetically related (Bigger, Palmberg and Becker 
1972, Becker et al. 1973) and may be HLA-linked (Becker et 
al. 1976). This may account for some of the reported 
variation in the incidence of steroid side-effects. 
Relationship to Steroid Dose
Both the prospective and retrospective studies suggest 
that steroid related complications occur more commonly if 
high initial doses of prednisolone or high maintenance doses 
are used, with a high total dose. This is perhaps not 
suprising but has not been previously documented in P.MR/GCA.
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In the prospective study all side-effects were 
significantly more common in those on the 'high' prednisolone 
regime. The weight change results have to be interpreted in 
the light of differing periods of follow-up. Those in Group 
2 who gained weight are not strictly comparable to Group 1 
and Group 3 patients because their follow-up period was 
significantly shorter. Their mean daily dose was less than 
patients in Groups 1 and 3, and although this partly relates 
to dose reduction over a longer period of follow-up, it 
suggests that persistent weight gain is more likely with a 
higher mean daily dose. However, Group 2 patients gained 
significantly less weight initially, despite initially 
similar prednisolone doses. This group may represent a 
subpopulation with a tendency to gain less weight and who 
coincidentally had a longer time to lose it.
Because the regimes used covered a relatively small 
dose range, it is not surprising that maximum and mean daily 
doses tended to be similar where the follow-up period was 
similar. However, 2 groups (1 and 3) with similar follow- 
up, mean and maximum dose showed very different patterns of 
weight gain? 40 (Group 1) gained a significant amount of 
weight and 9 (Group 3) did not. This suggests that weight 
gain is likely to be a significant problem for most patients 
but a subgroup may exist who do not gain weight? no clinical 
features distinguished these 2 groups.
Male patients were more likely to maintain a stable 
weight, even when taking 'high' rather than 'low- dose 
regimes. The cumulative dose in this third group was lower
251
than in those who persistently gained weight (although this 
did not reach statistical significance) despite almost 
identical follow-up periods.
It is difficult to explain why some patients lost 
weight - this was not because of longer follow-up, and was 
probably multifactorial, including both other illnesses and 
self-imposed calorie restriction.
In the retrospective group where a wider range of doses 
was used and follow-up was much longer, side effects were 
significantly related both to the maximum daily dose of 
prednisolone used and to the cumulative dose taken. The 
maximum daily dose was at least 3 times greater in those with 
side-effects, and the cumulative dose was double.
Nature of Side-Effects
The pattern of side-effects (Cushingoid facies and 
weight gain, skin changes, dyspepsia, osteoporosis and 
fracture, diabetes mellitus) is similar to that in other 
diseases treated with steroids, where the relationship to 
dose has been studied. Reid et al (1985) found that 
rheumatoid patients on higher doses of steroid had 
significantly more bone loss than those on low doses, using 
neutron activation analysis to measure bone mass. 
Longitudinal studies suggested that bone loss occurred early 
then tailed off. There was some evidence that PMR patients 
experienced less bone loss than rheumatoid patients, and 
this quantitative study emphasised the need to use low dose 
steroids from the start.
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Whether steroids cause or exacerbate peptic ulceration 
remains controversial, but proven and possible upper 
gastrointestinal ulceration have been shown to be increased, 
although not to statistically significant levels, in patients 
taking steroids, and the incidence of peptic ulceration 
shown to be related to both dosage and duration of treatment 
(Conn and Blitzer 1976). Another study showed a 
statistically significant increase in peptic ulcers and in 
gastrointestinal bleeding in patients treated with steroids 
compared with controls (Messer et al. 1983).
Corticosteroid actions do not have an equal duration 
and may be dose-related; hyperglycaemia for example persists 
for longer where higher doses are used (Walton, Watson and 
Ney 1970). The Boston Collaborative Drug Surveillence 
Programme (1972)found that psychiatric side-effects were dose 
related in a study of acute complications in in-patients; 
gastrointestinal side-effects and diabetes mellitus were 
common but not clearly dose-related. Other studies have 
documented the relationship of long term side-effects to 
dosage (Newman 1969, De Lange and Doorenbos 1975, Conn and 
Blitzer 1976, Messer et al. 1985). There was no evidence in 
this study that specific side-effects were related to high 
dose steroids.
The timing of steroid therapy is important in 
minimising hypothalmic-pituitary-adrenal axis suppression and 
side-effects (Dubois and Adler 1963, Nugent et al. 1965, 
Grant, Forsham and di Raimondo 1965, Walton et al.' 1970). 
Patients in this study were asked to take their steroids as a
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single dose in the morning? however, some preferred to 
divide the dose although it was not possible to relate this 
to side-effects in this small sub-group.
The frequent reports of hair loss or thinning suggested 
that this may be an unrecognised side effect of prolonged 
steroid therapy. Thromboembolism has been reported in 
relation to steroids - 2 cases were reported by Urui and 
Reinecke (1973) and 4 fatal cases by Wadman and Werner 
(1972b) where thrombosis but no arteritis was found in 
patients with biopsy-proven GCA. High dose steroids have 
been shown to induce a state of hypercoaguabi1ity (Ozsoyly, 
Strauss and Diamond 1962, David, Grieco and Cushman 1970) 
and animal studies have shown that hydrocortisone enhances 
haemostasis by inhibiting prostaglandin formation and 
allowing vasoconstriction to be maintained (Blajchman et al. 
1979). Pulmonary embolus occurred in this study in one 
patient after taking 40 mg prednisolone/day for one week and 
this may well have been steroid related.
These findings suggest that corticosteroid related 
side-effects in PMR/GCA occur more frequently than previous 
retrospective studies have suggested. They may be minimised 
by avoiding high dose prednisolone both initially and in 
maintenance therapy. Steroid withdrawal should be attempted 
from 2 years onwards.
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C H A P T E R  7
CONCLUSIONS
This thesis has attempted to resolve controversies in 
PMR/GCA by examining prospectively a large population of 
patients with active untreated disease, studied by one 
person. Original material on pathogenesis has been obtained 
using new methods of assessment, or a combination of 
techniques previously used separately in small studies. The 
limitations of a clinical study of PMR/GCA lie in the 
inevitable subjective diagnostic classification of patients 
and arbitrary definitions of clinical improvement or 
laboratory abnormality. The source of the population studied 
will also bias results. These limitations have been 
minimised in this study by using a large number of patients 
drawn almost entirely directly from the community and 
classified by rigid diagnostic criteria.
These methods have resulted in original findings in 
some areas and new results refuting previously held beliefs 
in others. In some cases the findings support results of 
previous retrospective reviews.
The major new features from this thesis are that 
firstly PMR/GCA appears to be much more common than 
previously suspected. The incidence and prevalence figures 
obtained in an original case-finding study in a general 
practice population were almost ten-fold greater than the 
highest figures in previous hospital-based studies. The 
difference was less (2-3 times higher) when prevalence
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figures were compared with 1 post mortem study and 1 study 
based on old people's homes. This supports the hypothesis 
that previous studies have underestimated the incidence and 
prevalence of PMR/GCA because they have been hospital based.
Study of the onset of the disease supported the case 
for an infective aetiology in a susceptible population but 
results were not sufficient to confirm this.
The temporal artery studies demonstrated for the first 
time by immunoperoxidase staining all classes of 
immunoglobulin and C3 adjacent to the internal elastic lamina 
in active arteritis. Electron microscopy demonstrated 
probable IEL degeneration in arteritis, and smooth muscle 
cell movement through the IEL in both normal artery and 
active arteritis. This combination of findings, not 
previously demonstrated, supports the antigenic role of the 
IEL in PMR/GCA, rather than the importance of smooth muscle 
cells in pathogenesis. Histological arteritis was 
significantly more common in older patients, suggesting 
increased susceptibility in this age group. Arteritis on 
TAB was significantly more common in GCA compared to PMR, but 
the presence of arteritis in 20% of PMR patients confirmed 
the overlap between them.
An original method of assessing liver involvement, by 
measuring the arterial:total blood flow ratio, showed a 
significantly lower ratio in GCA patients, which could be 
explained by hepatic arteritis. These patients were more 
likely to have elevated alkaline phosphatase levels. A study 
of follow-up isotope liver scans in PMR/GCA (not carried out
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before) produced an unexpected finding, as scans remained 
abnormal despite clinical improvement and normal liver 
function tests, although these patients were more likely to 
have elevated alkaline phosphatase levels before treatment. 
A third new finding was that elevated alkaline phosphatase 
levels were equally common in PMR and GCA. It is therefore 
unclear whether alkaline phosphatase is associated with 
hepatic arteritis, as might be deduced from the isotope 
studies, or whether it may be an independent marker of 
disease activity.
A detailed study of joint involvement using existing 
techniques to assess patients, controls and post mortem 
findings found no evidence for significant axial or 
peripheral joint involvement in PMR/GCA. This contrasts with 
findings in other studies and may be partly due to the unique 
combination of assessments used.
A new method of characterising immune complexes showed 
that a variety of components were present which differed from 
those found in rheumatoid arthritis. Comparison of levels 
of circulating immune complexes using 3 existing methods 
confirmed that these were present in some, but not all, 
cases? it seems likely that deposited immune complexes are 
of greater pathogenic significance than circulating 
complexes. ,
The clinical studies showed consistent similarities 
between PMR and GCA except in the small number of men with 
GCA. There was no evidence that those with both PMR and GCA,
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the overlap group, had distinct characteristics on 
presentation, although it was of interest that this subgroup 
had more persistent symptoms during follow-up. An 
unexpected finding, contrasting with specialist referred 
groups, was the benign course of the disease.
This is the only large study of both PMR and GCA to 
examine ESR and CRP in short (2 months) and long-term follow- 
up. ESR was a better indicator of disease activity. 
Although abnormal ESR values during follow-up were almost 
always related to relapses, these not uncommonly occurred in 
the face of a normal ESR and/or CRP. No other laboratory 
parameter was more helpful in assessing disease activity.
An original study of initial steroid regimes suggested 
that PMR required 15-20 mg prednisolone/day, rather than the 
low doses previously advocated, and conversely extremely high 
doses were unnecessary in GCA - 40 mg prednisolone/day was 
adequate. For the first time, steroid-associated side- 
effects were studied in relation to dose. The findings in a 
prospective study of short term follow-up and a retrospective 
study of long term follow-up were that such side-effects were 
more common than previous retrospective studies have 
suggested, and were significantly related to mean, maximal 
and cumulative prednisolone dose.
The benign course of PMR/GCA might suggest that 
carrying out TAB is unnecessary. However, the high rate of 
arteritis on biopsy (60% overall, 80% in GCA) in this study, 
coupled with the high incidence of steroid-related side- 
effects emphasises the need to obtain definite evidence for
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PMR/GCA before commencing steroid therapy which is likely to 
be necessary for at least 2 years.
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APPENDIX 1
Diagnostic Criteria for PMR/GCA (Jones and Hazleman 1981)
PMR
(1) Pain and stiffness of the muscles of the shoulder and 
hip girdle in the absence of true muscular weakness.
(2) Duration of at least 2 months, unless treated within 
this period.
(3) Morning stiffness of at least 1 hour.
(4) An ESR of > 30 mm/hr (Westergren) or CRP > 0.6 mg/dl.
(5) Absence of evidence of rheumatoid or other inflammatory 
arthritis.
(6) Absence of malignant disease.
(7) Absence of objective evidence of primary muscle 
disease.
(8) A prompt and dramatic response to corticosteroid 
therapy.
GCA
(1) Positive temporal artery biopsy or cranial artery 
tenderness.
(2) One or more of the following:
headache, visual disturbance, jaw pain, cerebrovascular 
insufficiency, and ESR > 30 or CRP > 0.6 mg/dl.
(3) Prompt and dramatic response to steroids.
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APPENDIX 2
CASE REPORT OF MYOMETRIAL AND AXILLARY ARTERITIS IN PMR/GCA
A 73 year old woman was referred to the gynaecologists 
because of bleeding from a cervical polyp. She was otherwise 
fit. The gynaecologists found prolapse in addition to the 
cervical polyp. Haemoglobin pre-operatively was 9.3 g/dl. 
She had an uneventful anterior repair and vaginal 
hysterectomy. Microscopic examination of the specimen 
revealed a benign polyp and an unremarkable endometrium. The 
myometrium included a benign leiomyoma. The myometrial 
arteries showed changes of florid giant cell arteritis, 
characterised by a predominating mononuclear and giant cell 
inflammatory infiltrate of the vessel wall associated with 
extensive destruction of the vascular elastic laminae. Many 
of the vessels showed fibrous intimal proliferation with 
obstruction of their lumina and in some there was fibrinoid 
medial necrosis.
Shortly after discharge she complained of a numb cold 
right hand and pain in the right forearm on exertion. The 
left arm was less severely affected. She felt tired, and on 
further questioning admitted to stiffness in the buttocks and 
groins especially in the morning. She had lost weight.
On examination both hands were cold and the right was 
blue. The radial and ulnar pulses were impalpable on the 
right and reduced on the left. The right brachial artery 
pulse was reduced. There was a short midsystolic apical
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murmur but no other bruits. Blood pressure in the left arm 
was 150/75. The temporal arteries and all other pulses were 
normal. Hip abduction caused discomfort.
The following investigations were carried out. Hb 11.3 
g/dl, WBC 8.4 x 10^/L, ESR 115 mm/hr (Westergren). Alkaline 
phosphatase 163 U/L (30 - 135 U/L). C-reactive protein 3.49 
mg/dl (<0.6 mg/dl). Albumin 30 g/1 (30-44 g/1). IgG 16.9 
g/1 (6-13 g/1), IgM 2.6 g/1 (0.4 - 2.2 g/1), immune complexes 
38% (0-24%). Urea and electrolytes, liver tests, Rose
Waaler, CPK, auto antibodies, T4, TSH, complement, CXR and 
ECG were normal or negative.
Arch aortography was carried out. This showed 
unfolding of the aortic arch and some dilatation and 
tortuosity of the innominate and both subclavian arteries, 
with occlusion of the right axillary artery over 4 cm. and 
almost complete occlusion of the left axillary artery. There 
was a moderately good collateral supply with good distal run 
off bilaterally and the brachial, radial and ulnar arteries 
were of reasonable calibre. These changes were felt to 
represent atheromatous dilatation and tortuosity proximally, 
but the .blocks and stenosis in the axillary arteries were 
felt to be due to arteritis.
A diagnosis of PMR and GCA affecting myometrial and 
axillary arteries was made, and treatment with prednisolone 
60 mg/day started. Her left arm returned to normal and she 
has only occasional claudication in the right arm. The 
radial pulse is now palpable but reduced. Her ESR is 7 mm/hr 
and prednisolone dose 14 months after starting treatment is
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murmur but no other bruits. Blood pressure in the left arm 
was 150/75. The temporal arteries and all other pulses were 
normal. Hip abduction caused discomfort.
The following investigations were carried out. Hb 11.3 
g/dl, WBC 8.4 x 10^/L, ESR 115 mm/hr (Westergren). Alkaline 
phosphatase 163 U/L (30 - 135 U/L). C-reactive protein 3.49 
mg/dl (<0.6 mg/dl). Albumin 30 g/1 (30-44 g/1). IgG 16.9 
g/1 (6-13 g/1), IgM 2.6 g/1 (0.4 - 2.2 g/1), immune complexes 
38% (0-24%). Urea and electrolytes, liver tests, Rose
Waaler, CPK, auto antibodies, T4, TSH, complement, CXR and 
ECG were normal or negative.
Arch aortography was carried out. This showed 
unfolding of the aortic arch and some dilatation and 
tortuosity of the innominate and both subclavian arteries, 
with occlusion of the right axillary artery over 4 cm. and 
almost complete occlusion of the left axillary artery. There 
was a moderately good collateral supply with good distal run 
off bilaterally and the brachial, radial and ulnar arteries 
were of reasonable calibre. These changes were felt to 
represent atheromatous dilatation and tortuosity proximally, 
but the blocks and stenosis in the axillary arteries were 
felt to be due to arteritis.
A diagnosis of PMR and GCA affecting myometrial and. 
axillary arteries was made, and treatment with prednisolone 
60 mg/day started. Her left arm returned to normal and she 
has only occasional claudication in the right arm. The 
radial pulse is now palpable but reduced. Her ESR is 7 mm/hr 
and prednisolone dose 14 months after starting treatment is
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7.5 mg/day.
This woman had an extremely rare presentation of 
PMR/GCA. There are only 7 reports in the literature of 9 
cases of arteritis of uterus, ovaries or fallopian tubes 
(Polasky et al. 1965, Pirozyoski 1976, Hugod and Schiebel 
1978, Schiffman 1979, Petrides and Robertson 1979, Evans et 
al. 1980, Gloor, Schaller and Dubois 1982). In none of these 
cases did GCA cause gynaecological symptoms. 6 patients had 
features of PMR/GCA. Our patient conformed to this pattern 
in that the GCA was an incidental finding on hysterectomy, 
although on closer probing she did have features of PMR.
She then developed another unusual manifestation of 
GCA, arm ischaemia secondary to arteritis of the axillary 
arteries. Aortic arch involvement was first described in 
1938 (Jennings). The typical findings (Petrie and Sheppeard 
1984) are arm claudication, reduced or absent radial and 
ulnar pulsation and on arteriography long segments of smooth 
stenosis affecting subclavian, axillary or brachial arteries 
(Rivers et al. 1982, Di Giacoma et al. 1984). Although 
symptomatic improvement occurs rapidly after treatment with 
steroids, it takes a mean of 23 months for pulses to return 
and surgery is not helpful.
The features of classical PMR/GCA present in almost all 
the reported cases of gynaecological PMR/GCA suggest that 
this is not an atypical arteritis but GCA in an unusual site, 
and it should be treated with oral corticosteroids in the 
standard way.
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INTERVIEW ADMINISTERED QUESTIONNAIRE TO RECORD 
STEROID RELATED SIDE-EFFECTS
’lease tick the appropriate column (YES, NO, NOT SURE) for 
iach question.
After you started treatment with steroids 
did you develop any of these complaints:
a) Face became fatter
YES NO NOT SURE
b) Put on weight
c) Skin bruised easily
d) Skin seems thinner or heals less well
e) Broken bone (fracture)
f) Diabetes (sugar in urine)
g) High blood pressure
h) Cataract, or other problems with eye sight
i) Stomach ulcer
j) Change of mood (depressed or very happy)
k) Infections at any site in body
1
'lease add any other details or problems in this space
26k
2. Has anybody in your family had similar
problems with muscle pains and stiffness, 
or headaches and problems with vision? YES/NO
If YES, what relation were they to you
And roughly how many years ago did they 
develop the illness?
3. Has anybody in your family had any 
of the following illnesses?
(a) Diabetes mellitus
YES NO NOT SURE
(b) Thyroid disease
(c) Shoulder problems
(d) Cancer
(e) Tingling in fingers especially at 
night (carpal tunnel syndrome)
If anyone has had any of the above illnesses, 
roughly how long ago was this?
What relation were they to you?
h. Have you had any of these illnesses? 
(a) Diabetes Mellitus
YES NO NOT SURE
(b) Thyroid disease
(c) Shoulder problems
(d) Cancer
(e) Tingling in fingers especially at nigt 
(carpal tunnel syndrome)
it
If so, roughly how long ago was this?
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5. Are you still taking steroid tablets (prednisolone) regularly?
YES/NO
Can you write down the names of any other tablets you take?
6. Do you feel better since taking the steroids? YES/NO 
Please add any other comments you wish.
THANK YOU FOR YOUR HELP
This questionnaire was used in an earlier study and is 
reproduced in full although questions 2 and 3 were not 
applicable in this study.
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APPENDIX 4
Statistical Methods and Details of Significant Tests 
Chapter 3.2
Results were analysed using X2 tests and analysis of 
variance. The Kruskal-Wallis test was used for the length of 
history and histology, and the follow-up and histology.
Test Details
p68 Active, healed and negative biopsies in PMR and in GCA
X2=24.65, 2 D.F., p<0.001 
p73 Age in active, healed and negative biopsies (A of V) 
F=7.3731, 2 and 49 D.F., p=0.0016
Chapter 3.3
Results were analysed using X2 tests, analysis of 
variance (albumin and alkaline phosphatase levels) and t 
tests (arterial fraction of hepatic flow and flow index).
Test Details
p93-94 Arterial fraction of total liver flow (A/P ratio) in 
PMR and GCA.
t=2.338 with 24 D.F. 0.05 > p > 0.02.
Chapter 3.5
Immune complex levels in PMR, GCA and Both were 
analysed using analysis of variance.
Chapter 4^
Age and laboratory data for PMR, GCA and Both were 
analysed using analysis of variance. 
pl58 Age in PMR, GCA and Both.
F=3.9577 with 2 and 75 D.F. p=0.0232.
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Chapter _5
Results were analysed using X2 tests, analysis of 
variance for ESR during relapse, Kruskal Wallis testing for 
(i) follow-up in PMR, GCA and Both, (ii) number of visits in 
PMR, GCA and Both, (iii) steroid dose at relapse in PMR, GCA 
and Both. Correlation of abnormal ESR and CRP values was 
carried out. Nonparametric testing was not used because the 
distribution of values was normal.
pl96, pl98 (Table 26) Grade 3 visits in PMR, GCA and Both.
X2 = 22.63 with 2 D.F.? p < 0.001
pl99 Grade 2 visits in PMR, GCA and Both.
X2=12.03, 2 D.F. p < 0.01
p202 Abnormal visits in PMR, GCA and Both.
X2=24.59 with 2 D.F. p < 0.001
p210 ESR absolute values in PMR, GCA and Both during 
relapses.
F=4.4796, with 2 and 84 D.F. p=0.0142 
p212 Correlation between ESR > 30 and CRP > 0.06 for
(a) PMR r=0.575 (27 D.F.) p < 0.01
(b) GCA r=0.627 (20 D.F.) p < 0.01
Chapter (S
Results were analysed using analysis of variance for 
age, time on steroids and length of follow-up for patients 
with no, minor or major side effects. Kruska1-Wa11is tests 
were carried out on the maximum daily dose and cumulative 
dose of Prednisolone in patients with no, minor or major side 
effects.
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p244 Maximum daily prednisolone dose for no, minor or major 
side effects.
H=14.28387 p < 0.001 
p244 Cumulative prednisolone dose for no, minor or major 
side effects.
H=9.61251 p < 0.01 
Chapter 3.3. Isotope Liver Scan Uptake and Flow Studies
There are no published studies which examine isotope 
uptake or blood flow in the liver in the normal elderly 
population. Many physical and technical factors may affect 
scan interpretation, but age does not appear to be important 
(I, II). In this thesis, scan abnormalities were reported 
only if these were prominent and definite; it was considered 
that slight patchiness in uptake in the elderly may be 
normal. None of the few published studies of hepatic flow 
has used a method identical to that described in this thesis. 
The age of control groups in similar studies using Tc
sulphur colloid or other isotopes ranges from 22-56 years or 
is unspecified (III - V). Although it is possible that blood 
flow may be altered by age, this does not affect the 
principal finding in our study, namely that GCA patients had 
a significantly lower arterial fraction of hepatic flow 
compared with PMR patients of similar age.
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